9812 All Companies - Worldwide

At 100XBIO we strive to deliver 100x more data on antigen specificity of the T cells in the limited sample volume (blood, tumor, lymph nodes), and as the downstream -- confirming the cells' phenotype and cytokine expression. Looking for (1) early investments, (2) R&D partners, and (3) early academia, biotech and pharma clients. We are raising $500K of pre-seed investment, and raised over $200K.

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.

13therapeutics is a research and drug development company identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. The company has an innovative platform for discovering and enhancing peptides, derived from naturally occurring pathogens (e.g., bacteria, viruses, fungi), which modulate the human immune response. This platform has produced a portfolio of peptides with demonstrated immune-regulatory activity and with varying mechanisms of action. These peptides have potential application for treatment of both acute and chronic inflammatory diseases. Many of the company’s peptides are capable of multiple methods of delivery, have shown serum stability, and have other desired features clinical therapeutics. Target conditions include the treatment of acute inflammatory diseases such as Acute Otitis Media (AOM), Systemic Inflammation, Meningitis, Traumatic Brain Injury (TBI), Uveitis and Ischemia. We are also evaluating peptides in chronic models for Lupus, Rheumatoid Arthritis (RA), Multiple Sclerosis, Atherosclerosis, Crohn’s Disease and Psoriasis, among others. Using our evolution-based methodology, we envision rapid development across several disease states.

16S Technologies delivers actionable, cost-effective and pain-free information using advanced DNA science to the oil and gas and industrial markets. Employing advanced DNA sequencing and proprietary data analytics, we offer a range of genomics diagnostics, biocide selection and consultancy services for microbial challenges faced by the oil and gas industry. In addition, 16S offers DNA-based oil and water tracers that have significant advantages when compared to legacy tracer technology. Specifically, DNA tracers are cheaper, more plentiful and not disproportionately affected by downhole environments. Please contact us directly to talk more about our tracer or biocorrosion application.

180 Life Sciences Corp. (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world's biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company's primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor).

199 Biotechnologies is an early-stage
company developing first-in-class therapies that target the fundamental mechanisms of aging, with the goal of transforming the landscape of age-related disease treatment and prevention.

1DROP saves lives through better faster near patient health monitoring. 1DROP enables personalized healthcare by providing actionable health information that is accessible to everyone everywhere. One drop of sample, a few minutes and you receive your diagnostic test results on your mobile phone. 1DROP makes this a reality: 1. 1DROP Chip, to which a drop of sample (usually blood) is applied; 2. 1DROP portable Analyser, which quantifies multiple biomarkers from the 1DROP Chip within minutes; 3. 1DROP App, which is synchronised with the 1DROP Cloud, and shares data with Electronic Health Records (EHR), streamlining clinical workflows by providing access to patient diagnostic results in real-time and anywhere.

At 1STBIO, we strive to transform the lives of patients by relentlessly discovering and developing novel therapeutics to address areas of significant unmet need. Inspired by science and innovation, we dedicate our expertise and experience in drug development to bring forward a pioneering change.

20/20 GeneSystems (‘20/20’) was founded in May of 2000 to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. Our headquarters are in the heart of the biotechnology corridor in Rockville, Maryland in close proximity to the National Institutes of Health with which we have extensive collaborations. 20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer. These tests generally fall into two categories: Personalized Medicine: Our patented platform technology for measuring biomarkers in tumors is highly unique in that it combines the visual advantages of classical pathology with the multiplex capabilities needed as a result of genomics and proteomics. This technology is now being used to develop tests to predict responses to several new targeted therapies for kidney and lung cancer. Early detection of lung cancer: 20/20 is developing a blood test for the early detection of lung cancer. This product will be used for screening smokers and former smokers to pre-select or enrich the patient population to receive annual CT scanning long before the disease becomes symptomatic. Biological Detection: 20/20 is on the leading edge of developing technologies to help in the detection of biological toxins.

We help accelerate the World's quest for sustainable food and materials The world needs new solutions to tackle the mounting sustainability challenges. Biotech offers an extraordinary potential to replace and improve many foods and materials with attractive sustainable bio-based solutions*. With the advances in technology, insight and data, the discovery of new molecules has only just begun. However, far too few promising molecule innovations have been successfully commercialized and made a true sustainable impact on the World. 21st.BIO helps you accelerate by building a competitive manufacturing foundation for your innovation - allowing you to focus on succeeding in the market and your next discovery. We partner with you on your journey to the market through: 1) Assessment of the technical potential in delivering your innovation – the expression system, the strain base, yield potential, investments required and the best way forward 2) Access to and optimization of high-performance strain platforms and production media across multiple expression systems 3) Building your scale up process and provide volumes for testing your innovations in the market 4) Providing a high quality, proven low investment way for you to manufacture in very large scale – your "fermentation cloud solution"

22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.

2A Pharma is a clinical stage Swedish/Danish biopharmaceuticals company focused on discovering, developing and commercialising novel, cost effective prophylactic and therapeutic vaccines based on our patented vaccine platform. Our lead vaccine candidate, 2AP01, is a HPV (human papillomavirus) vaccine formulated without adjuvant. We believe 2AP01 will offer significant advantages over existing vaccines including broader protection against more HPV types and lower production cost. Our vaccine technology is based on adeno-associated virus-like particles (AAVLPs), that assemble viral capsids without containing viral genomes; hence they are replicative-defective and non-pathogenic. The viral capsid has repetitive immunogenic sites that can be modified to encompass antigenic epitopes for a protein of interest, generating an immune response where both the innate and the adaptive immune system are activated. In other words, 2A Pharma exploit the efficacy of the individuals’ own immune system to generate AAVLP-based vaccines that, without the addition of adjuvants, are able to develop highly effective antibodies with selected specificities and functions. The technology enables the production of highly efficient vaccines with significant competitive advantages

2-BBB is developing medicines for the treatment of devastating brain diseases. Our proprietary liposomal G-Technology® facilitates entry to the brain while simultaneously enabling sustained delivery of systemically administered therapeutics. Our technology has been shown to be compatible with approved as well as novel therapeutic entities. We have two clinical programs, one targeting multiple indications of brain cancers and the other neuro-inflammatory diseases.

The 2bPrecise platform integrate genomic data withclinical knowledge and genomic research to identify relevant information for clinical care.

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

Every day in the US, approximately 34 patients are removed from the transplant waiting list either because they die or they become too sick to receive a transplant. Our mission is to bring that number down to zero by developing innovative technology and services that will extend the safe preservation times for unused kidneys.

35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Cardiometabolic Disease and Obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands. We believe in connecting rigorous science with our innate sense of urgency to rapidly generate breakthrough therapies for patients in need of a better quality of life. Our beautiful R&D and office facilities are located in the heart of Montreal, Canada, where a diverse team of industry professionals work together to execute on our mission to serve patients in need. If our corporate culture and dedication to patients resonate with you, we invite you to join our team: https://35pharma.com/careers/

360biolabs is Australia's most diverse bioanalytical and specialty laboratory offering science-driven expertise and laboratory services for Phase I-III clinical studies. Our advanced laboratories in Melbourne and Brisbane, specialise in using cutting-edge thinking and technology to support the development of novel therapeutics, vaccines and diagnostics. Our global team has laboratories in both the United States and Europe. With our every sample counts mindset, our meticulous attention to detail and adherence to global scientific standards under GLP, GCP and ISO17025 – ensuring the highest level of quality in every clinical trial we undertake. Our quality systems drive method development, tech transfer and assay validation, compliant with ICH, FDA and EMA. 360biolabs has an experienced team of scientists able to conduct a wide array of assays and offers diverse specialist services. Examples include: Pharmacokinetics (PK), Pharmacodynamics (PD), LC/MS, Flow Cytometry, Biomarkers, Molecular Assays, Virology, Central Laboratory services (kit production and lab manuals). __ Follow along in our journey enabling future medicines, or contact our team to learn more about our service offerings and get proposal estimates. Learn more at 360biolabs.com Get in touch via email at: bd@360biolabs.com

3BarBio offers increased profitability to discovery companies, bulk suppliers, and distributors by addressing the major hurdle to further adoption of biologics by designing innovative packaging to deliver viable microbes to the ag market. With its proprietary LiveMicrobe® Design. Develop. Deliver. process, 3Bar delivers on demand for partners around the world.

3billion is revolutionizing the existing methods and procedures to enable more people to benefit from faster and much accurate diagnosis at an affordable cost. [Who is 3billion?] - 3billion provides an AI-driven clinical diagnostic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases for patients and physicians in need. - 3billion reanalyzes the undiagnosed patients’ genomic data every day without any additional charge. About 10% of undiagnosed patients can receive diagnosis by reanalysis. - More than 40,000 rare diseases patients from more than 60 countries have been tested. - More than 93% of acceptance rate on the 3billion’s test report by physicians. - 3billion has been collaborating with 100 medical institutions across 33 countries to make a diagnosis for rare disease patients. [Core Technology Features] - 3billion has expertise in medical genetics. We have streamlined the analysis pipeline using an automated variant prioritization system and are currently leading diagnostic technology by developing a pathogenicity prediction model of human variants. - 3billion devised a variant interpretation system, EVIDENCE, to automate the process. With the help of EVIDENCE, the variant interpretation takes less than 5 minutes per patient on average. - The EVIDENCE produces consistent variant interpretation according to the current medical guideline, ACMG-AMP interpretation guideline. 3billion's medical geneticist gives the diagnosis and confirms reported variants by Sanger validation (Richards S et al, 2015). - The analysis reflects the latest updates on diseases and genetic variants on daily basis. If any diagnosed case is identified through reanalysis, 3billion provides a report without any additional charge. - We offer Whole Exome Sequencing (WES) & Whole Genome Sequencing (WGS) for rare disease diagnosis. - Web-based portal service – easy access from all over the world. For any inquires, please contact us at support@3billion.io

3CPM Corporation is a Medical Technology company that offers a non-invasive 45-minute test using AI-derived patented technology to accurately characterize gastrointestinal motility disorders such as gastroparesis and functional dyspepsia.

3Daughters is a clinical development company focused on enhancing women’s healthcare through innovative contraceptive solutions. The company aims to fill critical gaps in women's health by developing research-driven products that prioritize patient safety, efficacy, and accessibility. Their flagship products include 3D-001, a frameless, nonhormonal intrauterine device (IUD) designed to reduce insertion pain, and the Slider™ System, which features the i-Slider™ for insertion and the r-Slider™, a magnetic retriever for easy placement and removal. This technology leverages physics and geometry to improve comfort and minimize complications associated with traditional IUDs. 3Daughters targets women seeking reliable, long-acting contraception, particularly those who may be deterred by pain or hormonal side effects. The company has secured over $2 million in seed funding to advance its products through clinical trials, with a commitment to regulatory compliance and quality management. Their mission is to transform women’s healthcare by improving contraceptive accessibility and comfort.

Collagen fibers produced using our patented dry-spinning technology recapitulate the biomechanical and biochemical properties of natural collagen structures. With a fully automated manufacturing system, we are the first to produce collagen fibers at commercial scales for a variety of tissue engineering applications, including additives for 3D bioprinting and hydrogels, and cellular scaffolds for 2D and 3D cell and tissue culture.

3D Biotek, LLC is a high tech biomedical engineering company located in the state of New Jersey, USA. Using its Precision 3D Micro-fabrication Technology and Advanced Bio-manufacturing Technology, 3D Biotek is a leader and the industry's only dedicated driving force in the research and development of novel 3-dimensional cell culture devices for stem cell/tissue engineering, drug discovery and broad cell biology applications.

3-D Matrix is a medical device company that offers innovative peptide technology, revolutionising the way healthcare professionals manage oozing bleeding during surgery. Headquartered in Tokyo, Japan, 3-D Matrix has expanded across America, Europe, Middle East and Asia. The company collaborates with many researchers, surgeons, healthcare providers and distributors across the world to continually improve on our product. We keep patient outcome at our heart, operating on three main principles: agility, proactiveness and focus. Follow us on Twitter @3dm_emea Sign up to our newsletter for the latest clinical data and product announcements: https://news.3dmatrix.com/newsletter-subscription

3NT Medical is taking ENT endoscopy further, with a family of novel maneuverable, single-use endoscopes purpose-built for the unique needs of ENT specialists.

3P Bio is a Biologics CDMO that assists in delivering advanced medicines for biologics journey.

We are now 3PBIOVIAN! 𝗙𝗼𝗹𝗹𝗼𝘄 𝘂𝘀 𝗼𝗻 𝗼𝘂𝗿 𝗻𝗲𝘄 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗽𝗮𝗴𝗲, 𝟯𝗣𝗕𝗜𝗢𝗩𝗜𝗔𝗡, 𝘁𝗼 𝘀𝘁𝗮𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝗱 𝗼𝗻 𝗮𝗹𝗹 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝗻𝗲𝘄𝘀! 3P Biopharmaceuticals and Biovian join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO. Read more here: www.3pbiovian.com ***** 3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Our service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production. Additionally, we provide fill and finish services for recombinant proteins and viral vectors. With a combined track record of 40 years in process development and analytical methods development, complemented by our experience in process scale-up, GMP manufacturing, and commercial supply, we are equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Our manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of our clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing.

We are North America's premier HLVd testing company and tissue culture licensing technology all over the US and world. From Washington to Germany, we are here to help cultivators de-risk their operations, scale their production safely, and reap the benefits of this exciting crop. Almost every clonally-produced crop has moved to tissue culture plant starts for a reason. Plants that are starting disease-free tend to be highly vigorous throughout their life cycle and focus more energy on growth and secondary metabolite production, augmenting the performance of the crop and economic return. We work with established breeders in every region to ensure that our genetics will keep you compliant and help you succeed where you grow.

About 3S Pharmaceutical Group 3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of "Care for Life, Cherish Life, Create Life" to create a world's leading bio-pharmaceutical company in China.

3T is an immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations. By leveraging the power of the immune system to recognize, target, and destroy cancer cells, 3T's technology is advancing the development of next-generation therapies that have the potential to be safer, more effective, and even curative for difficult-to-treat cancers.

3Z uses advanced disease modeling and behavioral genetics to discover novel drug candidates for CNS disorders.

410 Medical is a medical device company dedicated to developing innovative products that enable clinicians to improve care for critically ill patients. LifeFlow® PLUS, 410's recently approved product, is designed to enhance the speed and efficiency of volume resuscitation, improving care for patients with life-threatening conditions such as sepsis, hemorrhage and cardiac arrest.

Founded in 2017, 48Hour Discovery (48HD) has a powerful technology platform for peptide-based drug discovery. We are reducing the cost, time, and risk of developing new therapies with our innovative target screening strategy to quickly identify the best and most promising drug leads.

4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.

4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our coveted 🧬genomic testing portfolio assesses the tumour genomic alterations by NGS from Tissue or Liquid biopsy for Somatic Mutation Analysis and Germline Mutation Testing for Hereditary and Familial Cancer from peripheral blood to personalize patient care in Oncology. 4baseCare is backed by a highly experienced Advisory board who are leaders in genomics and technology. Among them is Lip Bu Tan, Chairman of Walden International and advisor to Yali Capital, which has invested in 4baseCare. Also on the board is Francis deSouza, a Silicon Valley tech veteran and former CEO of Illumina, who brings over 30 years of expertise in genomics, technology, and healthcare. Milestones - 4baseCare’s journey has been marked by significant milestones in both funding and growth. The company has raised $6 Million in Series A funding led by Yali Capital with participation from Mathew Cyriac. In March 2021, 4baseCare had raised $2 Million in led by Mount Judi Ventures, growX ventures, Season Two Ventures, First In Ventures, and other angel investors. 4baseCare’s test has made a significant impact in Southeast Asia, with over 10,000 cancer patients taking the test. 4baseCare has collaborations with more than 300 oncologists in India. This growing network with oncologists and leading hospitals in India ensures that more patients are able to opt for personalized cancer care.

4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR). We are the first transcatheter MR therapy that directly addresses mitral regurgitation without replacing the native mitral valve, thus preserving the native mitral annulus and left ventricle. The device is positioned supra annular to the leaking native mitral valve to stop the leak from entering the left atrium. Its atrial only fixation ensures minimal disruption to critical cardiac structures within the left ventricle including the chordae tendineae and the left ventricular outflow tract. Our initial focus is to develop a novel therapy for mitral regurgitation (MR), and subsequently for tricuspid regurgitation (TR).

The market for polymeric biomaterials is growing quickly, but despite this growth, it is widely recognised in the industry that the ‘holy grail’ solution has not yet been developed. The ideal biomaterial for use in regenerative medicine must: be biocompatible; promote tissue regeneration; have non-toxic biodegradation, have mechanical properties suited to the host tissue and good handling properties in a clinical environment. Our people have developed a patented range of novel polymeric 3-D printing resin-inks that promise, uniquely, to meet all of the above requirements and offer important advantages over the next best alternatives. The polymers and their degradation products are non-toxic and their properties can be tuned to suit a wide range of tissue regeneration applications. These 3-D printable resin-inks will enable medical implants to be fitted to the exact shape and dimensional requirements of each patient, optimising outcomes in applications such as cancer treatment, degenerative spinal conditions and reconstructive surgery. Initial in-vitro and in-vivo testing has provided strong evidence of the anticipated biocompatibility and tissue regeneration properties that will enable multiple stakeholders in the health sector to benefit from improved treatment options for a range of life-changing conditions, not least the patients themselves.

About 4D Lifetec AG 4D Lifetec is a pioneer on a mission to revolutionize early cancer detection. Our easy and powerful blood tests can detect cancer at its earliest stages (I and II), offering you peace of mind and proactive well-being protection. Sophisticated artificial intelligence (AI) enhances our immunological high-throughput blood assays which in turn enables timely intervention and treatment.

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Execute Relentlessly Join us in creating the future of genetic medicine.

4G Clinical’s suite of innovative RTSM and clinical supply optimization software provides the right-sized support for any phase or trial complexity. At 4G Clinical, all studies are supported by a team of RTSM experts to advise trial teams on the best path forward. Our operations team distinguishes itself through their extensive industry expertise and deep understanding of trial designs and mid-study adjustments. 4G Clinical is committed to helping sponsors and CROs follow the science, wherever it may lead, as quickly and as safely as we can. While we will not discover the next novel compound in the lab, we are doing our part by leveraging our extensive experience and technological innovations to bring speed and agility to clinical trials. As a critical partner throughout clinical development, we can help you seamlessly transition and scale your trials through both protocol and supply complexities to help bring crucial medicines to those who need them, faster. To learn more about how we are tackling the bottlenecks in clinical trials through our innovative solutions, Prancer RTSM® and 4C Supply®, visit us at www.4gclinical.com.

4immune Therapeutics has developed the first CAR T therapy to target and destroy the autoreactive T cells responsible for specific autoimmune disorders. Our multi-component CAR system with its novel adaptor molecule (CAL) bridges autologous or allogeneic CAR T cells to the offending autoreactive T cells to kill the cells and stop the disease in its tracks. Our first therapeutic targets early-stage type 1 diabetes, presently an incurable disease. There are many excellent therapies that successfully tamper down symptoms or prolong onset of the disease and have enhanced the quality of life for many patients. Others are achieving therapeutic value with beta cells transplants for late-stage patients. Our mission is to eradicate the disease-causing cells early in the process before too much pancreatic tissue damage has ensued and conquer autoimmune disorders for life.

4Moving Biotech is a clinical-stage biopharmaceutical company founded in 2020. We are committed to develop first-in-class breakthrough therapies for the millions of patients suffering from osteoarthritis (OA) in the world. 4Moving Biotech is a subsidiary of 4P-Pharma, an innovation accelerator biotech company.

4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer's disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.

Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible.

Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S. patients annually, the first 30 days after diagnosis see persistently high mortality rates of 50-70%. Understand its pathophysiology, including the critical role of Dipeptidyl Peptidase 3, and the latest interventions.

4Tissue is an innovation-led research and clinical development organization. Our mission is to redefine the boundaries of tissue reconstruction, regeneration, and anti-aging, utilizing innovative biocompatible and bioresorbable polymers platform The first product, a bioresorbable injectable hydrogel, is focused on a better cell survival and the full regeneration of adipose tissue for breast reconstruction and augmentation applications.

In 2010, 60° Pharmaceuticals began its mission to build a better world by undertaking research and action focused on aiding in the prevention of infectious diseases. In 2022, we are continuing this mission with a broader focus on product development and commercialization for infectious diseases.

High throughput engineering of cell lines to enhance the design and manufacture of next-generation therapeutics.

An early stage start-up with three products in Pre-IND phase and several complex generics in the pipeline.

7D Surgical is a privately-owned Toronto based company that develops advanced optical technologies and machine vision-based registration algorithms to improve surgical workflow and patient care. 7D Surgical's flagship FLASH Navigation System delivers profound improvement to surgical workflows in spine surgery, providing the promise of similar future advancements in other surgical specialties.

7 Hills Pharma is a clinical-stage immunotherapy company developing a platform of novel, oral small molecules for the treatment of cancer and prevention of infectious diseases. Our compounds are first-in-concept allosteric integrin activators that leverage a unique mechanism of action to stabilize the cell-cell interactions required to mount an effective immune response. Our lead clinical candidate, 7HP349, is the only reported systemically safe immune stimulant that can activate both cellular and humoral immunity.

858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology. 858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell genomics, and innate immunity, 858 scientists are dedicated to the company’s mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies. 858 is headquartered in the biotech hub of San Diego, CA, and maintains lab operations in both San Diego and New York City, providing proximity to leading investigators and scientific talent on both coasts of the US.

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making

908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point of need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in bioprocessing, pharma/biopharma, forensics, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.

The commercially available Stockholm3- test, is a blood-test for early detection of prostate cancer. A3P Biomedical’s Stockholm3 test, combines protein markers, genetic markers and clinical data with an advanced algorithm in order to detect aggressive prostate cancer at early stage.

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

Aanika Biosciences, Inc. provides food security services for large food and agricultural companies. We use synthetic biology to ensure the integrity of supply chains and reduce potential losses.

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ® and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it has a broad network of distributors in more than 20 countries at the international level. aap Implantate AG is a stock listed company. Its share is quoted in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). .

Aardvark Therapeutics is a clinical stage biopharmaceutical company focused on leveraging host adaptive responses through gut-brain signaling for the treatment of metabolic and inflammatory diseases. The company has multiple programs in its pipeline and has received FDA orphan drug designation for its novel drug candidate for Prader-Willi syndrome.

Aarhus University is a higher education institution that focuses on research and academic programs.

Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.

AAT Bioquest®, Inc. (formerly ABD Bioquest, Inc.) develops, manufactures and markets bioanalytical research reagents and kits to life sciences research, diagnostic R&D and drug discovery. We specialize in photometric detections including absorption (color), fluorescence and luminescence technologies. The Company's superior products enable life science researchers to better understand biochemistry, immunology, cell biology and molecular biology. AAT Bioquest offers a rapidly expanding list of enabling products. Besides the standard catalog products, we also offer custom services to meet the distinct needs of each customer. Our current services include custom synthesis of biological detection probes, custom development of biochemical, cell-based and diagnostic assays and custom high throughput screening of drug discovery targets. AAT Bioquest® is committed to constantly meet or exceed its customer’s requirements by providing consistently high quality products and services, and by encouraging continuous improvements in its long-term and daily operations. While we continue to rapidly expand, our core value remains the same: Innovation and Customer Satisfaction. We are committed to being the leading provider of novel biological detection solutions. We promise to extend these values to our customers during the course of our service and to continue to support our customers with new products and services.

AATec Medical GmbH is a biotech company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. The first product candidate is a novel AAT formulation for inhalation to treat emerging inflammatory diseases of the lung and respiratory virus infections.

AaviGen GmbH is a biotechnology start-up located in Heidelberg, Germany. Our primary purpose is the development and commercialization of precision gene therapies for cardiovascular and cardiopulmonary diseases. Our business model builds on the success of the InoCard GmbH, a predecessor that was acquired by uniQure N.V. and subsequently entered into a development alliance with Bristol-Myers-Squibb. Please find our imprint ("Impressum") and data privavy statement ("Datenschutzerklärung") at https://aavigen.com/content/imprint.html and https://aavigen.com/content/privacy.html

AAVnerGene Inc is an innovative company specialized in AAV technologies. It is founded by a group of AAV gene therapy enthusiasts who dream to serve the community, promote and lead the future of gene therapy. Our passion is to solve the bottleneck problems in AAV gene therapy and find more and better cures for all the patients. We believe that hard core technologies are the key to achieve it. With 20 years of frontline gene therapy experience, our team develops novel AAV vectors, methods and strategies that can efficiently produce, deliver and express high quality vectors into specific cells. Our goal is to increase AAV gene therapy efficacy and decrease the cost, making it accessible and affordable to patients. Our highly complex AAV capsid libraries allow us to efficiently select the best AAV capsid for each cell type in a high-throughput manner.

Aavocyte, Inc. is a biotech company registered in the State of Washington in 2019. Aavocyte specializes in developing various precise targeting T cell immunotherapy products to treat solid tumors.

Our mission is to make you stronger. The company was founded by a family directly impacted by three muscle wasting diseases: Duchenne muscular dystrophy, cancer cachexia and COPD. Our fight is personal and our commitment to developing better and more effective therapies is undaunted. AVGN7 prevents muscle wasting in different animal models and can restore muscle mass and strength even after wasting has already occurred. It works when injected directly into muscle or when administered systemically to all muscles. It was also designed to avoid the potentially serious side-effects of other "myostatin attenuating" therapies. AVGN7 for the durable maintenance of muscle mass and function.

AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs in antibody-based medicine development. We aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. We are committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics. Technologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.

AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases with large unmet medical needs. Inflammation is a natural defense mechanism. However, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases, such as: NLRC4 mutation and XIAP deficiency (primary HLH), Macrophage Activation Syndrome (secondary HLH), Adult onset Still's Disease and others. AB2 Bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based diseases. Extensive Phase I, Ib and II clinical trials demonstrated a high tolerance and an excellent safety profile of our drug. We have advanced clinical programs in primary HLH: NLRC4 mutation and XIAP deficiency and in Adult onset Still’s Disease.

Abacus Bioscience is developing a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. Our Antigen-Specific Immune Accelerants (ASIA) are POTENT, SPECIFIC and DURABLE, with broad applications across infectious disease and oncology.

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system's power specifically against cancer cells. Through viral replication within cancer cells, Abalos' arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos' goal is to achieve a quantum leap in immuno-oncology.

ABANZA specializes in the Development & Research of Innovative Medical Devices in the field of Sports Medicine - Soft Tissue repair. With the goal of offering cutting edge surgical tools, ABANZA is supported by a first class medical advisory team in order to ensure that the devices developed are safe and easy to handle, thereby offering surgeons the utmost reliability and ensuring that patients receive the best possible care.

Abata Therapeutics - We are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to our lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). We bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers. We are bold in our mission and purpose and aim for nothing less than a transformative impact on people’s lives.

Abaxis develops and commercializes medical device and innovative technology and services that support best medical practices, enabling practitioners to respond to the health needs of their patients, while operating point of care, onsite diagnostics for human and animal health.Abaxis is now part of Zoetis.

AbBC is a next generation ADC company that utilizes a biological conjugation process to target and deliver Granzyme B to cells for internalization and irreversible toxicity without the requirement of cleavage. Our pipeline of 7 fully human fusion proteins in ongoing preclinical development demonstrate inhibition and regression of tumor growth without toxicity. The platform enables the opportunity to methodically select ADC targets for development of new Granzyme B fusion proteins with major focus in oncology.

Our Mission To create best niche antibody-based biologics for fulfilling the research and development needs in biomedical and biopharmaceutical communities. Our long range goal is to develop therapeutic and diagnostic entities. Core Competence ABB's core competence is in protein designs of biologics for diagnostic and therapeutic applications of immuno-oncological disorders. Specifically, our R&D for therapeutics is focused on biologics that are capable of modulating activities associated with antigenic targets and effector molecules. In addition, ABB has designed and produced a panel of immune related protein reagents that are available to biomedical researchers as investigational tools. History Founded in 2007, AB Biosciences (ABB) has been dedicated to the engineering of therapeutic biologics and research protein reagents. With decades of combined experience in research and development, ABB's scientists have built an efficient platform for the development of these two protein classes. The recombinant replacement of the traditional IVIG (PRIM program) is a great example of our engineering expertise in R&D of an unique protein drug for replacing the traditional serum-derived IVIG. Our Community Massachusetts provides a vibrant and nurturing environment for life science ventures like ABB, in terms of training grants and tax benefits, as well as an abundant talent pool possessing a wide range of expertise. Discovering breakthrough biotechnology and exploring biologics for biomedical study is our mission at AB Biosciences. As part of our commitment to science education, we open our doors to intern students, who can experience firsthand the R&D employment possibilities in the Biotech Industry. More than 15 students/interns have visited our laboratory since 2009.

As researchers are focusing their efforts on determining the biological functions, interactions and regulation of the human proteome, Abbiotec is dedicated to developing cell biology-based research tools that assist scientific discoveries. Besides custom services, Abbiotec offers over 12,000 antibodies, proteins, peptides, lysates and kits to assist researchers in understanding human biology and diseases at the cellular and molecular levels.

AB-BIOTICS is a leading probiotics player inspired by developing probiotic solutions at the forefront of an expanding field. Whether you are interested in unique, patented strains with characterized mechanisms of action, premium probiotic solutions targeting specific therapeutic areas, or finished products with easily-communicated benefits, our agile approach allows us to adapt to your needs. With science at the heart of everything we do, our strains, blends and market-ready products are supported by robust scientific documentation. Our global footprint gives us a unique view of the ever-changing probiotic landscape enabling us to offer regulatory support in not only supplements, and functional foods but also OTC and medical applications to meet the needs of consumers worldwide.

AbboMax is a biotechnology company that offers high quality, diagnostic-grade products and professional custom services for research purposes.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.htm

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

At Abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That's why we're constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.

Specialized in cell culture, Abcell-bio has a 10-year background and experience in Stem Cell Research and Development. Abcell-bio team is composed of experts that can advise you for your research projects. Our technical team is trained to produce high-quality products in the fields of hematopoiesis and vascular biology. We can process several cell types extracted from: * Cord Blood: CD34+ cells, CD133+ cells, CD34- cells, MonoNuclear Cells (MNCs), Endothelial Progenitor Cells (EPCs) * Umbilical Cord (Human Umbilical Vein/Arterial Endothelial Cells (HUVEC, HUAEC) We also created Cell Culture Media to match your needs for these particular cell types. Please contact us for more information

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

Abcentra develops oxidized LDL blocking therapeutics to treat cardiovascular inflammation. Many patients worldwide live with substantial risk of a major cardiovascular event because of chronic inflammation. This includes patients who have recently had a heart attack, and patients with calcific aortic valve disease. It also includes patients with chronic inflammatory diseases such as psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Abcentra is developing a potential solution for patients with cardiovascular inflammation – therapeutics that target oxidized low-density lipoprotein (LDL). Oxidized LDL is a well-described pro-inflammatory mediator that is strongly implicated in atherosclerotic cardiovascular disease, type 2 diabetes, calcific aortic valve disease and several inflammatory diseases. Oxidized LDL blockade offers a promising new way to treat cardiovascular inflammation and meet large unmet medical needs in cardiovascular disease. Our pipeline focuses on developing oxLDL-blocking therapeutics for patients who have significant residual risk of major a cardiovascular event from chronic inflammation (see Pipeline). Our lead candidate, orticumab, is a fully-human, first-in-class antibody that targets a specific oxidized LDL epitope. Orticumab is currently in phase 2 in psoriasis patients with cardiometabolic risk factors. Several additional indications are also being pursued. Abcentra has offices in Los Angeles. The Company’s ownership includes world-renowned Los Angeles hospital, Cedar-Sinai. Our team includes experienced drug developers and founding scientists that pioneered our approach to oxidized LDL blockade.

AbCheck discovers and optimizes human therapeutic antibodies with one of the industry’s most versatile technology platforms. Tailored to specific needs and desired Target Product Profiles, AbCheck leverages both cutting-edge (e.g., microfluidics, rabbit mass humanization) and state-of-the-art (e.g., phage/yeast display libraries) technologies to provide high quality leads. The company has proven its capabilities in multiple partnerships throughout the U.S. and Europe. AbCheck is a wholly-owned subsidiary of Ampersand Biomedicines, a Flagship Pioneering Company.

AbClon was founded in 2010 by a consortium of Korean and Swedish experts in antibody development. Our mission is to cure once incurable diseases such as cancer.

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.

AB Enzymes is an industrial biotech company specialized in enzymes and their applications. The company is part of Associated British Foods and represented worldwide. Our offices are located in Brazil, China Germany, Finland, Singapore and USA. Our products range from food grade enzymes for baking and beverages, grains and vegetable oil seeds processing, to enzymes for animal feed and technical applications: pulp & paper, textiles and laundry detergents. We partner with our diverse and unique customers to support them in their process optimization needs.

Abeomics Inc. is founded by scientists for the scientists. Our immunologists, cell biologists and business professionals have contributed for over 25 years to the growth and success of global companies including BD Biosciences, eBioscience and IMGENEX Corporation. We bring our experiences to develop well-validated and specific antibodies by traditional hybridoma technology and by genetic engineering to produce recombinant mouse and rabbit monoclonal antibodies.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Abera Bioscience AB is a Swedish biotech company headquartered in Stockholm. We are dedicated to develop novel vaccines and vaccine development technologies to improve health worldwide. The Company's unique expertise in Biochemistry and Molecular Microbiology is based on many years of research and has generated a patented platform technology for the development of novel vaccines. Abera brings Outer Membrane Vesicle (OMV) technology to the next level by decorating their surface with a palette of antigens at a high density. To this end, Abera has adapted a natural system for bacterial protein secretion into the most efficient and versatile system for surface display of antigens known today. Abera's platforms allows the development of efficient multivalent, multi-stage vaccines for oral and nasal administration. It also enables faster and more cost-effective production. Abera's OMV-based vaccines can be manufactured within 14-30 days.

Abcepta is a biotechnology company that specializes in developing primary antibodies and custom services for research and drug discovery.

Abilita Therapeutics is a biotechnology company focused on redefining the druggable landscape for multi-span membrane proteins, including G Protein Coupled Receptors (GPCRs), transporters and ion channels. We are building a rich pipeline of high-value assets for such targets, with the goal of becoming the leader in discovering and developing first- and best-in-class antibody therapeutics.

Ability Biologics is dedicated to developing innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The company utilizes its powerful AbiLeap™ discovery engine, which combines massively parallel, continuously learning AI with advanced cell targeting technology, to develop the most potent and selective antibody therapeutics for areas of great unmet need.

We are lateral flow CDMO experts based in the UK supporting global customers bring their assays to market, from proof of concept, through optimisation and scale up to routine manufacture, along with full-service regulatory consultancy support. Get in touch: email info@abingdonhealth.com today. We believe that by developing the high quality, effective lateral flow rapid tests combined with our manufacturing experience and scale, we can provide the means to accelerate access to rapid testing. This means faster diagnosis and screening in the field, accelerating the ability of decision makers to deploy a more rapid response to results. We are committed and honest in all that we do. We value the quality and contribution of all, priding ourselves on building long-lasting and trusting partnerships – because by working transparently with customers, partners and colleagues, we are better together. With an exceptional pedigree in developing and manufacturing rapid tests Abingdon Health are expert in responding to our customers varied needs with specific and customisable solutions. Our mission: To improve life by making rapid results accessible to all. By providing the best lateral flow rapid test solutions, we believe we can support the increase in access to diagnostics across many industries and locations throughout the world. Faster access to results allows for rapid decision making and solutions. This ability has a significant role to play in improving life in so many ways.

Driven by a bold founding vision: Empowering patients from within, Abintus is pioneering potentially curative, off-the-shelf genetic medicines that engineer cells directly inside the patient’s body, also termed in vivo. These therapies are based on Abintus' clinically proven Modular Delivery Platform (MDP). The company’s two initial, fit-for-purpose, In Vivo programs are: 1. Highly selective gene expression targeting cell type/state via synthetic biology (e.g., In Vivo CAR-NK/T/Treg, In Vivo TCR-T) with applications across multiple gene delivery systems (e.g., AAV, lenti, adeno, retro) and therapeutic areas including leukemia, solid tumors, autoimmune, infectious, and genetic disease. 2. Simultaneous engineering of a diverse repertoire of active innate and adaptive immune cells (e.g., In Vivo CAR-X) with applications in diseases such as lymphoma and solid tumors. Abintus is leveraging over 20 years and $275 million of prior technology advancement for in vivo engineering including the treatment of over 350 patients through Phase 3 registration trials. Our company name comes from the Latin words “ab intus”, which means “from within”. We chose this name for 3 reasons: 1) Patients: We are pursuing product candidates that are designed to directly empower patients’ own immune cells to fight their disease from within. 2) Science: Our team is committed to scientific excellence and continual learning. Our differentiated technologies have the potential to directly reprogram activated immune cells “in situ”, or from within. 3) Culture: We believe our ability to achieve our vision will come from within - by building a performance-driven culture that prioritizes career development and rewards outstanding contributions. Abintus’ initial funding syndicate included Takeda Ventures and The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP). Abintus Bio, Inc. (“Abintus”) is headquartered in San Diego. www.abintusbio.com.

Abiologics is pioneering a new class of supranatural and programmable biologics, called Synteins™. The Abiologics platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to create Synteins with powerful, desirable pharmacological properties, redefining what therapeutics can achieve for patients across a range of disease areas. Abiologics was founded by Flagship Pioneering in 2021.

Based in Danvers, Massachusetts, USA, Abiomed, Inc., part of Johnson & Johnson MedTech, is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit www.abiomed.com. Important Safety Info: https://bit.ly/39kvb47

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is a potential first-line advanced therapy for moderately to severely active ulcerative colitis designed to enhance the expression of a single micro-RNA, miR-124, which is a natural regulator of the immune response. Abivax’s focus is on indications where existing treatments have left patients with significant unmet needs, and where they believe their drug candidates have the potential to be meaningfully differentiated from currently available therapies.

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world's most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients' team – helping them advance today's ideas into tomorrow's medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL acquired all the patents and IP rights from TherapyEdge, Inc. in 2005 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. COVID-19: CE mark (07/2020)

Ablexis offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains for human therapeutic antibody discovery. AlivaMab Mouse strains are uniquely designed to be better for human therapeutic antibody discovery and development, for applications across antibody drug discovery including highest quality IgGs, singe-domain VH, multispecifics, ADCs, CARs, TCRm, and other modalities. The AlivaMab Mouse strains are well-documented for generating drug-like antibodies with broad combinatorial and somatic diversities, high affinities, specificity, and excellent developability properties. Users of AlivaMab Mouse include the world’s largest pharmas, public and private biotechs, and leading academic institutions. AlivaMab Mouse-derived antibodies in clinical development span formats including IgG, multispecific, ADC, and CAR. Many partners use AlivaMab Mouse at Ablexis’ sister company, AlivaMab Biologics, a leading provider of services in antibody drug discovery, engineering, and protein sciences. Visit us at www.ablexis.com to learn more. For inquiries about licensing the AlivaMab Mouse, contact us at info@ablexis.com.

ABM is an innovative drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers including GBM, as well as brain metastasis from melanoma, lung cancer, and breast cancer. It was founded in 2015 by a group of biotech and pharmaceutical industry veterans with more than 20 years of experience in the development of neurological drugs and enterprise management from North America. Since establishment, ABM is building its broad proprietary pipeline internally to construct a brain medicine R&D platform through collaborations with CROs and partners.

Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Our goal is to have at least one antibody to every human expressed gene in human genome. In Phase I of our business plans, we vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. There products are marketed through a combination of E-commerce based direct sales and a multi-tiered, sales network of over 49 distributors around the world. Starting from Year 2009 to 2013, in Phase II of the business plans, we have diversified into the systems arena focusing on antibody pairs, ELISA kits and instrumentation for rare cell isolation. In Phase III, we focus on in vitro diagnostics development concentrating on non-invasive, liquid biopsies of circulating tumor cells, ctDNA, and exosomes for precision medicine. Now in Phase IV (Year 2017 and later), we have focused on drug development specializing on immunotherapy. The value-added business has set the path of company's future growth and provided opportunity for Abnova to contribute to the biotech industry at large. We welcome researchers, biotech, and pharmaceutical companies to work with us and succeed together!

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.

Abolis is a French company delivering high-impact innovations in biotechnologies that supports industries in their transition to build a better future in collaboration with Nature. We provide tailor-made industrial solutions based on micro-organisms. Founded in 2014, Abolis is made up of a team of over 54 people, sharing a scientific and humanist ambition. Determined to become a key player in the transformation of manufacturing, we combine our expertise in biology, fermentation, IT, robotics, analytics and industrial property to reinvent the future of numerous industries - from food to healthcare, cosmetics and chemicals. We help industries make the ecological transition by rethinking their production models We rely on biotechnologies and the untapped potential of micro-organisms to develop new bioproduction solutions that are economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients. We take up the industry's current challenges by: ·      Using renewable raw materials ·      Relocate essential production and secure supply chains ·      Designing biocompatible products less toxic for the environment ·      Reducing greenhouse gas emissions Abolis is providing tailor-made industrial solutions, based on microorganisms Because each customer has its own unique story and challenges, we cultivate a multidisciplinary, tailor-made approach. Science, economics, intellectual property, industrial realities: each of our answers is based on the best possible practices. Thanks to our advanced knowledge of micro-organisms, we combine chemistry and biology, paving the way for a more sustainable future. We are… independent in thought and action rigorous in our approach and the way we work creative because we never stop innovating, while remaining pragmatic ambitious because we are passionate and determined to make a difference

Abologix is a biopharmaceutical company based in Geneva, Switzerland. The company is a spin out from the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva and the Geneva University Hospitals. The company is developing two monoclonal antibodies that selectively block two novel pharmacological targets. Several oncological medical indications are being pursued.

Abound Bio was acquired by Galapagos. Abound Bio is a US company whose mission is to generate novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious disease. Galapagos acquired Abound Bio in 2022.

Abpro Corporation is a biotech company developing next-generation antibody therapies. Established in 1897, Abpro offers competitive salaries and generous benefits with the opportunity to learn and grow in an employee-driven culture. They are focused on developing antibody therapies to improve the lives of patients facing severe and life-threatening diseases.

Antibody-based therapeutics for tissue repair applications

We provide licenses for the commercial use of our software, OpenGenomeBrowser, as well as support, development and consulting services help to advance your research and discoveries.

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.

AB Science is a clinical-stage company designing and developing novel drugs to address diseases with a high unmet medical need, including inflammatory diseases, pathologies affecting peripheral and central nervous system and cancers. Our science is based on a highly integrated research network associating a state-of-the art drug discovery department to the highly valuable knowledge of our scientific committee’s members in order to develop original and innovative therapeutic strategies. This is illustrated by masitinib, our main clinical compound, which was designed as a disrupting mast-cells and glial-cells targeted therapy, through inhibition of key tyrosine kinase targets (c-Kit, CSF1R, FYN, LYN), which is currently developed in four therapeutic areas: neurology (amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s Disease), inflammatory diseases (mastocytosis, severe asthma), oncology (prostate cancer, pancreatic cancer) and viral diseases (Covid-19). AB Science intends to push therapeutic innovation forward with its second clinical compound AB8939 in oncology.

Absco Therapeutics, Inc. (AbscoTx) is a stealth phase immune engineering company born out of collaborative work between clinicians at MGH and BWH, engineers at MIT, and an experienced team of biotech entrepreneurs and translational medicine experts.

Our mission at Abselion is to simplify protein quantification for the scientists making crucial decisions to accelerate the development of biotherapeutics. Our tools help researchers to develop the medicine of the future and to find the best ways to produce new biomolecules. We focus on convenient tools with high degree of automation and low hands-on time to accelerate access to actionable data. Our award-winning Amperia system, built on proprietary Redox Electrochemical Detection (RED) technology, brings a new approach to biologics and viral-vector quantification for confident and cost-effective automated, at-line titre measurement, at any bench or bioreactor. By enabling agile and straightforward access to titre data, we empower scientists to focus on the decisions that can drive bioprocess optimisation and innovation. We are a dynamic, interdisciplinary team working at the intersection of biology, nanotechnology and data science. We value a flat hierarchy, where everyone is encouraged to share their ideas and to follow their passion.

Absolute Antibody Ltd is a UK-based biotechnology company founded in Oxford in August 2012. It specializes in recombinant antibody technology and operates from an ISO 9001:2015 certified facility in Redcar, England. The company focuses on improving antibody reproducibility through genetically defined production methods. The core services include recombinant antibody production using mammalian HEK and CHO cell lines, allowing for animal-free and serum-free manufacturing. They also offer custom engineering, providing antibody sequencing and reformatting into over 180 formats, as well as bespoke projects for pharmaceutical, diagnostic, and academic clients. Their product range features over 21,000 defined recombinant antibodies, ensuring consistency across batches, and includes specialized formats for various applications. Absolute Antibody serves a diverse clientele, including 14 of the top 15 pharmaceutical companies by R&D expenditure, biotechnology firms, and academic institutions. The company emphasizes collaboration in therapeutic antibody development and assay standardization.

Absolute Biotech specializes in antibody reagents, kits and services, adding value to existing antibodies through annotation, validation, sequencing, engineering and recombinant manufacturing. Our company unites multiple antibody-centric brands to offer customers worldwide the full breadth of antibody-related products, services and expertise for research, diagnostic and therapeutic applications. Our mission is to serve as “antibody curators” for customers worldwide, treating each antibody like a work of art to deliver unique and absolutely defined reagents that empower scientists. Brands within the Absolute Biotech family include: - Absolute Antibody, experts in antibody engineering and recombinant antibody technology - LSBio, leaders in IHC validation with a comprehensive catalog of antibodies, proteins and ELISAs - Kerafast, which makes unique laboratory-made research tools easily accessible to the global scientific community - Nordic Mubio, which develops antibody and flow cytometry reagents according to ISO 9001 guidelines - Everest Biotech, specialists in anti-peptide and antigen affinity purified goat polyclonal antibodies - Exalpha, which offers cutting-edge antibodies, reagents, kits and custom IgY services

Ab Studio Inc. is a biotech company in the San Francisco Bay Area. We have extensive knowledge and expertise in the discovery, optimization, and development of therapeutic antibodies with complex designs, and combine conventional approaches with computer-aided antibody design in this process. Ab Studio believes in 'Quality by design' and aims to address current limitations in the field of therapeutic antibodies with novel technology platforms including multi-specific and internalization antibodies. Please visit our website for more details and partnership/service opportunities http://www.antibodystudio.com

ABT 360 manufactures media for embryo transfer. The media is used to collect, store and transfer embryos from cattle and horses and is used for the veterinary assisted reproduction industry.

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive partnership with Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and FTO. For over 20 years, AbTherx’s passionate, innovative, and collaborative team has pushed the boundaries of antibody discovery technologies, leading to over 1,000 successful antibody discovery campaigns and 13 marketed therapeutics. AbTherx’s industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes.

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company that develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is focused on developing therapies for a range of conditions.

Abveris is a world leader in in vivo antibody discovery and a division of Twist Bioscience. We partner with leading biopharmaceutical scientists across diverse organizations to discover and develop antibodies for diverse pharmaceutical and industrial applications.

Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy using proprietary antibody generation platforms. The company is located in the Eastern Pennsylvania biotechnology/pharmaceutical hub 30-miles west of Philadelphia. Unique to Abzyme is our proprietary and highly engineered eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody affinity maturation in combination with a FACS single cell sorting approach to identify desired antibodies. Abzyme’s modular antibody discovery platform incorporates a real-time screening ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity. Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.

The Acadian Seaplants Story Established in 1981, Acadian Seaplants is a family-owned business that revolutionized the seaweed industry in Canada and around the world. Over forty years later, Acadian is the world leader in marine plant products for people, animals and plants. With employees in seventeen countries, Acadian is a fully-integrated, biotechnology manufacturer of premium agricultural products for animals and plants, cultivated sea-vegetables and functional ingredients derived from select species of marine plants. The Seaweed Specialists Acadian is an ardent guardian of the marine environment. Decades of research has proven that properly managed, seaweeds are a rapidly renewable marine resource. A pioneer in hand-harvesting technologies that protect the habitat, Acadian is a recognized global leader in the sustainable management of the seaweed resource. Acadian’s products are also eco-efficient, eco-friendly and Acadian is committed to energy efficiency and waste reduction at all stages of manufacturing. Product Excellence Backed by over 40 years of extensive, global scientific research, Acadian products are exported to over 80 countries around the world. Unequalled in science, customer support, and delivering products with proven results, Acadian has two divisions - Acadian Plant Health™ and Human and Animal Wellness™. Both of these divisions have one thing in common – they improve health, productivity and sustainability.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Acandis GmbH is a medical technology company based in Pforzheim, Germany, founded in 2006. It focuses on developing, manufacturing, and marketing products for the treatment of neurovascular diseases, particularly in acute and preventive stroke treatment. The company is recognized for its innovative approach and has been named one of the TOP 100 most innovative SMEs in Germany multiple times. Acandis offers a variety of high-tech medical devices, including thrombectomy devices for removing blood clots, embolisation devices to block abnormal blood flow, stents to keep arteries open, and catheter systems for minimally invasive procedures. These products are developed in collaboration with healthcare professionals to ensure they meet clinical needs effectively. With a dedicated team of around 107 employees, Acandis aims to expand its reach internationally, providing essential tools for stroke prevention and therapy to endovascular specialists.

Acarix is a Swedish medical device company that innovates solutions for rapid Coronary Artery Disease (CAD) rule-out. The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing chest pain with suspected CAD and is designed to help reduce millions of unnecessary, invasive, costly diagnostic procedures. CADScor®System rapidly calculates a patient-specific CAD-score non-invasively with 96% confidence. Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Austin Community College is a nationally recognized two-year college serving Central Texas. ACC is focused on student success and providing affordable, flexible pathways to help students reach their education goals, learn new job skills, or advance their career. Check out our students'​ inspiring stories at austincc.edu/iamacc

AcceGen Biotech proudly develops innovative technologies for the pharmaceutical, biotech and specialty ingredients markets. We are committed to supplying the best products and services with global manufacturing, development expertise and advanced technologies to enhance the overall quality of life. AcceGen Biotech developed significant expertise in cell and genomic research. We provide a variety of high-quality human/animal cells, cell media/kits, cell-derived molecular biology products, gene-based assay kits, Clones, Fish probes and Sequencing products for research use. AcceGen Biotech offers custom cell line generation, microRNA sponges and microRNA Agomir/Antagomir services to simplify the gene research. The aim is to accelerate scientific discovery related to genetic analysis available to academic researchers as well as commercial enterprises. AcceGen Biotech has permanent facilities in Fairfield (New Jersey). We take care of our customers and their global, regional or local requirements. We welcome potential partners and distributors to explore our business all over the world.

The company providesmolecular biology services includingproduction of antibodies, GPCRs, kinases, nuclear receptors, and many other classes of drug targets and therapeutic proteins

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

Accelerated Biosciences Corp. is commercializing human trophoblast stem cells isolated from the trophectoderm of embryos from women with ectopic pregnancies. hTSCs are ethically sourced and have immune-privileged characteristics. It is an abundant and dynamic pluripotent stem cell platform for basic research, disease modeling, toxicology, drug discovery, and cell therapy.

Accelergy uses advanced catalysts and state-of-the-art process technologies to transform natural gas, biomass, and/or coal into clean specialty products and transportation fuels. Accelergy’s state-of-the-art Hydroconversion to X (where X = solvents, lubricants, performance fluids, or fuels) "HDX" technologies economically convert abundant natural resources into clean, low carbon products.

Accell Clinical Research is an international full-service Contract Research Organization (CRO) managing Phase I-III clinical trials for 15+ years across Europe and Eurasia. With a local presence, including highly qualified medical staff and legal entities in the region, we successfully recruit patients both in the EU and outside the EU in post-Soviet countries (CIS). All together we provide guaranteed fast patient recruitment in 20+ countries across the region. ⬇︎ ACCELL'S SERVICES for Phase I-III clinical trials: • Strategic guidance and trial set-up: • Feasibility research and site selection • Study documentation development • Regulatory support • Clinical supply import and management • Selection and management of clinical study vendors • Project management • Clinical & medical monitoring • Data management and biostatistics • Quality assurance • Safety management • TMF/eTMF services • Functional outsourcing of a clinical team ⬇︎ THERAPEUTIC AREAS • Oncology • Cardiovascular • Immunology • Gastroenterology • Neurology • Endocrinology

Accellix aims to enable cell and gene therapy companies to meet their key product QC requirements by providing fast and actionable multi-parameter results using the Accellix instrument and a room temperature stable cartridge. Accellix will continue to identify markets where its platform and assay migration expertise can be best combined to create meaningful opportunities.

Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.

Access Genetics, LLC is a privately held Minnesota-based company founded in 2001 by Dr. Ronald McGlennen, an internationally recognized molecular diagnostics expert with over a decade of experience in implementing and developing molecular genetic laboratories. As a medical technology service company, we offer turnkey solutions to assist laboratories in the implementation of molecular genetic testing by recommending a tailored, cost-effective and state-of-the-art suite of hardware, software, prepackaged materials and supplies, process guides, custom tools, staff training, technical support, telemedicine interpretations, and other optional consultative services. This comprehensive service package makes Access Genetics unlike other companies in the genetic testing market that may only provide a piece of the testing puzzle. Our Mission is to improve the availability and utility of diagnostic genetic testing through a base of laboratory providers using our Web-Enabled DNA Testing Model. We partner with qualified clinical labs to enable them to build a quality in-house molecular genetics program that is simple, fast, economical and complete.

Accession Therapeutics Limited is based in Oxford, UK. Its platform technology, TROCEPT, is delivering a proprietary internal pipeline for Accession Therapeutics with significant innovation opportunities available for partnering. Products from the platform are expected to have strong clinical and commercial potential, convenient intravenous administration for better patient access and compliance, and a competitive cost of goods sold via an established manufacturing route. The potential of TROCEPT is illustrated in the animation here. Accession Therapeutics has raised >$66m to date backed by high net worth individuals, iGlobe Partners, Primavera Venture Partners, Birk Venture and other international biotech investors.

Like it's predecessor, the Infectious Disease Reseach Institute (IDRI), the Access to Advanced Health Institute (AAHI) focuses on creating technologies that improve the body's response to disease.AAHI is a nonprofit biotech organization that works on a comprehensive approach to developing new solutions for infectious disease.

Access Vascular is offering our suite of vascular access solutions designed to help clinicians address common catheter complications that afflict patients while helping save hospitals time and money.

Accro Bioscience (Suzhou) Limited is a clinical-stage biotech company with a core focus on molecular mechanisms of regulated cell death such as necroptosis, pyroptosis, and ferroptosis. The company is a leading biotechnology company based in China and is privately-held. Accro Bioscience is dedicated to the development of treatments for inflammatory conditions and has recently announced a Series B funding round of over $50 million.

AccuBreak Pharmaceuticals is a pharmaceutical company that specializes in creating tablets that can be easily divided into smaller, exact doses, aiming to make it safer for patients to adjust their dosage.

AccuGenomics is a biotechnology company that specializes in a unique spike-in control technology to enhance the accuracy of clinical sequencing tests for low abundance biomarkers and infectious pathogens.

Accuitis Pharmaceuticals, Inc. is a US registered company with commercial operations located in Atlanta, GA. Accuitis is a participant in the Georgia Research Alliance Venture Lab program and our key technology was discovered by Emory University. We are engaged in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. Our lead product is a transformational first in class treatment for Rosacea.

Founded in November 2020, AccuPulse is dedicated to become a globally leading innovator in cardiac electrophysiology industry. The core team members come from companies such as J&J, GE, Acutus Medical and Abbott with in-depth experience in R&D, registration and commercialization of cardiac electrophysiological medical devices. The company has built R&D centers in both China and the United States, and the company is backed by top scientists, physicians and famous venture capital firms.

Since its inception in 2013, AccuraGen has pioneered the development of liquid biopsy technology to facilitate more personalized cancer treatment. Our international team of scientists brings together the best of industry with the best of academia. We currently operate from two locations: Menlo Park, California and Shanghai, China.

Founded in 2021, AccurEdit is dedicated to developing and commercializing safe, effective, and target-specific in vivo gene editing therapies, along with delivery technologies, for the treatment of severe or life-threatening genetic and acquired diseases worldwide. AccurEdit is advancing multiple pipeline products. ART001 (ATTR) and ART002 (PCSK9), its first two leading assets, have entered into human clinical trials and both demonstrate the potential to be the Best-in-Class or First-in-class therapies in respective fields. AccurEdit has established an industry-leading end-to-end technology platform for in vivo gene editing therapies. AccurEdit is the first company in China to advance its LNP-based in vivo gene editing product into human studies and the only company in the world to obtain IND clearances for in vivo gene editing product in both China and the United States.

Accu Reference Medical Lab is a state-of-the-art medical testing laboratory service that provides a complete range of tests for diagnosis, screening or evaluation of diseases and health conditions. We are certified under the federal government’s Clinical Laboratory Improvement Amendments (CLIA) and operate in compliance with all governmental regulations. We use the latest diagnostic technology. As new medical tests become available, we update our list of services. Our laboratory technicians are well trained and have many years of experience, providing the most accurate and precise testing results. We also continuously strive to improve the quality of our testing, data handling and reporting through integrating robust technique and technological advancements. Accu Reference Medical Lab is an equal opportunity employer.

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy.

Accuryn Medical is a predictive health company that is developing the next generation of smart sensors and artificial intelligence. Currently, Accuryn Medical is developing a predictive health platform to help medical teams better predict adverse outcomes in critical care settings. The Accuryn® Monitoring System is not cleared for prediction of disease states or clinical conditions.

We are a clinical stage diagnostics company committed to developing and commercializing novel products for the treatment and management of all cancers.

Overview: AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. The company’s hybrid based approach, which uses computational drug design followed by wet lab validation, greatly reduces the time and cost necessary for traditional drug discovery efforts. Accutar is committed to building strong partnerships, and collaborates across academia and the pharmaceutical industry to solve interdisciplinary problems. The company was founded in 2015 and has locations in both Shanghai, China and New York, NY. Products & Services: Accutar offers two software packages: Chemi-Net and Orbital. Chemi-Net is a molecular graph convolutional network for accurate drug property prediction. It was recently shown to improve the accuracy of ADME property prediction by a large margin in comparison to the widely-used methods https://arxiv.org/abs/1803.06236. Orbital is a deep neural network based docking platform. The prediction accuracy of protein-ligand complex (holo) from ligand free state (apo) structure is significantly higher than current standards. In addition to these tools, AccutarBio offers services in virtual screening for lead discovery; intelligent-SAR for lead optimization and drug property prediction.

Growing resistance against antibiotics is quickly becoming the greatest threat to human health. The use of antibiotics in food production is partly to blame. With that backdrop, it was a small sensation when ACD Pharma in 2018 got the approval for a phage product that efficiently removes a harmful bacteria and outbreaks of a disease which has antibiotics as its only cure. Bacteriophages, or phages, are the world most numerous organisms. Its only function is to attack and kill their specific target bacteria, and in the process multiply. They are natural predators of bacteria, and Nature’s own biocontrol tools, efficiently ensuring that no single bacterium becomes too dominant in an environment. In other words, bacteriophage-based products do not affect the commensal microflora of the patient or aquaculture farm water, which is a common side-effect of broad-range antibacterials. Our bacteriophage therapy project started in 2011 and has seen promising results of phage therapy against many bacterial pathogens common in aquaculture. Our first approved product, Custus®YRS, contains five hundred thousand billion Yersinia-killing bacteriophages per liter. As these are added in high density to production water or bio-filters an upper limit for the concentration of Yersinia ruckeri that can possibly prevail in the water is quickly established. If the infection pressure is already higher than this limit, it will quickly fall below the limit and prevent the spread of bacteria to healthy fish. We have several other applications in the pipeline and look forward to launching bacteriophage-products in the future.

AcelaBio, wholly owned by The Alimentiv Health Trust, was incorporated in 2020 and aims to meet the growing clinical research demand for quality and efficiency in laboratory service. Our state-of-the-art facility, located in San Diego, California, is built on deep expertise in clinical and precision medicine research and our scientific and operational experts are dedicated to delivering reliable, high-quality data.

Our mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning. To fulfill our vision, we work with our customers by becoming key technology partners, boosting their discovery workflow with the most innovative solutions. Science, research, innovation, and development are the founding pillars of our company.

Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinson's, diabetes and cancer. Acelot's platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases. We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS. Our platform was invented by UCSB Computer Science Professor Dr. Ambuj Singh. Acelot's first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimer's. ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a robust discovery pipeline.

ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates. ACELYRIN is embedding a corporate culture of Courageous Caring™ -- placing patients first and embracing the concept that all of us are better than any one of us -- as we seek to addresses the most basic human needs: to live a productive life free from diseases.

Calspan is an industry-leading research and testing partner to the great innovators of the aerospace and automotive industry. We assist both industries in overcoming developmental and technical challenges to ensure their creative concepts become viable commercial products. Calspan's business units work with integrity, collaboration, and years of experience to accelerate the world's greatest innovations on land or into the sky. Our operations span across the United States. Calspan's corporate headquarters are in Buffalo, NY and the headquarters for Calspan Flight are in Niagara Falls, NY. Additional test pilot training is conducted at Patuxent River, MD and Edwards Air Force Base, CA. Our main automotive testing campus is in Buffalo, NY with breakout locations in NY, PA, NJ, MD, MI, FL, NC and TN. Calspan Test Solutions provides aerodynamic testing, including hypersonics, and aerodynamic model solutions is in St. Paul, MN. Lastly, Calspan Test Systems provides R&D, T&E engineering and manufacturing solutions with locations in Newport News, VA, Hampton, VA, San Diego, CA, and Ronkonkoma, NY.

Ace has been delivering custom pharmaceutical solutions for specific patient needs for over 30 years. With our own registrations, compounded products and cosmetics we provide a solution for pharmacists all over the world. In addition we make clinical trial medication on behalf of our customer.

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.

aceRNA Technologies Co., Ltd. is a biotech startup established in 2018 based on RNA design technology developed in synthetic RNA biology research by Prof. Hirohide Saito at Kyoto University. We are developing "smart gene therapy” (mRNA-based and virus-base) that enables control of therapeutic transgene expression in cell-type and -state specific manner. By that, we are committed to develop new therapeutic approach, such as in vivo cell programming.

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Ace Vision Group, Inc. (AVG) is a privately held U.S. ophthalmic medical device company developing Laser Microporation Therapeutic technologies to address age-related eye dysfunction and address the eye's natural biomechanical performance. AVG's Laser Scleral Microporation (LSM) is a therapeutic eye laser treatment that aims to restore visual function naturally without sacrificing distance vision. AVG's brand promise is to provide the field of ophthalmology with innovative devices, Microporation Therapeutic procedures, and education for the treatment of age-related ocular dysfunction, disability, and disease.

Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Achira is building atomistic foundation simulation models to power the future of drug discovery.

Acidophil is an innovation company that uses technical and business information together with bio-chemical capabilities to create, manage and co-finance new products and biotechnology businesses in human health, agriculture, and animal health. With operations in both the United States (Lutherville, MD) and United Kingdom (Cambridge), Acidophil takes a global approach to innovation, management and investment that reflects the international perspective of its team and founders. Acidophil exploits a virtual business development model to enable capital efficient innovation in collaboration with scientists, entrepreneurs, corporations and investors who are interested in addressing global market needs.

ACIES BIO is a biotechnology contract research organization offering state-of-the-art R&D services to pharmaceutical, chemical, biotech and food industries. We provide full support from idea conceptualization through research to product development. Combining biotechnology and synthetic organic chemistry expertise, we offer a comprehensive service, covering all key development steps for efficient production of biosynthetic natural products or their semi-synthetic derivatives, as well as entirely synthetic compounds. Working with some of the largest international companies, we provide to our clients full R&D support both in our laboratories as well as on-site at the client’s facilities. With experience and know-how in natural product (bio)synthesis, milestone-based approach to projects, innovativeness and flexibility, as well as competitive pricing, ACIES BIO aims to become the premier partner in R&D outsourcing for pharmaceutical companies.

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

Acino is a Swiss pharmaceutical company headquartered in Zurich, with a clear focus on high-growth markets. We deliver quality pharmaceuticals to promote affordable healthcare and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. For more information: www.acino.swiss *** By engaging with Acino on LinkedIn (or any other Acino social media channel), you are agreeing to our Social Media Community Guidelines. If you do not agree to them, do not engage with Acino on social media. Please read our detailed community guidelines carefully here: https://acino.swiss/social-media-community-guidelines ***

Aclairo's experience as FDA supervisors, reviewers, and industry strategists has forged a unique comprehension of the product-specific complexities of pharmaceutical development. The Aclairo advantage is our experience-based approach to providing strategic, scientific and regulatory services. This has proven to be our greatest asset in focusing and streamlining our clients' development efforts, reducing both time and costs.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Aclid is a security and safety platform for synthetic biology. The company's DNA screening solution for biosecurity, export control compliance, and EH&S keeps researchers safe and protects national security.

Acobiom is specialized in the identification of new Biomarkers and in the development of innovative Diagnostics in Translational Research and Precision Medicine. The company provides also customized services in genomics, transcriptomics, bioinformatics and biostatistics (data science), thanks to its technology platform and its scientific expertise. For more information about Acobiom, please contact the company by email: busdev@acobiom.com, or visit its website: www.acobiom.com.

ACON Laboratories is an international diagnostic and medical device company with our corporate headquarters in San Diego, California USA. For more than 15 years, ACON has led the way in making high quality diagnostic and medical devices more affordable to people all around the world. The ACON name is well known in over 130 countries. Headquartered in San Diego, California, the US office is the center of strategic management, administration, business development, innovative research and development. Our state of the art manufacturing facility is ISO 13485:2003 certified, FDA registered and has been inspected by US FDA. Our current product lines include Diabetes Care, Clinical Chemistry (including Urinalysis and Point of Care Tests) and Immunoassay EIA/ELISA. We also have a number of new products in the pipeline for introduction in the future.

Acorai is developing a device for heart failure management through non-invasive cardiac and pulmonary pressure sensing, to help reduce hospitalizations and readmissions. Our product can monitor cardiac and pulmonary pressure sensing non-invasively through a machine-learning analysis of pressure dynamics in acoustics, vibratory, and waveform data. Our technology shows compelling precision, has a low-risk clinical and regulatory pathway, a low dependence on reimbursement, and a fast track to commercialization.

Acousia is a pioneer of novel medicines. Founded in 2012, the company’s experienced and entrepreneurial management team is committed to combating hearing loss. Thanks to its exclusive collaboration agreement with the renowned Translational Hearing Research Group of Tuebingen University Clinic and an ecosystem of experts and CROs, Acousia has made significant strides with its advanced small molecule drug candidates.

3D ultrasound therapy

Homology modeling of proteins, high throughput virtual screening of databases, and the assessment of compounds

ACRC, with locations in Austin, Carrollton, Frisco, Grapevine & Plano, conducts clinical trials with award-winning physicians. Our doctors are recognized by their peers, year after year, as D Magazine's "Best Doctors." Our team of physicians and research nurses provide convenient, accessible and high-quality patient care, all under one roof. Our goal is to advance medical knowledge and help introduce new and improved medications to the general public via pharmaceutical sponsored clinical research trials. We maintain an unwavering commitment to the highest level of ethical standards and safety. Participants go through a thorough medical checkup to determine qualification into a research study.

ACRO Biomedical was founded in June 2014 in Kaohsiung, Taiwan, by Dr. Dar-Jen Hsieh and a group of scientists and physicians. ACRO Biomedical develops and produces biomaterial medical devices for human tissue engineering and regenerative medicine (TERM). ACRO Biomedical uses its proprietary supercritical CO₂ extraction technology to remove cells, fat and non-collagenous proteins from animal tissues, while keeping the undiminished collagen scaffold as the biomaterial for high-end medical devices in the medical regenerative field of wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, cardiovascular and neural surgery, etc.

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

AcroViz develops novel imaging biomarkers for brain health, in an effort to prolong human health span with state-of-art technologies. Comprising eminent academia researchers and experienced industrial professionals, the team is devoted to advancing scientific research, maximizing its clinical significance and application, as well as commercialization to achieve extended positive impact. The first product: AcroViz Axonal Brain Age – Brain Health Report, is the first to the market that adopting diffusion Magnetic Resonance Imaging (dMRI) and Machine Learning techniques to provide accurate and objective brain health assessment, which can serve as a Mild Cognitive Impairment (MCI) marker in predicting the risk and prognosis of dementia, such as Alzheimer's Disease (AD). Web acroviz.com/en/ FB www.facebook.com/acroviz IG www.instagram.com/acroviz_brainhealth YT www.youtube.com/@acroviz LINE https://lin.ee/T2Ttyyj

ACS Biotech vision is to change the lives of millions of people suffering from osteoarticular pathologies through regenerative medicine and development of new cellular-based products. Our solution for cartilage repair, aims to regenerate articular cartilage damage with our Cartilage gel with only one precise and mini-invasive surgery, practised by specialized orthopaedic surgeons. A few months later, patients could remain their mobility and sportive activities.

Acta has licensed IP from Massachusetts General Hospital which provides the foundation for its initial two clinical development programs. The first program is the result of the screening from the Tanzi Lab utilizing its Alzheimer’s-in-a-dish™ mini-human brain organoid model to identify and validate dozens of combinations that affect Alzheimer’s brain pathology. Acta will further assess these Combination Therapies and will testing the most promising ones in humans in its Alzheimer’s Disease Combination Trial Initiative. The second development program benefits from a robust Gamma-Secretase Modulator (GSM) patent estate including GSM-776890 - one of the most promising amyloid-lowering novel Alzheimer’s drugs which Acta is readying to enter clinical trials.

Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France. The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

Actipulse Neuroscience® is a neurotechnology company focused on non-invasive brain stimulation therapies for neurological and psychiatric disorders. Founded in 2017, the company has offices in Cambridge, MA, and Paris, with a presence in Mexico. Actipulse aims to make neuromodulation treatments accessible by transitioning them from hospitals to home-based solutions, targeting conditions such as depression, Alzheimer’s, and Parkinson’s diseases. The company has developed a proprietary portable transcranial magnetic stimulation (TMS) device designed for home use. This device delivers high-frequency magnetic pulses to address issues like neuroinflammation and neuroplasticity loss. Actipulse is conducting clinical trials for major depressive disorder and exploring applications for neurodegenerative disorders. Their home-based treatment model allows for remote administration of TMS under clinical guidance, integrating with telemedicine platforms. Actipulse envisions establishing neuromodulation as a standard therapy alongside traditional pharmacological treatments.

ActiTrexx GmbH is a new biotech start up and was founded in 2020. Our vision is to offer a curative cellular therapy to prevent inflammatory reactions in conditions like GvHD, solid organ transplantation and autoimmune diseases. Regulatory T cells (Treg) - natural guardian cells of the immune system - are the key players of our cell-based drug product. Isolated Treg are activated ex vivo via specific methods and administered to patients intravenously. Unlike other comparable approaches, activated Treg (ATreg) will not be expanded in vitro, protecting them against a possible loss of function. Thus, ATreg is a safe and efficient treatment option for transplanted patients preventing and providing substantial decrease of GvHD severity and related mortality as well. The founders of ActiTrexx GmbH combine many years of unique experience in basic research, biotechnology, clinical application and pharmaceutical development. The management team is supported and complemented by a strong network of collaborators, advisors and key opinion leaders as well as experienced managers.

Activatec develops technologies to produce biobased ingredients from renewable sources. We are specialised in the evaluation, scale-up and commercialisation of processes to produce biotechnological and plant-based ingredients and materials from currently unused and low-value organic sources. Activatec is a B2B Partner that provides support to the industrial biotechnology sector in the form of research services on a contract basis. We are currently working within a number of international partner projects to design, develop and scale-up novel technologies for the production of emerging and high-value bio-based products.

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

ActivMed Practices & Research, LLC. was founded in 1994 and is headquartered in Methuen, Massachusetts. The Company operates 4 clinical research offices. Methuen, Massachusetts headquarters, Beverly Massachusetts and in 2 in Portsmouth, New Hampshire. The proximity of the offices gives ActivMed Practices & Research access to nearly 1.7 million potential patients. Having successfully completed over 900 clinical trials, nationally recognized ActivMed Practices & Research has developed the staff, processes, recruitment practices and facilities to exceed performance expectations for Phase I, II, III and IV clinical trials. Our goal is to offer a compassionate, friendly, and positive research experience for our patients while gathering information that may benefit all of mankind. Awards & Citations: CorporateLiveWire Innovation & Excellence Awards, 2019 & 2018 Top 25 Places to Work, North of Boston, 2014 Business of the Year, Greater Haverhill Chamber of Commerce, 2012 Business of the Year, Greater Haverhill Healthcare, 2011 US House of Representatives Special Congressional Recognition, 2011 Massachusetts State Senate Health Award Citation, 2011 Office of the Mayor of Haverhill Official Citation, 2011 Our President and CEO Terry Stubbs has received the following awards and recognition: eWomen's "Made It To A Million"​ 2009 Women's Mentoring Award, Finalist Greater Haverhill Chamber of Commerce, Woman of the Year, Finalist, 2010 Who's Who in America, 2000-2004 Board of Director's Greater Haverhill Chamber of Commerce, 2000-2016 Public Speaker for Clinical Research Industry, 2007-Present

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

Actnova is a South Korean startup specializing in AI SaaS solutions. The company platform automates the behavioral testing process in clinical and non-clinical fields with artificial intelligence image processing technology. Actnova is also a manufacturer of materials inspection, measurement, and analysis instruments.

Discovering novel functions of existing molecules

Actuated Medical has quickly emerged as a leader in the design and development of medical devices and components. Using proprietary actuation technologies, our innovations address a wide variety of medical challenges ranging from clearing occlusions to easing tissue penetration to enabling MRI assisted procedures. From start to finish, our team designs, develops and manufactures under an ISO-certified quality control system. In addition, we continually seek feedback from domain experts to ensure our products not only solve real problems but also are readily accepted by clinicians. With a proven track record of receiving federal grants to support research and development, the company has built a successful business model that takes medical devices from conception to regulatory approval to market.

Actuate Therapeutics, Inc. is a private clinical stage biopharmaceutical company focused on the treatment of cancer and inflammatory diseases leading to fibrosis.

ActX, Inc. is a dynamic venture that is focused on making patient genomic information truly useful in everyday medical practice. We are currently seeking a Linux System Administrator/DevOps Specialist to work in a unique, small team environment where innovative new processes assist everyone's productivity. Join our team and help us make personalized medicine a reality rather than a dream!

Actylis is a chemicals company that specializes in acetates and provides pharmaceuticals, fine chemicals, and industrial chemicals.

AcuCort has developed and commercializes Zeqmelit™, a new fast-dissolving oral film to put on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV) and for the treatment of patients with COVID-19 who need supplemental oxygen therapy. Zeqmelit™ is approved in Sweden, Denmark, and Norway; and AcuCort has signed its first commercial agreement. Altogether, this strengthens the company's assessment that the time to commercialization may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.se.

Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To provide our partners with the best LNP delivery technology for nucleic acid therapeutics · To support our partners to rapidly advance new therapeutics to address unmet medical needs · To continually innovate to maintain and strengthen our LNP technological lead Acuitas partners locally and globally with companies, academic institutes and other organizations to improve human health.

Aculys - Beyond the development and commercialization of new medicines, Aculys is committed to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted with neurological and psychiatric disease. The company looks to form comprehensive solutions through cross-sectional partnerships using new technologies to enhance the patient experience.

What started as a small family business in 1988 has since evolved into a global market leader, providing orthopaedic and medical solutions that improve patient care around the world. https://www.acumed.net/products/osteomed-hand-wrist/ Our story begins in Butler, NJ, where Mary and Randy Huebner founded Accurate Machine and Design, also known as Acumed. With only one machinist on staff, Acumed was contracted to engineer implant prototypes for some of the biggest names in the industry. After relocating to Oregon in 1991, we launched our first line of arthroscopy screws intended for ACL ligaments and haven’t looked back since. The successes of the Oregon Fixation Screw allowed Acumed to research, design, and manufacture the majority of our products while adding new lines each year. In 1999, Colson Associates, a division of The Marmon Group, purchased Acumed and provided the capital to purchase new equipment and a new facility to step up our production efforts. Currently Headquartered in Hillsboro, Oregon, with a global distribution network and offices worldwide Acumed is a multi-award-winning company, dedicated to innovative and quality medical device solutions. We are committed to the highest standards of manufacturing and proudly produce over 90% of our implants in the U.S. Throughout our history, Acumed has remained focused on the founders’ original vision of providing innovative solutions to meet the needs of the whole healthcare community, including hospitals, surgeons and patients.

Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.

Founded in 1998 and based in Plainview, NY (Long Island), Acupath is a nationwide provider of sub-specialized anatomic pathology services focused on the following specialties; Urology, Gastroenterology, Hematology / Oncology, Dermatology, Breast, Gynecology, Otolaryngology, Podiatry, and Oral. Acupath offers an extensive test menu on both a global and TC/PC basis, has well over 500 active clients, processes well over 150,000 specimens annually, and is one of the leading providers of cutting edge FISH testing for the detection of bladder cancer (UroVysion™), prostate cancer (PTEN ERG), and esophageal cancer (Barrett's esophagus FISH).

AcuPharma is a Canadian based company that provides a wide range of services for pharmaceutical and biotech partners. Our aim is to assist our clients in reaching their goals by providing chemistry expertise, as well as contract research and custom synthesis.

AcuraStem (acurastem.com) is a near-to-clinic, patient-based, drug development company pioneering drug discovery and ultimately how treatments are developed for neurodegenerative diseases—including sporadic ALS and FTD. Enabled by our ground-breaking iNeuroRx® technology platform - AcuraStem has discovered and is now advancing drug candidates that promise to strongly impact disease progression for most patients, including those for whom the genetic cause of their disease is unknown (i.e. sporadic ALS and FTD patients). The causes of neurodegenerative diseases are complex, and genetically defined forms of disease (e.g. C9ORF72-ALS and FTD) only account for a small percentage of cases. Thus, many scientists didn’t believe it was possible to develop a single effective treatment that could work broadly for all patients. But AcuraStem has shown with its extremely promising therapeutic programs for ALS and FTD that it can be done.

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.

Acutus Medical is a dynamic arrhythmia care company focused on developing distinct, innovative technologies that provide physicians and patients with improved results. AcQMap, AcQRef and AcQGuide devices are CE Marked and FDA cleared. Please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.

Development of antibodies from phage display discovery

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.

AdAlta (ASX:1AD) is the pioneer of a novel technology platform that mimics the shape and engineers key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease. AdAlta is utilising the power of its i-body technology platform to develop a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.

Adaltis S.r.l. is an international IVD company headquartered in Rome, Italy. Adaltis develops, manufactures and markets in-vitro diagnostic systems and reagents to detect viral infections, diagnose immune system diseases and measure human hormone responses. http://www.adaltis.net/products/ Personal LAB - fully automated 2 plate microELISA/IFA analyser NEXgen - fully automated 7 plate microELISA / IFA analyser EXTRAlab - Robotic systems for liquid handling, extraction/purification of nucleic acids Pchem Family - clinical chemistry systems for 120-500 tests/hour (Instruments and dedicated reagents). HEMO One - Point of Care Analyser (Diabetes / Vitamin deficiencies / Metabolic disorders / Inflammatory diseases) With more than 10 thousands of instruments installed worldwide, Adaltis is known for excellence in performance and innovation. Adaltis' development and production of reagents include a wide range of assays: - Diagnostic kits for detection of infection agents by real-time PCR (MOLgen Line) - MicroELISA kits (EIAgen) - Clinical Chemistry / Turbidity / Latex (CHEMgen) - Genomics & Bioinformatics MDx kits and reagents for DNA/RNA complete extraction kits providing a wide range of clinical specimens (liquids, tissue, cells etc.), compatible with most DNA extraction kits on market. Adaltis provides: Dedicated Customized Services and Antibody Production. Adaltis has a strong record in OEM / ODM development and production of systems and kits. Well known partners have experienced and enjoy the expertise and quality products of Adaltis. Adaltis is ISO 9001 and ISO 13485 certified. Our products are IVD-CE marked. All of our products are backed by dedicated application support and technical service. Customer Care Center: info@adaltis.net Sales and Marketing Office: sales@adaltis.net Order Handling and Logistics: order@adaltis.net Tel: + 39 0774 5791

Adamas Biotech is a clinical stage company pioneering the development of nutraceutical-based prophylactic and therapeutic solutions for a range of clinical and wellness indications. The company is specialized in the development of bioactive molecules derived from botanicals, in particular, green tea catechins. Its initial pipeline is based on 100% natural formulations of green tea purified compounds, which are under development for use in cancer prevention, anti-aging, wound care and sports medicine.

Adamed Pharma is a Polish pharmaceutical and biotechnology company that was established thanks to its own scientific thought and its own patents. Currently, it produces approximately 500 products offered to patients in 78 countries around the world. It has representative offices in Spain, Russia, the Czech Republic, Vietnam, Italy, Kazakhstan, Uzbekistan, Slovakia and Ukraine. It currently employs approximately 2,400 people. The company has been conducting its own innovative research and development activities for over 20 years. It cooperates with leading universities and research institutes in Poland and abroad. The company's intellectual property is protected by over 200 patents in most countries around the world. Adamed also owns a controlling stake in Dat Vi Phu, one of the fastest growing local pharmaceutical companies in Vietnam. This transaction was the largest direct Polish investment in Vietnam so far. In 2019, Adamed acquired a block of shares in the Italian company Ecupharma, operating in the field of neuropsychiatry and urology.

We apply proprietary computational tools to bacterial metabolomic and genomic data in order to identify, isolate, and assay novel drug-like small molecules in high-throughput to expedite the search for medicines that will better protect us from a wide spectrum of diseases.

Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities and teams include preclinical research, clinical development, translational sciences, autologous and allogeneic manufacturing, and in-house commercial and corporate operations. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page.

Adaptin Bio, is a pioneering biotechnology company dedicated to revolutionizing drug delivery. Our focus is on developing innovative technologies that enhance how medications and other therapeutic compounds reach their target destinations within the body. Our core mission is to overcome a major hurdle in medicine: ensuring effective delivery of drugs to specific tissues.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

Adaptive Clinical Systems, a global life sciences technology company, offers a simple, secure, validated, compliant and cost-effective solution for data interoperability as well as reporting and visualization for clinical trials. Adaptive Clinical offers the Adaptive eClinical Bus and Adaptive DataVIEW. The Adaptive eClinical Bus®, a cloud-based hosted service, will integrate with any EDC, eCOA, CTMS, ePRO/IWRS, Medical Imaging, IRT, Analytics, Data Acquisition Systems as well as RWD, EHR/EMR to reduce error and speed data management for any size study. With the Adaptive eClinical Bus, patient- centric clinical trials can ensure interoperability and full compliance from the many diverse eSources generated from the explosion of data from Digital Health Technologies (DHTs), such as wearables and remote patient monitoring (RPM) solutions. Key benefits of the Adaptive eClinical Bus include: ✔️ Fully-validated Platform with Detailed Audit Logs and Reports ✔️ Fully compliant with HHS 45 CFR Part 64, FDA 21 CFR Part 11, GxP and other regulatory guidelines ✔️ Standards-based for Interoperability ✔️ Easily Implement an eSource Data Capture Workflow ✔️ Adaptive Rules Engine offers Built-in Clinical Intelligence ✔️ Reusable components for Quick Installation ✔️ Full training and 24/7 support Adaptive DataVIEW provides a robust solution for visualizing and analyzing data from disparate sources quickly and efficiently. It provides real-time, bi-directional data from many disparate sources into comprehensive dashboards. Purpose built for clinical trial operational key performance indicators and dashboards. Reports can be created at the patient, site, study or program level, including across studies. Adaptive DataVIEW enables "single click-back" from any widget or dashlet to the data source regardless of eClinical tool.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

AdaptVac is a joint-venture between NASDAQ First North listed ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines. The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders. The combination of ExpreS2ion’s proprietary insect cell expression technology, ExpreS2, and NextGen’s unique expertise in proprietary Virus-Like Particle (VLP) technology makes us a strong and versatile player in the field of new vaccines and immune therapy.

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with expertise focusing on oral dosage forms for the Pharmaceutical industry. Adare's specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactures more than 45 products sold by customers worldwide.

ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by our mission to turn cutting-edge science into life-saving therapeutics and our desire to provide hope for patients with intractable disease.

Develops a rapid leukocyte differential instrument is used to screen for infections, allergies, and blood-related cancers including leukemia.

Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors. In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic. Read more at www.adcendo.com

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases.

AddexBio is a global provider of quality services and products in basic research and development for the academia, pharmaceutical, and biotechnology industries. Our headquartered is based in San Diego, California, USA , we are in a solid position to provide quality services and products which are both cost-effective and time-efficient. Our products include biological and chemical research tools.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in H1 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market, and trades under the ticker symbol "ADXN".

At Addimmune, our mission is to deliver the world’s first functional cure for HIV. Using viral vector delivery, we are seeking to give the immune system the tools it needs to resist and ultimately clear the virus.

Addison Biological Laboratory, Inc. is a Fayette, MO based manufacturer and marketer of exclusive veterinary technologies. For over a third of a century, J. Bruce Addison, president and founder, has been recognized as a leader in veterinary diagnostics and herd specific bacterin production. The reputable MAXI/GUARD® product line is best known for its M. bovis (pinkeye) cattle bacterin among bovine veterinarians and Nasal Vac (intranasal respiratory) baby pig vaccine among swine practitioners. Both technologies are recognized as efficacy leaders and privately labeled for large multinational biological manufacturer/marketers. Companion animal product offerings in veterinary dental home care, dermatology, otology, and wound care provide medical researched technologies that define today’s zinc-based product standards. Marketing accomplishments include a successful export history to over 25 countries and recognition as Missouri’s Exporter of the Year. The U.S. Chamber of Commerce selected Addison Biological Laboratory, Inc. as the recipient for its prestigious Regional Blue Chip Enterprise Initiative Award. “Our mission is to be the premier provider of exclusive and innovative technologies to assist the global betterment of animal care by solving problems for veterinary professionals, animal producers, and pet owners.”

We're thrilled to announce the launch of Adecco Search- The solution you need when your business seeks permanent, mid-level and leadership talent. To learn more, please reach out to your local Adecco representative or visit: https://tinyurl.com/yx9awhyx

Adecto is a pre-clinical stage, cancer therapeutics company, developing the first targeted therapy against ADAM8-expressing cancers and a companion diagnostic to identify patients who can benefit from it. ADAM8 is a critical driver of the growth and spread of many aggressive tumors, including those of the breast, stomach, colon, lungs, liver and pancreas, and is associated with poor patient survival. Adecto’s current focus is on breast cancer with a plan to expand to other oncology indications in the future.

ADEPT PHARMA AND BIOSCIENCE EXCELLENCE PRIVATE LIMITED is a mining & metals company based out of 10-3-561/3/A/102, Vijaya Nagar Colony, Asif Nagar,, Hyderabad, Telangana, India.

Aderans has developed artificial hair with artificial cuticles called "Cyber Hair" which in 2006, evolved into "Vital Hair." A wig made from this material can retain a natural texture after taking a bath or a dip in the pool and can be styled freely with a hair drier due to its natural texture and response to air, allowing for more styling options.

Adesis Inc. is a premier chemistry solution company backed by expert chemists and partnering with biotech and pharma industries to accelerate their research and manufacturing goals. Through the years, we've retained our original culture anchored in ethics, integrity, values, family, transparency, speed, safety and trust. We are one of the few companies that can turn a difficult whiteboard chemistry concept into a physical product. We specialize in organic and organometallic synthesis and deliver organic chemistry services in three areas: early-stage research, scale-up and development, and specialty manufacturing. Our turnaround times are recognized as among the fastest in the industry – a direct result of minimizing red tape, maximizing lab time and quick, efficient decision-making. When clients say ‘let's begin,' we've already started. The companion to this remarkable speed is our commitment to safety. The Adesis Facility Safety Program is designed to constantly raise the level of awareness of safe work practices. Our vigilance extends to the protection of client patents and intellectual property. Backed by the effective use of systems, security and formalized processes, client confidentiality is always a priority. We pride ourselves on our chemists being respected for their brilliance and enthusiasm to collaborate and adapt. If a client needs to shift, we pivot quickly to provide the necessary facilities and specialist brainpower to address any challenge and keep the project moving. The compounds we develop for clients have found use in life-enhancing oncology, anti-infective, animal treatment, central nervous system, immunotherapy, therapeutic, ophthalmic, biomarkers, skin care, catalysts and other applications. Reliably and safely solving the toughest chemistry problems in partnership with its clients is the core purpose of Adesis. Trusted collaboration with exceptional chemistry teams. In Adesis hands, the science is not complicated.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test.

At Adicet (Nasdaq: ACET), we are defined by our mission to deliver best-in-class gamma-delta T cell therapies for patients fighting autoimmune diseases and cancer. Every one of our team members, whether in the lab, manufacturing, or general business role, comes to work every day with the patient in mind. As pioneers in the cell therapy space, we are honored and humbled by the opportunity to put our talents to bear in developing transformative therapies to defeat autoimmune diseases and cancer. We believe that the best way to do this is through discovering and developing allogeneic gamma-delta T cell therapies, a novel type of cell therapy. Adicet has chosen the gamma-delta T cell because it: • Preferentially traffics to tissues and provides B cell depletion, potentially leading to an immune reset for patients with autoimmune diseases. • Has multiple ways to target and kill cancer cells including solid tumors. We also chose to use cells from donors (allogeneic) to enable our potential therapies to be readily available when needed (taken “off-the-shelf” or available to the patient on demand). We’re not just blazing new trails in cell therapy, we’re having fun along the way. With regular team gatherings, many shared meals, larger company events, and a consistent commitment to our values, we have a strong culture! We are proud to attract and retain some of the greatest talent in the biopharma and cell therapy space, and we’re consistently giving back to our employees. The Adicet benefits package includes generous financial compensation, comprehensive health plans, generous paid time-off, educational reimbursement, and access to many amenities in our state-of-the-art facility. To learn more or inquire about joining our team in Boston, MA or Redwood City, CA, please visit http://www.adicetbio.com

ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

Adient Medical is a medical devices company that specializes in absorbable devices that automatically vanish, eliminating the need for removal procedures.

Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We're committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.

Adimmune Corp (4142) is a biotechnology company based out of Taichung City, Taiwan.

ADInstruments is committed to providing innovative tools for research and education. Our company helps scientists and educators achieve their goals with our industry leading PowerLab and LabChart data acquisition systems. Since 1988, life science research has been and continues to be a key driver for innovation in our research product line. Today there are 40,000 ADInstruments data acquisition systems used worldwide in research, and in teaching. Our newest and most innovative product, Lt, takes education a step further with its cloud-based learning platform and 900+ pre-configured physiology, biology, chemistry, medicine, and nursing courses. ADInstruments is a brand synonymous with elegant research and education solutions tailored to suit, and our commitment to our customers is unmatched in our industry. #MakingScienceEasier

AdipoPharma SAS is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

Adipo Therapeutics, an Indiana biotechnology company, is developing polymer-based, Notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue to induce browning, or white-to-beige adipocyte transformation. The goal? Reducing weight and restoring metabolic balance for millions of people living with diabetes.

At Adiso, we create medicines to treat inflammatory diseases, improving the lives of patients and their families. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, we are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action. ADS024 (SS-LBP) is currently being evaluated in a Phase 1b study for the prevention of recurrent CDI and a Phase 2 study in mild-to-moderate ulcerative colitis (UC). ADS051 is currently enrolling a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor in discovery phase which is being initially explored in respiratory inflammation, with multiple future therapeutic areas to pursue.

Aditxt is a social innovation platform. Every year, billions of individuals face health challenges such as autoimmune diseases, misdiagnosis, infectious diseases, organ failure, reproductive health issues, malnutrition, cancer, as well as barriers to accessing healthcare. Innovations with immense potential to address critical healthcare challenges are all around us. Untapped innovations hold the key to transformative solutions. Socially owned and capitalized as  a Nasdaq listed company with a mission of discovering, developing and deploying promising health innovations. Now is the time to inspire and mobilize the social capital inherent in a global community of stakeholders to actively participate in the discovery, development, and implementation of health solutions that could benefit humanity.

We are committed to the growth and development of companies and organizations using advanced therapeutic technologies to revolutionize medicine through specialized, bespoke advisory services. At Adjuvant Partners, we leverage our expertise, professional network, and pan-industry perspectives to provide unique, tailored solutions to our clients to best suit their needs. We believe in active participation with stakeholders throughout the industry, and in concert with our clientele work to foster continued growth, expansion, and implementation of advanced therapies across the healthcare spectrum.

We are a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, we have built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. We have assembled a world-class management team, built our unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation. We are committed to becoming an innovative biopharmaceutical company with global vision and strives to benefit patients worldwide. Our ultimate goal is to transform cancer into manageable conditions.

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

Admetsys is a biomedical technology company specializing in critical care automation. The company's flagship PrecisionOne system is the first fully automated glycemic control system and continuous blood diagnostics platform for hospital care. The company was founded to commercialize the next generation of medical automation technology: continuous real-time biosensing, robotics, artificial intelligence and learning algorithms, intelligent therapeutic delivery, and advanced data telemetry.

Genetic progress in recent years is only comparable to the advancements in the field of computer science. Our vision is to enable everyone to learn about their unique genetic code and inspire new ideas and scientific approaches. Since the completion of the human genetic code in 2003, the number of studies and sources of information on genetic markers, along with the scientific drive to better understand the genotype-phenotype has grown exponentially. In ADNTRO we help you navigate all present & future findings. Invest in your DNA – its for Life.

"Innovative medicine for everyone, everywhere"​ Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : https://www.adocia.com/careers/adocia-careers/

Adolore Biotherapeutics, Inc., is a biotechnology company focused on developing novel therapies for the treatment of chronic pain and other pain and nervous system conditions or disorders. Our best-in-class lead programs are long-acting locally acting gene-therapies that are opioid-free Disease Modifying Anti-Pain therapies (DMAPs) for the treatment of a variety of chronic pain indications. The Company’s two current CA8* gene therapy programs are in preclinical development for treatment of patients suffering from erythromelalgia, a life-long heritable chronic pain condition representing an orphan drug disease with no approved therapy, and chronic osteoarthritis knee pain, affecting a large number of patients that is often treated with opioids due to the lack of alternatives, thus contributing to the ongoing opioid crisis.

Adoram Therapeutics is an Swiss-based biotech startup focused on developing cutting-edge therapeutic assets. Our pipeline includes two differentiated preclinical-stage allosteric modulators, backed by compelling preclinical proof-of-concept (PoC) data from ex vivo human and in vivo mouse studies. Asset 1 is a negative allosteric modulator of A2AR, a best-in-class immuno-enhancer with excellent potential for immunotherapy in solid tumors. This asset is poised to synergize with existing and emerging blockbuster therapies, including immune checkpoint blockade (ICB) monoclonal antibodies, to offer enhanced efficacy in cancer treatments. Asset 2 is a first-in-class positive allosteric modulator of A2AR, with the potential to transform the treatment of various inflammatory, immunological, and metabolic diseases. This asset has wide-ranging therapeutic applications aimed at improving patient outcomes across multiple disease areas. Our allosteric approach to drug development offers a safer, more targeted, and effective alternative to conventional 'orthosteric' small molecules. At Adoram Therapeutics, we are committed to developing the next generation of small molecule medicines that improve the lives of patients worldwide.

Adovate develops novel drugs that target adenosine receptors involved in major diseases. These drug candidates have been created using our next-generation adenosine drug development platform, which enable design of patented compounds with favorable physiochemical characteristics and distribution kinetics that historically limited drugs acting against the adenosine receptors.

Adrenas Therapeutics is a company that was created with a single mission: to work with scientists, physicians, and patients in developing a gene therapy for people affected by CAH. Adrenas is a subsidiary of BridgeBio, a public company dedicated to finding, developing, and delivering breakthrough medicines for genetic diseases to patients as quickly and safely as possible.

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Enibarcimab is a first-in-class monoclonal antibody. Enibarcimab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Enibarcimab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.

Adroit Pharmaceutical Development was founded to efficiently identify new formulations and process technologies for our clients. We also work with clients to identify and correct problems with their existing formulations and processes.

Preclinical biotechnology company leveraging proprietary structure-based technology to develop small molecule disaggregators and inhibitors targeting previously undruggable misfolded proteins in neurodegenerative diseases. Our pipeline consists of tau, TDP-43 and alpha-synuclein programs.

Since 1983, surgeons and neurologists have turned to Ad-Tech for Gold Standard products that help them deliver life-changing care to patients around the world. Our innovative electrodes are used to treat intractable epilepsy, in neurodiagnostics and neurosurgery. With devices ranging from intracranial electrodes for Long Term Monitoring (LTM) and Intraoperative Monitoring, (IONM) and a wide variety of device specifications, we manufacture the devices medical professionals count on for optimal care outcomes. We're humbled by the important role our products can play in the work of caregivers and the lives of their patients. That's why Ad-Tech products are registered and approved for use in more than 60 countries. All are manufactured in the United States. As an ISO 13485 certified company, we observe the highest standards of quality and an unwavering commitment to regulatory compliance. At Ad-Tech, surgeons and their patients always come first.

Valuing Life, Granting Advanced Therapies to Patients- that Is Adva Biotechnology’s Vision and goal. Adva Biotechnology developed the ADVA-X3- a simple, smart, easy to use, automated, sensors-based, flexible cell manufacturing platform. The ADVA-X3 enables full manufacturing process based on the CAMP™ technology, of different applications, such as CAR-T, TCR, TIL, NK, Exosomes, Viruses and More.

The company develops vaccines toinduceimmunotolerance or stimulate T cells, for certain diseases. Beijing Advaccine is also collaborating with Inovio Pharmaceuticals on a novel vaccine to prevent COVID-19.

Welcome to Advaita, where innovation meets expertise in B2B services. Our expertise lies in 360 degrees solutions to your corporate needs. We specialise in Corporate Events, Corporate training, Data analysis based AI solutions, Market Research, Analytics, Business consulting, Networking and Partnerships. We are a technology driven organization and keep ourselves up to date with the changing trends and market needs. At Advaita, we understand that each client is unique, and our services are tailored to meet your specific needs.

AdvanBio Inc., www.Advabio.com, a subsidiary of Autobio Diagnostics in the U.S is a fast-growing biotechnological company based in Irvine, CA. Established in 2021. We specialize in providing cutting-edge IVD Quality Control products & Reagents designed for a diverse range of analytes. In addition, we are committed to providing global partners with high-performance IVD Critical Raw Materials and services such as: • FDA Submission • Assay Development • Product Sales • New Technology/Biomarker Development We are committed to the advancement of medical laboratory technology and dedicated to the promotion of human health. We empower medical providers in making pivotal biomarker & diagnostic decisions with our portfolio of innovative technologies. #Advanbio#ADLM

Personalised therapies for the heart and vasculature Innovative, independent, close to the patient. We are a biotech company that independently develops innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. We have a unique product pipeline that we are consistently moving into clinical trials. Our lead compound has been successfully tested in two Phase II studies. We work closely together with excellent academic and clinical teams in basic and clinical research. We use state-of-the-art analytical methods, and we develop our products according to the highest quality standards (GLP, GMP and GCP). Revacept is a therapeutic agent for the prevention and treatment of acute arterial thrombosis, which can lead to heart attack, acute limb ischemia and stroke. A Phase II clinical trial in 160 patients with stroke or transient ischaemic attack (TIA) has been completed. It showed beneficial effects in patients treated with 120 milligrams (mg) of Revacept. Another Phase II clinical trial investigated Revacept in 332 patients with stable coronary artery disease (ISAR-PLASTER) has been completed. This study conducted by the German Centre for Cardiovascular Research (DZHK) confirmed the very good tolerability of Revacept. Overall, Revacept did not lead to increased bleeding despite of its additional platelet aggregation inhibition on top of conventional standard therapy. It decreased ischemic strokes in NMR and improved the net clinical benefit of MACE and bleeding. Recently, the FDA has approved the preclinical and clinical development and the further phase 3 protocol until market approval. Antibody therapeutic In collaboration with Morphosys an anti-GPVI Fab antibody has been discovered. The candidate is currently in preclinical evaluation for the treatment of acute coronary syndrome and stroke. Imprint: https://www.advancecor.de/imprint/ privacy policy: https://www.advancecor.de/privacy-policy/

Advanced Bifurcation Systems Inc. has developed a novel technology to enable effective stenting of coronary arteries at their branch points (bifurcations). This comprehensive platform is a paradigm shift in interventional cardiology that will reduce the need for open-heart surgery, hospitalizations, and repeat coronary angioplasties. The technology will simplify procedures and improve outcomes while reducing angioplasty times which results in significant improvement to the overall patient care at a reduced cost.

Founded in 2010, Advanced BioDesign is a clinical stage company developing a highly promising therapy for cancer with high unmet medical needs. Advanced Biodesign has developed a therapeutic approach based on a selective inhibition of ALDH enzymes. Advanced Biodesign project consist in the development of small-molecule that will selectively inhibit specific ALDH enzyme. By targeting this family of enzyme, will block specifically the intracellular mechanism of detoxification that cancerous cells have developed in order to escape form the programmed cell death called apoptosis.

Scientists today rely on advances in computer science, applied mathematics, and computational science, as well as high-performance computing and networking facilities, to increase our understanding of ourselves, our planet, and our universe. The mission of Computing Sciences at Berkeley Lab is to achieve transformational, breakthrough impacts in scientific domains through the discovery and use of advanced computational methods and systems and to make those instruments accessible to the broad scientific community. The Computing Sciences organization advances computational science throughout the U.S. Department of Energy's Office of Science research programs. Our greatest strength is our people. They specialize in solving scientific problems using expertise in computer hardware and software, computational science, applied mathematics, networking, and middleware services. Computing Sciences carries out its mission by operating two national user facilities — NERSC and ESnet — and by conducting applied research and development in computer science, computational science, and applied mathematics, the three essential elements of computational modeling and simulation. Combining computer and network operations with research and development provides tangible benefits to both the scientists who use our systems and their research programs. Just as our R&D programs benefit science, the needs of scientists influence the direction of our research. These two sides of Computing Sciences'​ work — systems and services, and research and development — are more than complimentary. Each enhances the quality of the other. Computing Sciences is comprised of three divisions: the Computational Research Division (CRD), the National Energy Research Scientific Computing (NERSC) Center Division, and the Scientific Networking Division, which manages the Energy Sciences Network ESnet.

Advanced BioMatrix provides innovative 3D matrix products, transforming science to a new level of discovery. We extract and manufacture highly purified, native, extracellular matrix proteins for tissue engineering, 3D bioprinting, cell culture, drug discovery and any other application with cells. Visit us at www.advancedbiomatrix.com or our 3D bioprinting page at www.bioprintabm.com

Since 2014, Advanced Biomed Inc. has been focusing on the integration of multiple interdisciplinary technologies and established its own microfluidic technology platform. The Company aims to provide rapid and affordable assay products and services to cancer patients. The Company has a range of innovative devices, including A+Pre, AC-1000, A+CellScan, and A+SCDrop, along with three corresponding biochips: A+Pre Chip, AC-1000 CTC Enrichment Chip, and A+CellScan Chip. The Company’s technologies and products can be used for early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers in blood samples, capture of single circulating tumor cells, and single-cell sorting and determination. Additionally, the Company has completed the research and development stage for four matching immunostaining kits, A+CTCE, A+CTCM, A+EMT, and A+CM, utilizing multiplexed staining with fluorescent-labeled antibodies to identify tumor cell types. The Company has also introduced A+LCGuard, a product designed for early screening of lung cancer to assist in the determination of benign and malignant pulmonary nodules. With the Company's primary operations, design, and development based in Taiwan, Advanced Biomed is expanding in China while preparing for the establishment of operation centers in North America and Europe.

AB is proud to be the only U.S. based manufacturer of cochlear implants and equally proud to be a part of the larger Sonova group. At AB, success begins with a passion for hearing restoration and is driven by our global workforce of over a thousand employees. For more than 25 years, AB has removed limitations for those otherwise isolated from the world of sound. Always focused on bringing meaningful change through innovative technology, AB has set the standard for performance, lifestyle support, and access to sound in the field of cochlear implantation. Having implanted over 100,000 ears in over 130 countries and established a track record for developing high-performing, state-of-the-art products, our team of talented scientists, engineers, audiologists and other professionals are driven to succeed, work with integrity, and stay firmly committed to quality. Sonova companies include brands focused on hearing aids, cochlear implants, wireless communications, and clinical service. Together, we strive to create a world where everyone enjoys the delight of hearing and lives a life without limitations.Advanced Bionics is a global leader providing solutions for severe-to-profound hearing loss.

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world’s most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients’ team – helping them advance today’s ideas into tomorrow’s medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

Over the past decade, Advanced Brain Monitoring has developed and implemented mobile, user-friendly platforms for acquiring, integrating, analyzing and reporting multi-sensor data in real-world applications. Our strong and growing technical team includes PhD- and masters-level hardware engineers, biostatisticians, software engineers and experts in signal processing, experimental design and clinical trials. ABM seeks to build on existing collaborations within the academic community and develop strategic partnerships across industry with like-minded professionals.

Advanced Cellular Dynamics (ACD) is a world-leader in the production, provision and application of novel cell-based assay systems. Our capabilities provide us with a unique capability to explore a variety of biological entities and systems. We have deep-rooted expertise in kinases, GPCRs, ion channels and transcription factors - to name a few. Those skills are applied to a variety of experimental systems that include (but aren't limited to) oncology, immunology and neurobiology. We also leverage these skills to provide our global clientele with contract research services. Whether you want to disrupt a specific gene in stem cells, or create a new biological cell-based assay in your tissue/cell line of choice, we have the knowledge and skills to help you succeed!

Advanced Clinical is a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey. Our goal is to improve the lives of all those touched by clinical research – approaching each opportunity with foresight, character, resilience and innovation. Based on decades of experience, we help our clients achieve better outcomes by conducting candid conversations and anticipating potential issues through our customized solutions. Visit our website to learn more: www.advancedclinical.com.

Our focus on service, quality, and reliability has made Advanced Instruments a leading developer and manufacturer of analytical instruments and services for the biopharmaceutical, clinical, and food & beverage industries for more than 65 years. Globally, we provide innovative technologies aligned with the needs of the markets we serve, helping to improve efficiency, enhance productivity, and ensure best-in-class performance. Our Solentim portfolio of best-in-class imaging and single-cell deposition technologies enables the clonal isolation, outgrowth, and characterization of the highest value cells for monoclonal antibody upstream development and cell and gene therapy. Our robust line of micro-osmometers is built specifically for the biotech industry and seamlessly integrate into both non-regulated and regulated GMP workflows ensuring increased yield, quality, and purity. Similarly, clinical labs worldwide rely on our products to provide high-quality results and optimize workflow efficiency. With products for clinical chemistry, microbiology and hematology labs, our innovative solutions enable the delivery of accurate and timely patient results to help improve health outcomes and help simplify workflows to support an increase in lab productivity. Our newest addition, the Artel portfolio, includes leading analytical instruments, software and services that validate, automate, and calibrate critical liquid handling processes and instrumentation. We are a global leader with products supported by a worldwide network of direct salespeople and distributors, with 24/7 technical support. Our direct presence is growing as we continue to expand the team with a continued focus on being the supplier of choice. Contact us if you are interested in joining a dynamic team! For more information, visit www.aicompanies.com.

With a complete platform of core trauma and extremity products, AOS has become a trusted leader with its entire focus on the orthopaedic trauma industry. Relying on the professional guidance of the four original founding partners, as well as the clinical expertise and training of skilled surgeon champions, AOS designs and manufactures innovative orthopaedic trauma products with intra-operative and postoperative clinical benefits. AOS’s products are distributed worldwide through independent distributors and agents. By continuing to build strong relationships with our valued distribution network and surgeon users, AOS continues to improve every aspect of the way we do business. Especially for our patients and their families worldwide.

Advanced Pharma - Miami is a dedicated Phase I­-IV Clinical Research Facility. With our 40,000 sq. ft. turnkey facility we house a 100+ bed capacity Phase I unit with three 6-­8 bed IPUs (Intensive Procedural Units) as well as our Phase II­-IV group experts. Our principals have participated in clinical trials since 1992 and our team has 50-­plus years of combined research experience. Our multi-­specialty Physician Investigators enable us to engage in many aspects of Phase I­-IV Pharmaceutical, Bio­tech and Medical Device Trials. Our team of experts is dedicated to sustaining safe, ethical, high-quality medical research so sponsors can exceed their deadline and patients can benefit from the development of new treatments and therapies. We pride ourselves on bringing efficiency, innovation and value to the clinical research process. Our strict adherence to protocol and GCP standards, along with our uniform delivery of quality data guarantees the most efficient and timely outcome in all trials. Our historical patient data confirms that we have outstanding recruitment and retention percentages in the upper 90's.

Serving the SynBio materials, foods and pharma industries with comprehensive facilities/equipment service programs, We help customers optimize their processes with the most cost effective systems, services, and processes to keep them running on schedule and in budget. Facilities/Equipment Performance Management Service Contracts Upstream Process Consulting - Bioreactor specification - Sensors, Sampling solutions - Automation - Integration Downstream Process Consulting - Filtration - Chromatography - Separations - Drying Calibration – instruments measuring -Temperature - Pressure - Flow - Mass - Optical - Volumetric - Dimensional NIST traceable "cradle to grave" calibration - Performance - Logging - SOP's - Records management Validation – IOQ generation, execution and reports OEM Post Sale Services Management - Installation - Calibration - Integration - On-site Services - Mail-in or Remote Service Center repairs - Warranty Record and Services Management Laboratory/Plant - automation, integration and maintenance Labor Services - field and contract service Equipment Sales - OEM supporting services in process design and performance service contracts - OEM Services Partners include;; Sonotec Non-invasive Flow Meters, BlueSens offgas Analyzers, APS Corp. Industrial Bioprocess Systems, Chemglass Labware, Hamilton Instruments, SecureCell Laboratory Automation

Advanced Radiation Therapy is the provider of AccuBoost. AccuBoost is the latest innovation in breast radiation therapy. The primary beneficiaries of the AccuBoost Technique are the breast cancer patients: who receive conformal radiation with better targeting, less toxicity, much less skin reaction, minimum exposure to the heart and lungs and a superior cosmetic result.

Advanced Resilient Biocarbon is a company that specializes in biocarbon production through licensed pyrolysis systems.

For more than 30 years, Advanced Solutions, a privately held company, focused on long-term investments in technology companies that deliver profound and positive engineering solutions for healthcare, manufacturing, workflow optimization, logistics and education. Companies include: Advanced Solutions Life Sciences, Power of Public Speaking, Expedient, and IDS Engineering. Advanced Solutions Design Software and Advanced Solutions PLM are now part of IMAGINiT Technologies

AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy.

Advancells offers stem cells for various chronic conditions and lifestyle disorders.

ADvantage Therapeutics - Headquartered in the Wynwood neighborhood in Miami, ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a central focus on Alzheimer’s disease. The Company’s lead compound AD04™ is an injectable therapy in the process of entering into a confirmatory Phase 2b clinical trials in Europe to evaluate safety and efficacy of the product in early Alzheimer’s Disease. The Company believes that AD04™ may act as an immunomodulator, stimulating and regulating the immune system to reduce AD pathology, rather than limiting therapy to the aggregation of the proteins present once pathology is present. The Company is also exploring additional approaches to mitigating neurodegenerative disease, which it believes will eventually have an overall impact on longevity.

Partner of choice in specialty, hospital, and rare disease medicines ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients' lives by providing the specialty, hospital, and rare disease medicines they depend on. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with innovative biopharma and pharmaceutical development companies to bring medicines to patients. Headquartered in London, UK, we have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia. Our Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network complement our global operations. ADVANZ PHARMA's product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products and pipeline cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and, more broadly, rare diseases. We can only achieve our ambition with the passion of our dedicated and highly qualified people, acting in line with our company values of entrepreneurship, speed, and integrity.

Advenchen is a pharmaceutical company that focuses on small molecule cancer drug discovery programs with a specialization in protein kinase inhibitors.

At AdventHealth, Extending the Healing Ministry of Christ is our mission. It calls us to be His hands and feet in helping people feel whole. Our story is one of hope — one that strives to heal and restore the body, mind and spirit. More than 80,000 skilled and compassionate caregivers in physician practices, hospitals, outpatient clinics, skilled nursing facilities, home health agencies and hospice centers provide individualized, wholistic care. Our Christian mission, shared vision, common values and focus on whole-person health is our commitment to making communities healthier with a unified system: 50 hospital campuses and hundreds of care sites in diverse markets throughout nine states.

Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA. We are a highly experienced team with a long-standing track record of entrepreneurial and investment success through turning break-through science into approved medicines or medical products. We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach. Our investments are focussed in new drug discovery - small molecules, biologics and new modalities - med tech, enabling technologies and vaccines. As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well connected team to support each investment. We work in close alignment with our management teams, and partner with them to realise their vision - achieving superior financial returns by bringing innovation to patients. The companies in which we have invested since the year 2000 have discovered and developed, fourteen approved medicines and products - to the benefit of patients, physicians and our investors.

Adventris Pharmaceuticals is a biotechnology company focusing on cancer immunotherapy

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases. Advicenne have spent more than 10 years developing products for the treatment of rare renal diseases. At Advicenne, we are committed to developing and commercializing medicines that are suitable for both children and adults – groundbreaking treatments for rare diseases should be available to patients of all ages.

Advin Biotech is a FDA Registered growing corporation and manufacturer specializing in rapid diagnostics products for drugs of abuse testing with China and US based manufacturing facilities. Offering a complete line of one step drug tests for medical workplace and criminal justice professionals. Advin's 501k cleared products are intended for OTC, CLIA and professional use in cup, dip-card and cassette test formats. With full R&D and manufacturing capabilities located in our San Diego, California plant we are positioned to respond to the needs of partners and customers worldwide. We have the intra-company organic chemistry expertise to facilitate the design and synthesis of immunogens and the complementing ability to use the resulting immunogens to generate antibodies for the sensitive and specific detection of antigens and biomarkers. We encourage partnerships and co-development opportunities accordingly. Our short-term strategic goal is to augment our existing FDA cleared test menu with first-to-market, "organically-grown" assays targeted to fill the many gaps in the diverse toxicology market. Our long-term goal is to foster partnerships in the worldwide medical and forensic communities with a shared goal of providing affordable, accurate and actionable tests that fill unmet needs.

Advion is a manufacturer and supplier of mass spectrometers and analytics systems for life science and pharmaceutical sectors.

Founded by Dr. Elizabeth Ruzzo, adyn is helping people find birth control without side effects based on a person's genetic risk and hormone profile. Despite the 47M birth control users in the US, virtually no studies examine the biological factors that explain why individuals respond differently to a given contraceptive method. Launched in May 2022, The Birth Control Test is the first test designed to prevent birth control side effects. While we are improving the birth control experience, we are also committed to closing the gender health gap. By partnering with individuals, adyn leverages personal preference, medical history, and biological data to proactively help every (unique) body select the most desirable birth control option – with the least dangerous side effects. Our vision is to be earth's most inclusive and patient-centric personalized medicine company. When a person uses The Birth Control Test, they can opt in as an anonymous research participant to help close these research gaps. This means you can simultaneously find the right birth control for your body, while helping others do the same.

Adze Biotechnology is a biotechnology company that develops a platform of immunotherapies to treat solid tumors and enhance anti-tumor immunity.

Aegea Biotechnologies, Inc. is a technology company that is developing a series of reagents, research kits and in-vitro diagnostic (IVD) products for molecular analysis based on novel, patented and proprietary nucleic acid chemistries and methodologies.

Aegis Life, Inc. is a biotechnology company founded in early 2020 with a mission to prevent and treat existing, emerging, and future contagions. Our nucleic acid delivery technology Fusogenix PLV stems from more than a decade of research and development in gene delivery. We actively leverage the Fusogenix PLV platform to accelerate the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.

Founded in 1990, Aegis Sciences Corporation is a forensic toxicology and healthcare laboratory that provides science-driven drug testing and consulting services based in Nashville, TN. Aegis delivers evidence-based, clinically actionable information related to medication compliance, substance abuse, and drug-drug interactions through definitive testing of urine, oral fluid, or blood specimens. Aegis healthcare testing services are designed for the unique needs of healthcare specialties in the areas of Pain Management, Behavioral and Mental Health, Substance Use Disorder, Prenatal and Chronic Disease Management. Aegis provides clarity for enhanced patient care to a wide array of clinicians that serve Medicare, Managed Medicaid, Commercially Insured and Workers'​ compensation populations. In addition to healthcare testing services, Aegis offers anti-doping and forensic testing services to professional and amateur sports organizations, college and university athletic programs. Aegis’s biopharma lab provides molecular diagnostic services, including clinical trial services, pharmacogenetic testing, and other services.

Aegle Therapeutics Corp. is a clinical-stage biotechnology company developing novel extracellular vesicle (“EV”) therapies to address rare and serious diseases and disorders with significant unmet medical needs. Aegle’s proprietary platform technology safely isolates native extracellular vesicles (“EVs”) from stem cells. These EVs carry complex assemblies of biologic molecules such as proteins and nucleic acids that can induce a wide variety of effects in recipient cells, including the promotion of regenerative healing, while reducing inflammation and modulating the immune system. Aegle’s EV therapy has the potential to treat a broad range of indications in multiple therapeutic areas, including dermatology, immunology-based diseases, protein deficient disorders and others.

Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases. Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments. These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology. Two initial drug candidates are already in clinical trials in indications with high unmet medical needs: • AEF0117, to treat disorders due to excessive cannabis use, has already provided evidence of efficacy in a phase 2a clinical study and has entered a phase 2b clinical trial in Q2 2022. • AEF0217, to treat various cognitive deficits, including those associated with Down syndrome (Trisomy 21), is currently being evaluated in phase 1 clinical trials, with no major adverse effects observed in the three patient cohorts treated to date. Phase 1/2 clinical studies with AEF0217 in Down syndrome subjects are expected to start in Q4 2022. These studies could provide initial efficacy results in H1 2023. Given the involvement of the CB1 receptor in numerous pathologies, Aelis Farma is also developing using its proprietary platform, several new CB1-SSi with differentiated pharmacological properties to target other brain pathologies. Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis Farma has a team of 24 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement.

Aelius Biotech is a UK-based biotechnology company founded in 2018, located in Newcastle upon Tyne. The company specializes in developing in vitro gastrointestinal models, which simulate the digestive process. This innovative model includes cell-compatible mucus, allowing for a comprehensive understanding of digestion and absorption. Aelius Biotech offers contract research services focused on animal-free testing for pharmaceuticals, consumer health products, and functional foods. They have collaborated with notable clients, including Huel, and have attracted interest from the alternative protein and lab-grown meat sectors. The company has experienced significant growth, expanding its workforce and revenue following successful funding rounds in 2023 and 2025.

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen.

🚀 Aenitis designs, develops, and markets sole-in-class acoustofluidic technology that makes cell and gene therapy manufacturing better, safer, and less expensive. By precisely controlling levitated cells with sound waves, our systems handle cells in full sterile conditions and radically increase productivity while preserving the native state of cells at every step of the engineering process. This technology enables gentle, non-invasive manipulation of cells at the millifluidic scale, allowing for the handling of tens of milliliters per minute. Such capabilities are critical for scaling applications from research to clinical and industrial use. 💡Today, we have achieved proof-of-concepts for our contact-free & label-free proprietary technology across multiple cell types & processes. Mitis™, our flagship product, is already used for a wide range of applications, including cell sorting, isolation, concentration & washing, from research to clinical and industrial scale. 🌍Co-founded by pioneers of acoustic levitation & fluid mechanics and a biotech entrepreneur, the company benefits from the support of the European Commission & the French Government and from the commitment of leading investors, notably the European Investment Bank and Seventure Partners.

AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. The company is dedicated to innovation in the rapidly expanding therapeutic botulinum toxin market. This therapeutic-only focus will allow AEON Biopharma to advance safe and effective treatment options to patients, while delivering differentiated economics to payors and physicians. The company continues to evaluate additional therapeutic indications for development based on a comprehensive product assessment process designed to identify those indications where it believes ABP-450 can attain clinical, regulatory and commercial success.

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases. Our lead development candidate, AV078, is a first-in-class CNS penetrant selective mTORC1 inhibitor being developed for the treatment of TSC refractory epilepsy and is currently being evaluated in a Phase 1 trial. TSC is a rare genetic disorder caused by the hyperactive signaling of mTORC1. Beyond AV078, we've developed a proprietary library of small molecules, which are potent and selective mTORC1 and CD38 inhibitors that have the potential to precisely target the underlying biology of multiple rare and age-related disease

Aequor -- pronounced Acorn without the "n" -- means "The Sea" in Latin. Aequor's Founder discovered new chemicals in the ocean that are more potent and less toxic than anything known to kill bacteria and fungi -- including the antimicrobial resistant (AMR) Superbugs. PRODUCTS: Our platform includes "green" chemicals and products containing them for B2B sales and licensing: --Available now: 25 specialty chemicals - EPA/TSCA-approved --ingredients for consumer products to replace harmful biocides --proprietary formulations - sprays, washes, paints, coatings, etc.: --treatments for improving algae and yeast biomass production processes up to 40% in half the time for biofuels and renewable co-products --surface cleaners --water treatments --Pending EPA/FIFRA approval: 30 antimicrobials that are "green" and non-toxic for products and treatments making antibacterial, antifungal, antibiofilm and antifouling claims --Pending FDA approval : 30 new drug candidates The NIH offered Aequor free pre-clinical trials for 4 of the new drug candidates if we can deliver to them half-kilo samples. The DOD offered the same for up to 5 new drug candidates. SERVICES Aequor offers microbial and biofilm testing services for third parties seeking to determine efficacy of their formulations, devices, etc. UNMATCHED EXPERTISE Aequor's Founder Cynthia Burzell, Ph.D. - Marine and Medical Microbiology -- is considered a pioneer in Biofilms. She lectures internationally and offers educational training programs on biofilm and its impacts on the costs and operational inefficiencies in agro-industry, consumer, and healthcare sectors. UNMATCHED MODEL Aequor is a resident company at JLabs San Diego, raised $1.2M cash and is a Woman Owned Small Business, eligible for 5% of government contracts. For our in-house and virtual management team and updates, see our website. For further information: Marilyn Bruno , CEO - mbruno@aequorinc.com

Aera was founded with a vision to unlock the potential of genetic medicines across a broad range of modalities and therapeutic areas. Our protein nanoparticle (PNP) delivery platform leverages the discovery of endogenous, human proteins that can self-assemble to form capsid-like structures and that can package and transfer nucleic acid cargo. This platform has the potential to address many of the limitations of today’s delivery technologies and to enable various genetic medicine modalities.

Nasal breathing is a very important function of human life and any obstruction in the nasal airway also known as a congested or blocked nose, can dramatically impact the quality of life.The VIVAER treatment, performed in a doctor’s office, is a non-invasive procedure without any incisions. The patient'snasal valve area is gently reshaped using low-temperature radiofrequency energy with lasting results.

AeroFarmsis an indoor vertical farming company. They usea patented aeroponic growing system to grow produce.

From economic headwinds to talent complexities, the challenges facing North American industry are real. To rise to this moment, Aerotek® Inc. helps companies, and careers evolve. Aerotek provides staffing and services solutions in manufacturing, logistics, construction, aviation, facilities and maintenance. We partner with our customers to offer the expertise, solutions and people they need to rise to the challenges of North American industry. Our 12,600+ employees across 250+ offices work relentlessly to serve 180,000+ light industrial and skilled trades workers with 14,000+ employers every year. Let us rise to meet your challenges.

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

We are a research-oriented provider of innovative, efficient products and services for early detection, diagnosis and prognosis of autoimmune and infectious diseases, allergies and food intolerances. We strive to improve the diagnosis and management of different diseases as a provider of innovative in-vitro diagnostic products that really work. Built on a tradition of innovation and an interdisciplinary knowledge network, AESKU.DIAGNOSTICS offers unique diagnostic options: faster, more efficient and reliable test systems designed to improve clinical outcomes for the benefit of patients and physicians. Follow us on our other Social Media Profiles. https://www.linkedin.com/company/dst-diagnostische-systeme-&-technologien-gmbh/about/ instagram: https://www.instagram.com/aesku.group/ Contact us: Website: www.aesku.com⁠ E-Mail: socialmedia@aesku.com⁠

Aether's mission is to build a future of abundance for the human race. We believe that the machinery of nature can be reverse engineered to manufacture any arrangement of atoms desired, enabling the production of new products anywhere on earth.

The statistics are overwhelming: more than 130 people a day die from opioid related drug overdoses. In 2020 in the US alone, 2.7 million people aged 12 or older had Opioid Use Disorder (OUD) and 4.2 million people entered a drug rehabilitation program. While treatment programs and rescue medications are critical, æther THERAPEUTICS is focusing our efforts upstream: preventing addiction and creating a more effective treatment of OUD. æther THERAPEUTICS' main candidate is Low Dose 6β-Naltrexol (ATX-001). Animal models indicate that ATX-001 may prevent opioid dependence while not blocking pain relief or causing withdrawal & other adverse effects. Our vision is a world where the devastating effects of opioid addiction are alleviated, leading to: • Safer opioid pain therapy without the fear of addiction, • Cessation of opioid addiction • Prevention of Neonatal Opioid Withdrawal Syndrome (NOWS) æther THERAPEUTICS is focused on our vision, driven by innovation, embraces lean operations and engaged with urgency.

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Aethon takes a novel approach to fighting cancer, creating custom antibody therapeutics that unite immunotherapy and targeted therapy.

Aevice Health Pte Ltd is a Singapore-based MedTech spin-off from Nanyang Technological University at the forefront of addressing chronic respiratory disease, one of the generation's biggest healthcare challenges. The company's non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time, so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients' health and track their responses to treatment plans easily from the Aevice analytical platform. In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives. More information about the company can be found at www.aevice.com.

AfaSci, Inc., a San Francisco Bay Area biotech company committed to enhancing health care by conducting R&D in both Biotechnology and Therapeutics. Our bioengineering team has designed, produced and been marketing an in vivo drug screening platform, SmartCageTM. This system enables automated, and objective assessment of drug effects on rodent behavior and increases throughput of phenotyping of transgenic animals. Elevating our proprietary platform and well-established electrophysiological techniques, AfaSci’s scientists have been discovering IND drug candidates targeting ion channels and GPCR for the treatment of CNS disorders, especially neuropathic pain, epilepsy and Alzheimer’s disease.

Who are we? We are AF ChemPharm, established in Sheffield, England, in 1998. We are a chemistry-based contract research organisation, and are specialists in driving discovery by simplifying synthesis. We provide a straightforward, cost-effective and convenient route for bringing expertise in chemical synthesis into your projects. Whatever your core focus, AF ChemPharm is on hand to help you streamline your workflow if you require chemical synthesis. Though we are principally involved in the drug discovery and pharmaceutical sectors, we are a reactive and versatile company, and have current and previous clients from a diverse range of industries. We've worked with biomedical academic research groups, functionalised polymer manufacturers, fine chemical suppliers and emerging-technology firms, amongst many others. What do we offer? Our clients expect high quality, reliable and cost-effective consultancy, custom synthesis and contract research, and we are proud to say that we can deliver on these expectations. We are situated in purpose-designed, state-of-the-art laboratories in central Sheffield, equipped with kilo-lab facilities, and we use a world-class analytical suite for the characterisation of your projects. We work with multi-national companies, universities, SME's and brand new start-ups; whatever the size and direction of your company, we pledge the same commitment to excellence in science, communication and customer service . Our team are all PhD chemists, with backgrounds in synthetic organic and organometallic chemistry from both academia and industry, and we have recently appointed two external scientific advisors of the highest calibre - Prof. Joe Harrity of Sheffield University and Prof. Alan Spivey of Imperial College, London.

Afecta Pharmaceuticals is an early clinical stage small molecule therapeutics company focused on developing precision medicines to treat chronic disorders and cancers more effectively. Afecta has a validated, proprietary Artificial Intelligence disease/drug targeting platform, PharmetRx®, to discover and optimize Multi-Target drug compounds and formulate them in NanoRx®, our tissue-specific drug delivery technology. Backed by an experienced management team, Afecta is currently advancing AFX-220, our clinically proven lead candidate that effectively treats the disruptive behaviors that occur in children and adolescents with several neurodevelopmental disorders such as Autism, AD/HD, and others. Please visit our website to learn more, register to access our Executive Summary, and receive our latest updates.

Afekta is a metabolomics service provider specialized in microbiota-associated compounds and bioactive phytochemicals present in plant-based foods. They can analyze any biological sample and measure a wide variety of metabolites, with no need to choose a list of compounds in advance!

Affera is a venture-backed medical device company founded by a seasoned team of leaders in the industry. We are developing an innovative system to treat heart rhythm disorders, a prevalent condition affecting millions of patients worldwide. Follow us as we share updates about our progress.

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that targets psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody has ongoing commercial relationships with several companies such as AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Affibody AB is a holding of Patricia Industries.

At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Affina Biotechnologies is dedicated to excellence in helping our customers develop measurements of activities, kinetics and affinities of interactions and concentrations of biomolecules. We offer a unique mix of label-free and label-dependent assay technologies supported by scientific and technical expertise and a wide range of instrumentation: Surface Plasmon Resonance (SPR) Light absorbance, luminescence, fluorescence polarization, time-resolved fluorescence Affina scientists will work with you on developing custom-built measurements and screens that are tailored to your requirements. Once a method is developed and validated we will help you transfer it to your facility of choice or perform it at Affina. The services listed are the major ones that we provide. If there is a type of measurement that can use our technologies and is not listed here we will be happy to work on it with you! Affinity and kinetics of molecular interactions Enzyme activity Total and active concentration

Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world.

Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.

Affinity Biologicals Inc. is a biotechnology company based in Ancaster, Ontario, Canada, specializing in hemostasis diagnostics and research. Founded in 1987, the company develops, manufactures, and markets over 250 high-quality reagents and kits used in coagulation and thrombosis studies. Their product offerings include coagulation-related antibodies, matched-pair antibody sets for ELISA, depleted/deficient plasmas, and a line of complete ELISA kits. The company also provides tailored services such as research and development, custom manufacturing, and contract services to support clients in the biotechnology and healthcare sectors. Affinity Biologicals maintains a strong commitment to quality, operating under an ISO 13485:2003 registered Quality System and holding licenses from regulatory authorities like the US FDA and Health Canada. With a dedicated team of around 30 employees, Affinity Biologicals serves a global market through a network of distributors.

Founded in 2006, Affinity Biosciences is a pioneering Life Science and High-Tech company whose biochemical products and services are mainly applied in biotechnology, medical research and pharmaceutical development. Dedicating to advancing customer success through innovation, Affinity Biosciences has established R&D affiliates in the United Kingdom and United States with the aim of providing outstanding service around the globe.Our customers include scientists and technologists in life science companies, university and government institutions, hospitals and industry. To underline our commitment to our customers and enhance our standards of service, we have opened packaging and quality control facilities in the People’s Republic of China. Our goal is to develop high-quality antibody that focuses on Cell Signaling Transduction research, including Akt,AMPK,NF-KappaB,TGF-beta,etc,as well as inhibitors and related reagents.

AffinityImmuno Inc. is a provider of R&D support services for your biological drug research and discovery. We specialize in antibodies, antibody lead discovery, protein engineering, and assay development for targets in cancer, autoimmune, and endocrine disorder therapeutics. Our goal is to help you advance your life science research through innovation and creative problem solving. Let us put our experience to work for you.

Affinity Life Sciences for over 10 years providing the highest quality services for Lyophilization, Reagent Manufacturing, Immunoassay test and more.

We are a clinical-stage biotechnology company that strives to challenge established treatment options for neurodegenerative diseases in order to preserve the quality of life of patients.

Affirma Biotech is a privately owned preclinical company that develops new orally available immunotherapeutic drugs for the treatment of severe infections.

Affluent Medical est un nouvel acteur français de la medtech ayant pour ambition de devenir un des leaders européens dans les domaines cardiovasculaires et urologiques. Affluent Medical développe des implants innovants mini-invasifs de nouvelle génération pour restaurer des fonctions physiologiques essentielles dans ces domaines : - Kardiozis vise à prévenir les endofuites et les risques de récidive de l'anévrisme de l'aorte abdominale permettant aux patients de vivre plus sereinement face à un risque de rupture imprévisible ; - Kalios et Epygon visent à offrir des traitements chirurgicaux plus physiologiques pour la réparation ou le remplacement de la valve mitrale du cœur. Kalios permet de traiter les fuites résiduelles post-opératoire et l'insuffisance mitrale récurrente sans avoir à réopérer les patients. Epygon est aujourd'hui la seule valve transcathéter en développement permettant de restaurer les flux sanguins naturels et de sauvegarder le ventricule gauche. - Enfin, Artus est le premier sphincter artificiel activable électroniquement pour traiter l'incontinence urinaire d'effort des hommes et des femmes. Nos avancées technologies permettent d'offrir des dispositifs médicaux qui respectent davantage la physiologie du corps humain. Nos implants sont mis en place grâce à un chirurgie mini-invasive et visent à limiter les risques de récidive précoce ou tardif de la maladie. Les trois prothèses innovantes et la technologie d'Affluent Medical sont en phase sont préclinique ou clinique.

Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.

AFYX is an innovative niche developer of pharmaceuticals aiming at securing better treatments of diseases with unmet medical needs, such as cancer, women's health and severe pain. Our Research & Development, as well as reformulation of pharmaceuticals based on our patented technologies, helps to improve challenging health issues. We believe our focus will change people's lives. Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and secured successful IPOs of 3 companies in the BioPharma Industry (OXiGENE, Inc; Genmab A/S and Y-mAbs Therapeutics, Inc.) OUR HISTORY is based on the merger of three great and innovative companies bringing significant synergies together – the companies were: INPHENA A/S, a company that already has commercial activities in several countries and develop repurposed existing pharmaceutical substances for new indications. LIONHEART, a company focused on treatment of chronic and intermittent cluster headache. A dramatic a severely debilitating disease with limited treatment options available – We have patent protection for the use of ketamine as nasal administration in this indication. AFYX THERAPEUTICS A/S, a company based on development of a proprietary patented patch technology that sticks to wet surfaces and delivers pharmaceutical products locally where the patch is applied. Our two first projects focus on inflammatory diseases in the oral cavity – oral lichen planus – also a significant unmet medical need and precancerous stages of head and neck cancer in the mouth where we aim to develop a chemotherapy containing patch.

AG3 producesherbaceous perennials, grasses, sedges, bulbs, insectivorous, ferns and tropical varieties. The company uses tissue culture to produceand sellcloned plants.

AGADA Biosciences is a biotechnology company that specializes in providing expert assistance with drug development programs in neuromuscular disease, offering pre-clinical trials in mouse models and human clinical trial support.

Your Best Partner In Diagnostics 28 years of dedication has made us what we are today, one of the forerunners in the Indian diagnostics industry. The 2nd biggest Diagnostic Companies in India with a formidable Domestic and International presence for the entire range of Reagents and Equipment. Our Reagent range includes Biochemistry Kits, Serology Kits, Immunoturbidimetry Kits, Specialized Kits, Coagulation Reagents, Hematology Reagents and System Reagents for Fully Automated Clinical Chemistry Analyzers. We are an ISO 9001- 2008 and ISO 13485:2003 certified Company. We conform to GMP standards and have an FDA approved most modern manufacturing facility. We have been successful in obtaining CE Marking as well for all our products. We have formed a wholly owned Subsidiary Company in Switzerland called Agappe Diagnostics Switzerland GmbH to cater to the needs of the world market effectively. We are the sole distributors of companies such as Toshiba Medical Systems Corporation (Japan), Mindray (China), I-Sens (Korea) and many other giants in the diagnostic industry. Our Vision To Establish Globally As A Premier In-Vitro Diagnostic Corporation And To Be The Best Partner In The Diagnostic Field For The Welfare Of Mankind. Our Mission To Expand And Continuously Improve Our Products And Services With A World Class R&D Program And To Provide The Best Work Environment For Our Employees To Meet And Exceed Their True Potential And To Thrive In A World Of Excellence.

Agastiya Biotech merges advanced, Eastern knowledge with rigorous Western R&D in order to deliver breakthrough innovative pharmaceuticals to the marketplace. Over 40% of all pharmaceutical drugs, including sophisticated chemotherapy and anti-viral drugs, are derived from natural plant sources. Through investigation of ancient Eastern botanical knowledge combined with high throughput and AI driven analysis, Agastiya Biotech engineers best in class novel small molecules for treatment of disease. We are leading the discovery and design of ground-breaking small molecules to revolutionize medicine and find a cure for the diseases of our time.

Agathos Biologics is a biotechnology company pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy. Discoveries in bioprocessing and genetic characterization and control have created an abundance of scientific possibilities that can help us all lead better lives. Our mission as the good science company is to create breakthrough products and services within a strong ethical and moral framework that benefit everyone. We believe in science that serves and have a relentless focus on serving our clients, employees, and society. For more information, please visitÂ

AgBiomeis usingknowledge of the crop microbiome and an extensive network of field-sampling partners to build a proprietary microbial strain collection that is both diverse and large—larger, in fact, than the major public strain collections. Unlike many programs, which only use metagenomics surveys, the AgBiome platform is focused on true isolated microbial strains, which provideinsight into the genomic composition of crop-associated microbes. The company uses this collection as a resource for discovering new biologicals and trait genes.Existing microbial classification systems based on 16S rDNA sequences or other fingerprinting technologies are imprecise—microbes that are classified as ‘the same’ often differ by hundreds of genes. AgBiome uses proprietary algorithms based on whole genome sequence to classify organisms in their collection. This allows the company to measure the true diversity of plant-associated microbes at the gene level—and genes determine function and performance. The company has also applied our whole-genome methods to their straincollection.

For nearly 20 years, AgBiTech has been on a mission to make pest management more sustainable and farming more profitable. As the world's leading producer of NPV-based insecticides, we apply our expertise in research, field development and state-of-the art manufacturing to bring our solutions to major row crops around the world. We manufacture all products in-house at our global headquarters in Fort Worth, TX. Our relentless focus on quality and efficiency, allows us to produce consistent and cost effective biological products that have established us as the market leader in NPV production and commercialization. For further information, visit www.agbitech.com.

AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics (using mammalian and microbial systems), mRNA, pDNA, viral vector and cell therapy products, from pre-clinical to commercial production, including our proprietary CHEF1TM Expression System for efficient protein production with CHO cells. Our company DNA drives us to provide innovative solutions to partner with our customers in helping them reach their goals and accelerate their projects at our cGMP-compliant facilities in the US, Europe and Japan, as well as to facilitate approval and manage spending during the product lifecycle. We forge exceptionally strong partnerships with our customers and we never lose sight of our commitment to deliver reliable and compliant drug substance. Visit www.agcbio.com to learn more.

In 1976 Alister Voller, Mike Clark, and associates reported the successful and sensitive detection of plant viruses by ELISA. Two years earlier, Voller, Engvall, Bidwell and Huldt developed the microwell ELISA plate. This technology arrived just in time to test and select plants grown by tissue culture and to assist clean plant programs using one-way pass-through propagation methods. The rapid exploration and acceptance of ELISA created an immediate need for optimized, validated tests, for kits, for quality controlled antibodies, enzyme conjugates and accessories. Agdia, Inc. was formed to meet this need. Agdia's first tests were developed for common potato pathogens, i.e., the viruses, PVX, PVY, PLRV, PVS, PVM, PVA and the bacteria, ringrot [Cms] and blackleg [Eca]. Next, a Testing Service was developed to help those who needed testing results but did not want to perform the tests themselves. The products and services were an instant hit. Agdia grew quickly as its products and services became known worldwide. In rapid succession many tests were developed for fruit, ornamental and field crops. And, significant advances were made in test formats and test type, including, the PathoScreen® test format, the potyvirus group test, membrane assays for viroids, nested PCR for phytoplasma, PCR virus group tests and ImmunoStrips®. All of this was possible only because a worldwide community of scientists and customers provided technology, biomaterials, plant samples and constant encouragement. Agdia's continuing focus on developing and performing tests for plant pathogens and dedication to confidential customer service and support have earned a special trust and place in the worldwide agricultural community. We value and treasure this trust. And, with each day, we dedicate ourselves anew to providing you with products and service that enable you to grow healthy crops with confidence.

AgeCurve Limited is a company that offers tools to measure scalable single cell somatic mutation burden across the life sciences market space. They also provide a deep age profiling kit intended to calculate comprehensive biological aging patterns in a saliva sample.

Aging is the main cause behind most illnesses that eventually kill us. Your chance of dying doubles every 8 years. By the time you turn 80, half of your peers are dead. However, it turns out aging is a biological process, amenable to treatment. Research has demonstrated that we can postpone the onset of age-related disease. Lab mice know this already. Experiments with caloric restriction, senolytics and metabolic inhibitors have extended life and reversed aging - in mice. But how do we know these treatments will work in humans? We can wait and see if patients receiving these new treatments die later. Or see if onset of age-related disease is postponed. But this is slow. It takes many, many years to know for sure if the treatments work. Wouldn’t it be great if we had a faster way? Thanks to the discovery of the epigenetic clock, we can now accurately describe changes to gene regulation caused by aging. By turning this discovery into a blood test, we can measure the exact aging status inside human cells. This will be incredibly useful to researchers involved in aging research. They would know if a treatment works, much earlier than before. So that’s what we’re making: A biomarker for aging which is accurate, affordable and quick.

Ageless Biotech (ABT) is in the development of discardable, minimally manipulated umbilical tissue based regenerative medicine biologics to address all forms of Osteoarthritis via intra-articular procedures in cooperation with leading scientists and medical professionals. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives. We believe that the formation of life itself is contained within after birth tissues. ABT believes that it is morally, religiously and politically acceptable to use afterbirth materials that would be considered discardable in virtually every country. Furthermore, we believe this to be the right course to addressing problems that a vast majority of the population will face at some point during their lifespan.

Agena Bioscience® empowers research laboratories worldwide to deliver scalable targeted genomic data. Our advanced platforms deliver timely molecular insights in the areas of mutation profiling, liquid biopsy, pharmacogenetics, and more. Agena offers the MassARRAY® System, an open platform that provides researchers with insights through a highly multiplexed solution. Headquartered in San Diego, with offices located around the world, Agena Bioscience fosters a highly collaborative culture for both our customers and employees, encouraging diversity, creativity, and most importantly, innovation.

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

AgeneBio, Inc., is an emerging pharmaceutical company dedicated to developing innovative therapeutics that prevent neurodegeneration and preserve and restore cognitive function for unserved patients battling amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of aMCI. If approved, AgeneBio’s Phase 3-ready lead candidate, AGB101, will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. Learn more at www.agenebio.com and follow us on Twitter @AgeneBio.

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFS TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Agile Therapeutics® is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. Our product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options.

Agilis Robotics is a spin-off company from The University of Hong Kong that develops flexible robotic instruments for endoscopic surgery. We aim to provide clinicians with enhanced robotic dexterity and precision while leveraging current clinical workflows.

agilvax.com is your first and best source for all of the information you’re looking for. From general topics to more of what you would expect to find here, agilvax.com has it all. We hope you find what you are searching for!

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

AgonOx, Inc.is a spin-off company from the Providence Cancer Center located in Portland, Oregon. We are developing immune system activators for use in cancer therapy. Research in the field of T-cell modulation conducted worldwide with OX40 and other agents has demonstrated that the use of T-cell modulating therapies in combination with specific anti-tumor therapies have the potential for yielding therapeutic benefits for patients with cancer. AgonOx is focused on the development of immune system modulators in combination with other promising agents in the immune oncology space.

Agragene has developed Precision-Guided Sterile Insect Technology that will reduce grower's reliance on the 6 billion pounds of pesticides used on crops each year. Agragene is ready to deploy its first "Knock-Out" product in the field which targets spotted wing drosophila. The "Knock-Out" product will benefit crop growers in 3 key ways. 1) The product is much cheaper than the chemical pesticides used now, 2) scarce and expensive field labor is not required and 3) the resulting pesticide-free crop can be Organic-approved which increases grower's profits. Importantly, "Knock-Out" is non-toxic to bees, other beneficial organisms, the environment and humans. With many states and countries banning pesticides growers must look to safer and cheaper alternatives. Agragene has the solution.

Genuity was an early ISP (Internet Service Provider) focusing on commercial customers. It was among the pioneers to offer data center services at facilities with high Internet capacity. It was acquired by GTE/BBN. The company was made independent through the process of consolidating various companies to what is today Verizon.

AgriForest Bio-Technologies Ltd., an agri-tech company located in Kelowna, British Columbia, was originally established in 1984 with a mission to provide tissue culture dwarf fruit tree rootstocks to local orchardists. Since then, we have expanded to produce high quality tissue culture Shade trees, Ornamental shrubs, Roses, Clematis, Lilacs, Saskatoon berries, Haskaps, Grapevines, Hazelnuts and Nutraceutical Plants. The list does not stop there! Our Research and Development department is constantly working on developing new tissue culture varieties. Producing over a million plants, AgriForest is now one of the largest suppliers of tissue culture plants in North America. The AgriForest Wholesale Division caters to nurseries and garden centres, and is committed to providing AgriForest customers with high quality tissue culture plants!

AgriGro’s® formulations deliver plant nutrition along with a prebiotic concentrate, which significantly increases the growth of beneficial native microbial species. The company sells prebiotics for crops, livestock, gardening, golf, and wildlife. The company also makes a prebiotic formulation for treating organic waste or bio-solid residue.

AgriStart enables innovative early-stage businesses and SMEs to grow faster and with the confidence they have a scalable business model. We provide the expert advice and industry connections that fuel growth. We're on the lookout for those genuinely innovative ideas that once brought to market and adequately supported through collaborative partnerships, are industry changing and have global potential.

Agrivida is a biotechnology company focused on developing and commercializing a new generation of enzyme solutions to feed livestock more efficiently, reduce negative environmental impacts, and produce more healthful food for an expanding consumer population. Agrivida’s first product, GRAINZYME® Phytase, grows enzymes that are crucial for livestock’s health and well-being directly inside the animals’ corn feed. The enzymes improve feed digestibility, increase mineral availability, and reduce nutritional inhibitors within the animals. The traditional process for enzyme delivery is costly and inefficient. It requires enzyme additives to be administered alongside animal feed, and the process for producing the enzymes is complicated, generates excess waste, and requires tremendous energy. By growing necessary enzymes directly inside the feed, Agrivida eliminates the need for these enzyme additives, ultimately reducing costs to farmers, minimizing feed waste, and improving the environmental footprint of the entire process. Agrivida’s team is led by food and agribusiness industry executives and scientists with expertise in the fields of biochemistry, plant biology, molecular biology, and nutrition.

AGS, based in Paris, France, is a group of interrelated companies developing biomedicines based on microalgae extracellular vesicles, or MEVs, as a safe, targeted and highly versatile delivery system for innovative biologics, such as mRNA, siRNA, miRNA, proteins, peptides and oligonucleotides for a broad range of human diseases. AGS-M, a contract development and manufacturing organization, produces the MEVs needed to support preclinical and clinical development of MEV-based product pipelines from AGS Therapeutics, and from pharmaceutical and other companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a 2-billion-year-old single-cell algae used for decades as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with simple cell culture media production techniques that are both eco-friendly and easily scalable. For more information visit www.ags-tx.com and www.ags-m.com.

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products Find AGTC on YouTube at goo.gl/sMdJqX.

Ahammune Biosciences Pvt. Ltd. is a startup company based in Pune. Ahammune Biosciences is an innovation-led drug discovery company started in 2016 which focuses on developing new treatment options for immune mediated diseases of the skin. Our current program is on the depigmenting disorder, Vitiligo. The current treatments for Vitiligo provide only temporary and symptomatic relief. Thus, there is an enormous unmet global need in treating patients with Vitiligo. The mission of Ahammune Biosciences is to arrest the progress of Vitiligo and to induce re-pigmentation of depigmented patches. We are committed to take our innovation-driven drug discovery platform to the next level to demonstrate to the world that we as a nation can foster new molecules for complex diseases.

a:head’s drug discovery approach is based on human cerebral organoids, a revolutionary, paradigm-shifting new technology that allows the generation of mini brains from human stem cells in vitro. They capture the essential aspects of human embryonic brain development including brain patterning, formation of brain ventricles, differentiation into the various neuronal and supportive cell types and their correct three-dimensional arrangement. The technology has been pioneered by the company’s co-founders Madeline Lancaster and Juergen Knoblich and is exclusively licensed to a:head by the Institute of Molecular Biotechnology, Vienna, Austria. a:head applies these complex 3D tissue cultures for modelling of various brain disorders in a human context and aims at translating the technology into a powerful high content, high throughput phenotyping platform for the development of novel CNS therapeutics.

We help entrepreneurs form new teams and build AI-first startups. Apply on our website for $500k investment, up to $1M in free AI compute, and network of AI founders and researchers. We bring together world-class engineers, researchers, and entrepreneurs to create new companies together from scratch. From ideation to execution, we help generate ideas, find co-founders, secure pilot customers, integrate cutting-edge AI, and more. Our hands-on support guides founders through building, scaling, and raising millions in venture funding. In 6 years, we've backed 40+ companies now valued at $1B+, raising $220M+ and creating 700+ jobs. Our startups are transforming industries: improving immigrant communication (Yoodli), accelerating cancer research (Ozette and Modulus), enhancing legal efficiency (Lexion, acquired by DocuSign), turning smartphones into medical devices (PreemptiveAI), and so much more. Any VC can write a check, but what truly sets us apart is our unparalleled technical and AI expertise. With our heritage at the Allen Institute for AI—founded by Microsoft co-founder Paul Allen—we’ve been singularly focused on commercializing AI long before it became a buzzword. AI2 has 200+ PhDs, researchers, engineers, professors, and support staff—and is well known for its contributions to the A.I. research community including 600+ papers, 20+ best paper awards, and numerous products/open-source offerings including SemanticScholar, AllenNLP, and more. Our core team includes pioneers like Oren Etzioni, a leader in AI for over three decades, and our deep technical expertise means we don’t just back you financially—we help you build breakthrough products, navigate complex challenges, and accelerate your company’s growth. We're soon launching AI House in Seattle, a central hub for AI innovation. In partnership with the Mayor of Seattle and supported by Washington state, this space will serve as a central hub for the region’s AI community.

A.I. Analysis, Inc. is a medical software company specializing in the application of artificial intelligence (AI) to radiology. A.I. Analysis, Inc.’s first product is the Change Detector for Brain Imaging, a machine-learning based system that compares serial MR imaging studies and presents changes in the form of a color overlay superimposed on the anatomical images. The Change Detector saves radiologists time at the beginning of their reading — perhaps up to 10 minutes for diseases such multiple sclerosis. The Change Detector highlights the locations of changes and degree of those changes, so the radiologist can more quickly reach clinical judgments. Using the Change Detector, it may be possible for radiologists to detect changes months earlier than is possible with manual inspection alone, with greater reproducibility.

Aiberry is an AI-powered multimodal platform that offers providers and care managers rapid, objective, and unbiased behavioral health assessments. Aiberry delivers evidence-based insights virtually (in telehealth scenarios) and at the point of care, offering unique outreach and scale opportunities.

-Artificial Intelligence powered Drug Discovery. -a Biopharma company specialized in medicinal chemistry research of preclinical drug candidates. Ai-biopharma has in-silico solutions of Chemoinformatics, Molecular Modeling, Docking, Data analysis, SAR formatting/interpretation and also an Artificial Intelligence platform for the accelerated drug design towards the selection of new preclinical candidate drugs .

AiCuris (from 'Anti-infective Cures'​) is a pharmaceutical company focused on the discovery, research and development of novel antiviral agents for the treatment of severe and potentially life-threatening infectious diseases in immunocompromised patients. Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris has a broad and innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis, across a variety of fields from oncology to neuroscience and more. From empowering researchers in the identification of novel biomarkers of disease, and supporting R&D scientists in speeding up time-to-market of novel drugs, to helping pathologists enhance the accuracy of cancer diagnostics — Aiforia has the expertise and experience to transform healthcare all the way from discovery to diagnosis.

Aigen is accelerating the transition to regenerative agriculture. We're launching the world's first AI-driven, network connected robotic fleet, powered entirely by the elements. Aigen is building a future with no harmful chemicals in our food. Backed by NEA, GFC, AgFunder, Regen.vc, and Bessemer Ventures

We aim to advance current state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient discovery, ultimately leading to high success rates in the clinical phase. Our award-winning AI drug discovery platform enables the direct discovery of high potency drugs that induce desired cellular-level activity with minimal off-target effects and toxicity. AIGEN Sciences will revolutionize AI-based drug discovery.

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE).

AILIS is a pioneering technology. It combines Dynamic Parametric Imaging, artificial intelligence, and telemedicine to immediately detect symptoms of breast cancer and estimate the risk of developing the illness. Our mission is to provide women with dense breasts with access to efficient and comfortable testing based on imaging that detects early symptoms of breast cancer, and to guarantee them with comprehensive care in terms of monitoring their health. Technologies that change the world are always a result of long and hard work of a team of non-accidental people. At AILIS, everyone has a purpose. We are a team of experts and specialists in a number of fields and we share common values. At AILIS, we share common values and principles that we follow in everyday work. To protect the health of millions of women in an honest, responsible, and respectful way. Never to lose our passion for science. And to develop a technology that is authentic in terms of its mission, as well as a service that will become a synonym for protectiveness.

AIM ImmunoTech Inc., an immuno-pharma company headquartered in Ocala, Florida, is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3). Ampligen® represents an RNA being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina. Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older. We operate a 30,000-square-foot facility in New Brunswick, NJ to produce Ampligen® and Alferon®. We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.

Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies.

Ainnocence is a next-generation biotech company with a fast, self-evolving AI drug design platform. The company's third-generation AI system delivers lightning-fast virtual screening and multi-objective pharmacological profile optimization for small-molecule, antibody, and other complex therapeutic modalities. This platform provides a computational screening capacity of up to 10^10 protein sequences or chemical compounds within hours. The end results are a shortlist of candidates with a very high wet-lab hit rate, and a dramatically reduced discovery time and cost. To learn more, visit ainnocence.com.

Ainos Inc. is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, women's health, pneumonia, Ainos Pen, AI Nose, and other medical technologies. The company was founded in 1984 and is engaged in developing innovative medical technologies for point-of-care testing and safe and effective treatments for various health conditions.

Aiosyn is a Dutch healthtech company that is developing precision pathology software solutions for breast cancer and chronic kidney disease. Aiosyn launched its first automated QC test on the EU market (AiosynQC) and the first clinical diagnostic test for breast cancer is pending regulatory approval in the EU. With our NephroPath platform we support CROs and Biopharma with quantifying kidney biomarkers thereby accelerating (pre-)clinical drug development studies.

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.

AirLife is the global leader in consumable breathing products, specializing in respiratory care, anesthesia, and patient monitoring solutions. AirLife has brought together the most trusted brands in anesthesia and respiratory care, such as SunMed, Salter Labs, Ventlab, Ethox Medical, Westmed, Vital Signs and Ballard. Our family of brands offers a product portfolio that spans the continuum of care from first responder to home care, with safety, patient comfort, and clinical performance in mind.

AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.

AIROS™ Medical, Inc. is a medical technology manufacturer, designer, and specification developer specializing in compression therapy. Our team of engineers, quality and regulatory experts, and clinical partners create medical devices that improve quality of life for patients battling lymphatic and venous disorders, including the AIROS 6 and AIROS 8 Sequential Compression Device systems.

Created in 2011 as a spin-out of Cincinnati Children's Hospital Medical Center (CCHMC), Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is in advanced preclinical phase of developing AT-100 (rhSP-D), a product targeting bronchopulmonary dysplasia (BPD) in newborns.

aitiologic is an Austrian precision medicine startup developing ai-powered solutions for early disease detection and targeted therapy.

AIVITA Biomedical is an Irvine, CA based company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development. These proprietary capabilities enable us to turn therapeutic discovery into reality, developing revolutionary cell-based treatments and healthcare products for the patients who need them. AIVITA is developing treatments for cancer, vision loss, and is bringing next-generation skincare formulations to consumers through its commercial product offerings.

AiViva BioPharma, Inc. is a privately owned clinical stage biotech developing novel technologies to address unmet medical needs by transforming existing treatments to create localized, targeted treatment of diseases while limiting systemic exposure. Our core competency includes development of drugs using our proprietary JEL™ Technology in specialty therapeutic areas of Dermatology, Ophthalmology, Urology, and Oncology.

Aix Scientifics is a Contract Research Organisation that specializes in planning, implementing, and evaluating clinical research for pharmaceutical products and medical devices.

We are creating a new category of medicines with the application of spatial biology and AI.

Improve yield, reduce deviations, and ensure product quality in GxP pharmaceutical manufacturing with real-time, practical Artificial Intelligence (AI)- powered software as a service solutions.

AJA Labs is materials science and fiber innovation firm pioneering in dermotextiles and cosmetic textiles. We have brought to market "the fake hair of the future" under the brand mantle, Nourie, manufacturing and selling hair extensions made from biopolymers. Harvested in SOSV's IndieBio accelerator and NC State's Wilson College of Textiles, AJA Labs is where cosmetic efficacy, intellectual property, and sustainability intersect. Not only is our Raleigh-based team creating and defining a novel category in cosmetic haircare, but we are doing so through IP-backed platform technology that borrows the methods and means from time-release technology popularized in OTC pharmaceuticals. Each fiber of hair is wrapped in a nutrient rich cosmetic coating loaded with active ingredients you'd find in the Sephora skincare aisle to penetrate the hair shaft and scalp. Nourie's plant-based cosmetic performance fibers nourish your body during wear by releasing a cosmetic coating; it performs for you to address often overlooked beauty concerns while achieving style-forward hair looks. Much like the category-creating lab-grown diamond industry before it, AJA Labs approximates key properties of human hair including tensile strength, diameter, and biocompability. Currently undergoing human clinical trials for efficacy, AJA Labs proudly manufactures in the USA.

Ajax Therapeutics is a biotechnology company developing precision therapies for blood cancers called hematologic malignancies. The company has a unique partnership with Schrödinger, Inc. to develop novel small molecules targeting cytokine signaling pathways for hematologic malignancies.

Ajinomoto is a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients and consumer food products.

Ajna BioSciences is pioneering the development of FDA-approved botanical pharmaceuticals to revolutionize the world of medicine. Our strategy encompasses a focus on select plant and fungi species with a well- established history of therapeutic use, which streamlines the drug discovery process, mitigates late-stage clinical trial risk, and propels us towards unprecedented medicinal breakthroughs. With a specialized infrastructure and industry expertise, we're strategically poised to lead and create significant value in this exciting, nascent category of pharmaceuticals. Join us as we tap into the transformative potential of nature, shaping the future of health and medicine.

From our headquarters in Copenhagen, we develop and manufacture vaccines, diagnostics, and therapeutic solutions for the world. We are proud to contribute to disease control in more than 50 countries through our collaboration with WHO and UNICEF. We have more than 600 colleagues, and we pride ourselves on being a diverse workforce with passports from 39 nationalities. Being part of AJ Vaccines means joining a common mission towards a healthier and safer world. Whether you're an experienced professional or an emerging talent, you'll find a platform here to contribute, innovate, and create meaningful change.

Akadeum Life Sciences® has developed a next generation platform that solves long-standing problems across cell therapy and other research, diagnostic and therapeutic markets. The proprietary buoyant microbubble technology platform addresses the need for high cell quality, scalability, time and workflow that current magnetic particle-based products commonly used in cell therapy manufacturing and research can’t address. The Company has several GMP grade and Clinical Ready kits to enable each stage of cell therapy manufacturers pipeline. Harnessing the microbubble capability, the Alerion™ Microbubble Cell Separation System enables cell isolation from tens of billions of cells in apheresis material in under an hour, significantly expanding capacity of manufacturers. Akadeum is currently working with some of the largest corporations and forward-thinking leaders in the industry. The power of the Akadeum microbubble platform is an elegant and easy-to-use technology that can enable faster, more accurate, and scalable workflows to improve human health. Better Isolations. Healthier Cells.

Akamis is a clinical-stage oncology company whose mission is to leverage its groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. We are developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis’ growing pipeline of T-SIGn® therapeutics is anchored by its lead clinical-stage program, NG-350A, which is being investigated in an ongoing Phase 1 clinical study in patients with metastatic or advanced epithelial tumors. Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akashi Therapeutics is a clinical stage biotechnology company developing a portfolio of products for Duchenne muscular dystrophy and other rare diseases. The lead clinical asset is HT-100, and drug candidate with potent anti-inflammatory and anti-fibrotic properties that also promotes healthy muscle regeneration. The company's second clinical candidate is DT-200, a Selective Androgen Receptor Modulator (SARM), targeted to build muscle mass and strength.

AKAVA Therapeutics is developing first-in-class small molecule therapeutics that inhibit protein aggregation, inhibit enzymes and inhibit cancer for a variety of neurodegenerative diseases.

Since our founding in 2007, we’ve put tenacity and innovation to work to develop novel therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal community. Today, we are a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization.

Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs. Over 21 million adults suffer from Neuropathic Pain in the US alone†, for which opioid medication is a common treatment. Associated costs exceed $90 billion/year in the US,† and roughly 40 ‐ 70% of people do not receive proper medical treatment and are at risk for either over‐ or under‐treatment.‡ Akelos: Building New Frontiers to Address Neuropathic Pain Akelos is an innovative research-based biotechnology company founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. Akelos holds an exclusive worldwide license with Columbia University and Cornell University and is working in collaboration with Weill Cornell Medicine. Researchers at Weill Cornell University and Columbia University have developed novel compounds for the treatment of neuropathic pain, resulting in intellectual property that is jointly owned by Cornell and Columbia. Akelos has licensed this intellectual property and is developing a treatment for neuropathic pain using the novel compounds.

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco.

Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address global medical needs. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode. Akeso is actively developing a diverse pipeline of over 50 innovative assets in cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, and 13 pivotal/phase III trials ongoing. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.

3D substrate, drug-containing microparticle device, formulation services, polymer drug delivery

We, at Akira Science - a Stockholm based tech start-up-, use the latest manufacturing technologies to provide you with pliable scaffolds for soft tissue engineering. Our solutions results from the synergistic combination of degradable polymers synthesis expertise, mechanical simulation approach to develop suitable scaffold design to tailor the biological response.

AKL Therapeutics is a pharmaceutical company changing the way drugs are developed by seeking inspiration from nature to combat some of the biggest challenges facing modern medicine today. We are committed to transforming patient’s lives through pioneering innovation. We begin by identifying secondary metabolites of plant origin, with proven efficacy and safety. These metabolites are then synthesized before undergoing standard pharmaceutical clinical development. This innovative approach greatly increases the chances of success, while reducing the risk of side effects. Formal human clinical trials are currently underway assessing the safety and efficacy of an investigational oral therapy, ‘APPA’ in the treatment of osteoarthritis, a common and devastating disease with limited treatment options and no cure. APPA is also being evaluated in other inflammatory diseases and other molecules are also under investigation. AKL Research & Development Ltd, trading as AKL Therapeutics Ltd, welcomes enquiries from potential investors and partners as we continue the development and commercialisation process.

Akonni Biosystems is a molecular diagnostics company that develops, and manufactures at scale, sophisticated yet low cost genetic testing devices for complex infectious diseases like multi-drug-resistant tuberculosis (MDR-TB). Our approach is based on a revolutionary gel-drop microarray platform, along with associated instrumentation for high yield sample preparation and multiplex array imaging/analysis.

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss.

Akribion Genomics discovers novel groundbreaking CRISPR nucleases and develops them into a new class of genetics-based cancer therapies and advanced genome editing tools. Akribion Genomics' flexible CRISPR-based gene editing technology platform features distinct technology families (G-dases®) with broad application in Industrial Biotechnology (and Agriculture), and offers a groundbreaking technological advantage for therapeutic and diagnostic solutions. Akribion Genomics is committed to using its technology with high ethical standards to improve products, processes and medical treatments. Our mission is to enable new treatment approaches in oncology by employing novel CRISPR technology that allows targeted cell depletion using RNA biomarkers. On top, we aim to provide access to advanced CRISPR genome editing technology with freedom-to-operate. All this is summarized in our motto and brand "Gediting". Akribion Genomics is a company in founding and soon-to-be spin-off of BRAIN Biotech AG, a renowned international group of companies providing innovative biobased products and solutions to industry.

Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E payload has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed. Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), Akribion is exploring additional applications in oncology, autoimmune diseases, fibrosis, and infectious diseases. The flexibility and broad potential of Akribion's technology makes it a promising platform for various therapeutic areas, as by simply changing the guide RNA, the technology can be quickly adapted to target different cells, making it much faster to develop new treatments compared to traditional methods. Founded in 2024 and based in Zwingenberg, Germany, Akribion was spun out of BRAIN Biotech AG, the specialist in biosolutions for industrial applications.

Akrivis solutions cool equipment and deliver cleanroom conditions in modular buildings and cabins. Specialist units delivering exceptional performance, outstanding reliability, and ultra-low energy usage.

Akrivita (formerly SeeTrue), a woman-owned company, specializing in microcapillary needles for precision microinjection. At AkriVita, we've developed the MultiPort Microcapillary Needle using advanced 3D printing and unique resin, ensuring precise and consistent needles. This innovative design eliminates recalibrations, reduces downtime and costs, and minimizes clogging. Our high-contrast needles offer consistent flow, improving the success rates of microinjection procedures. AkriVita provides biomedical scientists and healthcare practitioners with reliable tools that enhance outcomes, save time, and cut costs, enabling them to focus on advancing human health through discovery and innovation.

Akrotome Imaging, Inc. is focused on the clinical translation of cancer-targeted molecular probes into enhanced approaches for surgery and diagnostics, leading to improved outcomes and patient quality of life while positively impacting healthcare economics. Akrotome is a Delaware C Corporation with offices in Ohio, Indiana, and California. The company was first incorporated in 2008 and the current management team has been in place since May of 2012. The company's approach stresses the efficient use of capital, coupled with strategies that emphasize the fastest routes to the clinical market with the lowest regulatory overhead.

Akseera, is a science driven, innovative, and distinctive company that draws on the unique experiences of our team to bring ingenious solutions that address unfulfilled medical needs globally. We endeavor to do this independently and in collaboration with world class institutions to help improve lives.

A vertically integrated entity, which maintains quality control starting from importing finished and semi finished drugs, to assembly and retail. We work with industry leaders to source quality products. With retail operations with stores located in heavy traffic areas to serve the customers 24 hours. With a pharmacist on site, customers can receive consultation around the clock.

Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha radiopharmaceuticals for the mainstream of cancer care.

Alabama Agricultural and Mechanical University(AAMU) is a historic, student-friendly and community-focused institution of higher learning. Reflecting on its heritage as a historical black college and university (HBCU) and a traditional 1890 land-grant institution, AAMU functions as a teaching, research and public service institution, including extension.

ALACRIS Theranostics GmbH is a Berlin-based systems medicine company founded in 2008, originating as a spin-off from the Max Planck Institute for Molecular Genetics. The company focuses on developing innovative solutions in healthcare, particularly in biomarker discovery, drug development, and precision medicine, with an emphasis on molecular oncology. The company offers comprehensive Next-Generation Sequencing (NGS) services that enhance precision medicine. By integrating advanced omics technologies with mechanistic computer modeling, ALACRIS develops biomarkers of drug response. Their services include high-dimensional data analytics and bioinformatics systems, tailored to meet medical needs in collaboration with clinicians. ALACRIS Theranostics is actively involved in partnerships with academia, biotechnology, and pharmaceutical companies, contributing to various research projects and applying their technologies in clinical settings. ALACRIS is committed to delivering data quickly while ensuring quality and confidentiality. Their interdisciplinary team combines expertise in sequencing technologies, advanced computing, and bioinformatics to provide effective healthcare solutions.

Alacrita is a pharma and biotech consulting firm whose value to clients is founded on the first-hand experience of its subject-matter experts. Consultants who have spent their careers discovering, developing, manufacturing and commercializing drug products. Our core team leverages a purpose-built network of over 250 such experts who are brought into project teams when specialist expertise is needed. This allows us to provide clients with precisely relevant support on a range of R&D and business issues. We do this while also offering the speed and flexibility expected from a professional life science consulting firm. Our expert teams are ready to support you through every step of the pharmaceutical product development process, leveraging our scientific, clinical and commercial expertise to help you maximize value at each stage. We offer substantial expertise & experience in the following areas: Product Development Services: - Clinical Development - CMC & Supply Chain - Interim Chief Medical Officer Support - Preclinical Strategy & Execution - Regulatory Affairs - Research & IP Evaluation Strategy & Commercialization Services: - Business Plans & Fundraising Support - Opportunity Mapping - New Product Planning - Launch Planning Business Development Services: - Asset Scouting - Due Diligence - Licensing, Partnering & Dealmaking - Pharma & Biotech Valuations Visit www.alacrita.com to learn more.

Alafair Biosciences is a privately-held, commercial-stage medical device company focused on the development of novel clinical products using its proprietary hydrogel technology. With a patent portfolio covering a broad range of clinical applications, Alafair is focused on building a robust product pipeline. Its products are distributed through a dispersed network of independent distributors across the United States.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

Alar Pharmaceuticals Inc. (abbreviated as Alar), a new drug development company, was established in 2016. We focus on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and major depressive disorder.

Alator Biosciences is a privately-held company providing quality research products and custom manufacturing services located in Sun Prairie, Wisconsin minutes away from the heart of Wisconsin's biotech community and University Research Park.

Alaunos Therapeutics (previously Ziopharm Oncology, Inc.) a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient’s immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is based in Houston, Texas.

At Alaya.bio, we're developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells. Our platform eliminates the need for activation factors or cytokines, resulting in reduced exhaustion of transduced cells while preserving their naive and memory phenotypes, leading to better clinical outcomes.

Alba Health is on a mission to improve the health of next generations. Join our movement to fight the chronic disease epidemic from childhood.

Albatroz Therapeutics is a pre-clinical stage biotech company developing therapeutic antibodies and ADCs to treat solid tumours and arthritis, based on its proprietary position over a novel target critical to ECM degradation.

The Genomics Core serves the Einstein scientific community by providing a broad range of services, utilizing current and emerging nucleic acid technologies. Single-cell assays, MPS, Microarrays, real-time PCR, Sanger sequencing and assay automation are available. The Core provides a number of technologies for genotyping DNA from humans or model organisms, varying from SNP (single nucleotide polymorphism) typing to targeted sequencing for variant discovery.

Albumedix is an England-based biotechnology company that manufactures and markets albumins for vaccine stabilization, cell and gene therapy applications.

Alcala Labs was founded by a partnership between a healthcare attorney specializing in the defense of individual and institutional healthcare providers and a physician with one of the largest pain management practices in Southern California. The lab grew out of frustration with existing laboratory providers and the conviction that Alcala Labs could do better. Smaller labs were not scientifically up to the task and, in many cases, were simply dishonest about the services they provided. Larger labs were either unresponsive or subcontracted critical complex lab services to unaccountable third-party labs . Alcala Labs was built to react quickly to the needs of physicians who need to understand drug use and efficacy in their practices. The Alcala difference is accessibility to its physician customers, responsiveness to their needs and inquiries, and customizable lab testing. If a physician has a medical-legal question that arises from testing, he can immediately reach the company's healthcare attorney President. If a physician requires insight into how a particular test affects the course of a patient's care, she can engage in a dialogue directly with the lab's Medical Director. If there are questions about science and the development of new tests, our highly credentialed scientific team can be reached directly. Widely in demand among a variety of specialties, Alcala Labs is of especial importance to drug rehabilitation, pain management, and psychiatry practices. We're able to add assays as illicit "designer" drugs begin to appear, and our new pharmacogenetic department gives physicians the power to anticipate the right drugs and dosages to best treat their patients. Located in San Diego, Alcala is a laboratory of national reach and reputation. It is among the fastest growing labs in the country, dedicated to state-of-the-art science and the highest quality service.

Alcami is a pharmaceutical CDMO that offers contract development and manufacturing services for the healthcare and biotechnology industries.

With over 30 years of experience, Alcedis combines medical expertise with ground-breaking technologies to pioneer data-driven clinical research. Our module-based service concept and flexible data capture systems adapt seamlessly to any project structure and accompany your entire research process - from Phase I to drug approval and beyond market access into real-world evidence.

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Alchem Laboratories is a pharmaceutical company that specializes in custom organic synthesis, cGMP manufacturing, and analytical services.

We build and operate in-house pharmacies for safety net clinics, with a focus on STD clinics, Ryan Whites, and FQHCs serving patients living with HIV and Hepatitis C. We provide the entire physical, clinical, and digital infrastructure needed to operate and grow best-in-class 340B pharmacy programs. Our team has deep clinical pharmacy, technology, and operations experience. Together, we have spent 18 years in Africa building the largest HIV access program in the world, and we have set up, operated and scaled pharmacies that have dispensed over 25M+ prescriptions to patients across all 50 states in the US. After setting up your in-house pharmacy, we design and implement clinical pharmacy programs and deploy technology products that leverage your pharmacy to expand patient reach, improve clinical outcomes, and increase the financial impact of your 340B program. We are on a mission to serve safety net clinics and their patients. Drop us a line at hello@alchemyhealth.com.

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company’s lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.

Alcyone Therapeutics is a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions. The company integrates innovation in neuroscience, precision dosing platforms, and manufacturing capabilities to deliver transformative therapies to patients. Alcyone leverages the synergy between FalconTM, the company’s proprietary intrathecal precision dosing and biodistribution platform that incorporates deep knowledge of cerebral spinal fluid (CSF) dynamics, computational modeling, and bioengineering, and four novel gene-based therapeutics platforms developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital (AWRI). This comprehensive approach allows for the optimization of central nervous system (CNS) dosing and delivery to better target the pathophysiology and anatomy specific to various neurological diseases. Alcyone’s lead programs utilize X chromosome reactivation for X-linked disorders and targets the treatment of Rett syndrome, and gene replacement for the treatment of IGHMBP2-related disorders including spinal muscular atrophy with respiratory distress type 1 (SMARD1) and Charcot Marie Tooth disease type 2S (CMT2S).

Aldatu Biosciences advances the development of innovative diagnostic tools that drive our collective response to global health emergencies. Aldatu's proprietary PANDAA technology is a qPCR-enabling platform that overcomes long-standing diagnostic challenges to enhance the quality and affordability of high-throughput infectious disease diagnostics and improve patient access to diagnostics in resource-limited countries. Our PANDAA qDx™ SARS-CoV-2 assay is being implemented in numerous clinical labs and we have established Aldatu Diagnostics, a clinical lab dedicated to supporting our community's needs for COVID-19 testing using Aldatu Biosciences' PANDAA technology.

Aldebaran Therapeutics leverages human genetics and best-in-class antisense oligonucleotide (ASO) technology to deliver life-changing, precision ocular ASO medicines. Our focus on differentiated ASO technology, powered by Alloy Therapeutics' Genetic Medicines platform and novel AntiClastic™ ASO format, paves the way for a unique and rapid path to meaningful ocular solutions for patients.

Founded in 2017 and headquartered in Paris, France, Alderaan Biotechnology works with world-class teams in the fields of immunomodulation and immunotherapy of cancer focusing on the development of monoclonal antibodies with technologies aiming at Treg depletion in solid tumours. The company raised €1.5M ($1.7M) in 2017 from co-founder AdBio partners and €18.5M ($20.7M) in 2019 from AdBio partners and Medicxi. Alderaan Biotechnology works in partnership with the French national Institute for health and medical research (INSERM) and with the Institut Paoli Calmettes, Marseille, France.

Alder Renewables harnesses the power of abundant and sustainable biomass to create a low-carbon to carbon-negative renewable platform.

Aldevron is proud to be part of Danaher. Aldevron is a leader in advancing biological science. Our custom development and manufacturing services have provided scientists around the world with the tools to make significant scientific advances. We provide high-quality plasmid DNA, proteins, enzymes, and other biologicals to help our partners achieve ground-breaking science.

Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.

Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions.

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Alectos Therapeutics is a privately held pharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics for the treatment of human disease. We focus on preclinical drug development, target validation, hit-to-lead optimization, and IND-enabling studies. Alectos develops innovative new strategies to address medical conditions for which there are no effective treatments.

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).

Aleph Farms®, an Israel-based cellular agriculture company, enhances sustainability, food security and animal welfare by diversifying the supply and decentralizing the production of quality animal proteins and fats as a complement to sustainable methods of conventional animal agriculture. Founded in 2017, the company unveiled the world's first cultivated thin-cut beef steak in 2018, the world's first cultivated ribeye steak in 2021, and cultivated collagen in 2022. Under its product brand, Aleph Cuts™, the company is launching its first product, the cultivated Petit Steak, grown from non-modified cells of a premium Black Angus cow. For its contributions to climate leadership, including a net zero commitment made in 2020, it has received top accolades from the World Economic Forum and the United Nations.

Alere is now Abbott! Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.

Alesi Surgical announced in 2023 that it had attained FDA clearance for its groundbreaking Ultravision2 smoke management solution. The breakthrough new Ultravision system includes the world's first surgical tool integrating electrosurgery and class-leading surgical smoke control in a single laparoscopic device. Alesi Surgical was founded to develop and commercialise products that improve the safety, efficacy, and outcomes of surgical procedures. The company is a spin-out of the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical training centre in the UK. Alesi Surgical has a unique level of access to experienced surgeons, surgical trainers, and trainees, which allows it to identify issues in procedures and design devices to address these issues. The company is active in the research and development of novel surgical technologies. It has a ‘needs-driven' pipeline and product development is informed by robust testing by surgical trainers who advise on the utility, usability, and integration of products into surgical practice. Ultravision is designed to deliver rapid and continuous resolution of surgical smoke. It is a small, stand-alone, portable unit fully compatible with current laparoscopic equipment and electrosurgical instruments. Alesi Surgical welcomes approaches from research-based companies or inventors who are interested in exploring potential synergies.

Alessa Therapeutics is a biotechnology company that specializes in developing localized treatments for solid organ disease.

Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package.

Aleta Biotherapeutics’ unique portfolio of multi-antigen targeting solutions for cell therapy address are designed to enable approved CAR T cell therapies to work better in B cell lymphoma, B cell leukemia and multiple myeloma. Our technology is designed to further enable CAR T cell therapies to successfully treat non-B cell cancers such as acute myeloid leukemia (AML), and solid tumors such as breast cancer, gastric cancer and pediatric brain tumors, an area where advances are desperately needed.

Privately-held Montreal-based biotechnology company Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. Currently having one clinical-stage program with phase I data. Portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology. Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline. Established strategic partnerships to access mAb generation, humanization, antibody-drug conjugates, and CHO production technologies

Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world. Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, as well as local and regional operations in countries around the world. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day.

At Alex Therapeutics we provide digital health solutions that enable pharmaceutical companies to better support their products, and their patients. Leveraging our proven modular technology platform allows partners to reduce time-to-market and enables frictionless deployment of safe, secure and effective digital health products. Over 100,000 patients have used our products globally, with our best-in-class user experience design ensuring better health engagement and outcomes.

Alfa Wassermann Diagnostic Technologies is a provider of medical diagnostic instrumentation and reagents to the physician office, veterinary lab, and biopharmaceutical markets.

Alfred University is a small, comprehensive university in the Village of Alfred, Allegany County in Western New York, United States, south of Rochester and southeast of Buffalo

Pharmaceuticals, diagnostic reagents, medical devices

Algae-C is developing a platform for the sustainable and low cost production of plant-based ingredients. The companycreates designer microalgae that produce valuable ingredients for the pharmaceutical, nutraceutical and therapeutics industries.

Algae Systems is a full service algae to energy technology development and commercialization firm focusing on autotrophic algal solutions for the production of carbon negative high-BTU liquid fuels, water treatment and other high value products. Algae Systems was founded by a group of renewable energy veterans, NASA engineers, business executive consultants and IT experts. We are developing low-tech, highly scalable carbon-negative fuel production infrastructure that simultaneously treats wastewater and provides other services to industralized and developing economies.

We have broken the barrier to produce any microalgae on a commercial scale using a patented technology modular system. Our algal biomass is distributed as live, natural, high density, and of unequaled nutritional value. We partner with you to create a data driven knowledge network of best practices.

ARC specializes in mass culturing of sensitive marine and freshwater microalgae that are challenging to grow on a large scale. We are also experts in finding the proper medias for difficult to culture species and isolating species from wild samples. Our main group of focus are dinoflagellates, but we have recently expanded our services to include diatoms, such as Haslea sp., and freshwater species, such as the green algae Oophila sp. ARC also provides toxin analysis, DNA extraction and sequencing, photomicrographs, and HPLC pigment analysis. Feel free to contact us at arc.uncwilmington@gmail.com or view our website for service pricing and available strains.

Nature's solution for food's future. Engineering sustainable food solutions for all. As a food-tech company, Algama harvests the potential of algae to create food that's good for both people and the planet. Algama's goal is to feed 10 billion people by 2050, while preserving the planet and offering consumers additional and better choices in foods. Our story After consuming microalgae for numerous reasons, Alvyn and Gaëtan conclude that it was a viable solution with the potential to redefine our food system for good. Algama was founded in 2013. World leader in algae food Since its founding, Algama has been the world leader in microalgae food and is proud to have the support of world-class impact investors like Horizons Ventures, Blue Horizon Ventures, CPT Capital, Veginvest, Beyond Impact, Alwyn Capital. All the team is dedicated to innovate and make microalgae a key resources for tomorrow's daily food. Algama team We are focused on bringing microalgae-based foods to market, we are working hard to make our ingredients and products super tasty, affordable and widely available. We are expecting the team and we are looking for talents, innovateurs and entrepreneurs.

Introduction NannoStar® and NutriSpring® are a premium quality micro-algae products for producers and end users in aquaculture and human nutrition. NannoStar and NutriSpring are 100% Dutch quality microalgae products and produced in a pristine location at the banks of the IJsselmeer at the edge of the largest protected natural area of the Netherlands. Our microalgae are grown on ancient borehole seawater (Pleistocene 130.000 years old) which is free of contamination and heavy metals. The water is extracted from 80 meters below the surface. NannoStar® and NutriSpring® are year round produced in a full controlled photobioreactor system by our dedicated team of PhD microbiologists who have 20 years of combined experience in microalgae production. The microalgae are grown on selected food grade nutrients under ISO22000 and GMP+ certification. Natural and sustainable The AlgaSpring team developed an advanced algae production system which enables the production of premium quality marine microalgae at a competitive cost level. AlgaSpring micro algae are produced environmentally friendly and no pesticides or herbicides are used. We use selected, natural algal strains and pure water and nutrient sources. Production batches are continuously monitored for quality control. AlgaSpring microalgae are cultivated in a mono-specific culture under controlled conditions in a semi-continuous process with optimum provision of nutrients, CO2, light and mixing. Cultivation and processing conditions are standardized which ensures a constant quality and a high content of valuable components in the microalgae product. AlgaSpring microalgae are produced with just daylight and no additional heating other than to keep the production facility frost free during the winter. Our marine climate zone with cool summers and mild winters ensures us of year round production at the best quality.

AlgenAir makes an air purifier that uses Spirulina to create oxygen and reduce carbon dioxide. According the company, one air purifier provides a benefit equivalent to 25 houseplants.

Algen Biotechnologies is a biotechnology company that specializes in revolutionizing therapeutic drug discovery through advanced CRISPR gene-modulation and AI.

Our scientists redesigned plastic materials to harmonize with nature. Our patented Soleic® technology is the world’s first high performance, renewable, and fully biodegradable plastic material made from algae. Algenesis was founded in 2016 by three professors from UC San Diego, Dr. Stephen Mayfield, Dr. Micheal Burkart, and Dr. Robert Pomeroy. Together they combined their knowledge and background and worked their way into the polymer market where customers had an unmet sustainability need. Traditional petroleum plastics are responsible for a tidal wave of air, land, and sea pollution that is destroying ecosystems and harming wildlife. Soleic® technology was developed to address this global plastic pollution crisis. Our initial product line consists of soft foams for footwear and hard foams for surfboards. We continue to research new applications for Soleic® technology. Algenesis is also developing new technologies with exciting product applications across multiple industries

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF) is a clinical-stage pharmaceutical development company. Our unique drug repurposing strategy enables us to discover new therapeutic uses for existing drugs. This business model lowers investment, risk, and research periods while increasing active patent life. Twitter: @AlgernonPharma Facebook: @AlgernonPharmaceuticals

AlgEternal Technologies LLC will reduce human dependence on fossil hydrocarbons and create sustainable economic activity resulting in a healthier planet and improved quality of life for all, by harnessing the power of the PLANET'S PRIMARY PRODUCERS—ALGAE. MISSION: AlgEternal Technologies LLC will systematically apply microalgae as THE SUSTAINABLE INTEGRATED SOLUTION to the major existing and emerging issues facing our species, faster, more efficiently, and with greater environmental, social, and economic benefits.

Algomedix is an emerging biotechnology company which is using the advances in precision medicine to accelerate drug discovery and development for TRP (Transient Receptor Potential) targeted therapeutics. Critical members of the large TRP superfamily include TRPA1, which is a validated target recognized by the pharmaceutical industry for the discovery and development of novel therapeutics to treat pain, inflammation, ocular and dermatological disease. Algomedix has successfully identified novel small molecules that target human TRPA1 with both high potency and specificity, and have been optimized to have excellent drug-like properties. Thus, the Algomedix compounds represent a major advance in next-generation pain killers which have no opioid related, NSAID related, or gabapentanoid adverse effects, and have been rationally designed to have no addiction or abuse liabilities. These advantages are further enhanced by a primary peripheral mechanism of action, blocking pain at its source. Algomedix possesses near-term clinical development opportunities combined with novel approaches to developing its first-in-class novel therapeutics addressing a critical unmet medical need. Algomedix's most advanced patented compound is in late-stage preclinical development and prepared to advance to clinical trials. This compound has demonstrated potent analgesic activity activity in multiple established pain models, which are recognized as the gold standards in the areas of osteoarthritis pain (OA), neuropathic pain, and chemotherapeutic-induced peripheral neuropathy. Due to the critical and fundamental role of TRPA1 in mediating the initial steps of pain signaling throughout the body, there are multiple therapeutic applications for treating chronic and acute pain in patients. In addition, Algomedix is pursuing programs developing a pipeline of novel, first-in-class molecules for other indications, which include chronic kidney disease and cardiac hypertrophy

Algorithmic Biologic's vision is to create a bountiful and healthy world by bringing scale efficiencies to molecular discovery and diagnostics. Our transdisciplinary team has a deep modeling-based understanding of the chemistry and mechanics of molecular technologies. Our first product, Tapestry, is award-winning, regulatory approved algorithmic solution to provide affordable large-scale COVID-19 testing.

Alia Therapeutics is a pioneering gene editing company with a vision to revolutionize medicine by curing genetic diseases at their roots. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomic sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which are required for therapeutic applications.

Alida Biosciences is an early-stage, VC backed startup in San Diego focused on developing novel genomic analysis tools. The company’s technology will advance the understanding of RNA biology and provide actionable information for improving human health.

Building a modern operating system for IVF, powered by artificial intelligence.

Aligen is a Pharmaceutical, Nutraceutical, and Cosmetic manufacturer that specializes in Softgels, Capsules, Tablets, Gummies, and Skincare Topical Creams.

We are dedicated to transforming lives by improving the journey to a healthy, beautiful smile. Discover your straight path to a bright future at Align Technology. As a part of our smart, diverse and fast-moving global team, you'll make an impact on the market leader that's moving an industry forward. Want to find out what's next for us—and for you? Follow us on LinkedIn for business updates and check out our current opportunities at www.aligntech.com/careers. 25 years ago, we pioneered the market for clear aligners. Since then, we have continuously innovated with new products and technologies that revolutionize treatments for doctors and their patients. Today, doctors and labs in over 100 markets use the Invisalign system, iTero intraoral scanners and exocad software to improve smiles for patients – from simple tooth alignment to complex corrections, kids to adults, orthodontics to multi-disciplinary restorative treatment. Learn more about Align Technology and our products: www.aligntech.com www.invisalign.com www.itero.com www.exocad.com

Our strategy is to develop pharmacologically optimized drug candidates, which are first assessed in healthy volunteers and patients as monotherapy prior to their use in combination regimens designed to achieve improved treatment outcomes in patients. Our initial areas of focus are viral and liver diseases where our team can leverage their in-depth knowledge and expertise to develop potentially best-in-class combination regimens for each disease area with significant unmet medical need.

We develop breakthrough diagnostic solutions for disorders of gastrointestinal function and motility.

Aliri is committed to solving industry challenges by bringing innovative bioanalysis and spatial solutions to biotech and pharma, as the complexity of the drug development landscape continues to rise. Our mission is to support our customers with bringing life-saving therapies to market with speed and agility. We are focused on providing pharma and biotech companies with bioanalysis lab, spatial bioanalysis, and spatial biology solutions that will bring unique, comprehensive data to enable strategic decision making for lead optimization and strengthen regulatory submissions.

Developing solutions that simplify and streamline the generation of "big RNA data", which we believe will constitute the foundation of tomorrow's research and medicine.

AlivaMab Biologics is a biotechnology company based in San Diego, California, focused on therapeutic antibody discovery and development. The company provides integrated solutions to accelerate the creation of biologics, delivering fully human antibodies with a commitment to speed and reduced development risks. Their mission is to create efficient pathways for partners in the pharmaceutical and biotechnology sectors. The team at AlivaMab includes experienced professionals from leading global pharmaceutical companies, contributing to over 500 discovery programs and 35 clinical candidates. They utilize advanced technologies, such as the AlivaMab® Mouse platform, to generate high-quality antibodies and offer a range of services, including antibody engineering and target validation. AlivaMab collaborates with numerous top-tier pharmaceutical companies, with several of their antibodies currently in clinical trials.

AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third-party providers to manage their patients' and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving ISO 27001 Certification, SOC 2 Type 2 Certification and HIPAA compliance attestation. AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers. For more information, visit alivecor.com.

They are focused on the discovery and development of novel biotherapeutics to combat the debilitating muscle and bone loss and the loss of functional capacity, as occurs in various neuromuscular diseases, cancer cachexia, congestive heart failure, geriatric sarcopenia and frailty, as well as in other chronic diseases, for which no approved therapies are currently available.

Alivexis, Inc. (formerly Modulus Discovery, Inc) is a technology-driven drug discovery enterprise with operational foundations in both Japan and the US. By merging state-of-the-art drug discovery platforms with profound knowledge of disease biology and a dynamic global business approach, we are propelling forward our distinct portfolio of small molecule drugs along with a variety of research and development collaborations.

Alixia is a medical research company that engages in developing new modalities to treat cancer, aging, and inflammation.

At ALK, we go to work every day to make a difference for the many people with allergies around the world. It is our ambition to make life with allergy surprisingly simple for as many people as possible, and we build upon our strong heritage as a pioneer in allergy immunotherapy, when we continue to innovate, develop and market new products and solutions to help improve the health of people with allergies. Every day, our employees contribute to our aspiration of becoming the world leader in allergy by coming to work to do their best in the pursuit of providing new and better allergy treatments and solutions. We work in a high-energy, international setting where it is imperative that our people thrive and develop. Creativity, influence and opportunities are key elements in developing our people. ALK is a global company with production sites in Denmark, France, Spain and the United States. ALK was founded in Copenhagen in 1923 and today we employ around 2,900 people around the world. Our global headquarters is located in beautiful surroundings in Hørsholm, north of Copenhagen. Read more about ALK at www.alk.net

Alkahest, a subsidiary of Grifols, is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline -- key medical challenges of our generation. The company’s breakthrough research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimer’s disease models in mice. Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases. Alkahest is based in San Carlos, Calif., while Grifols, a global healthcare company, is headquartered in Barcelona, Spain.

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Alkermes seeks to develop innovative medicines that help address the unmet needs and challenges of people living with debilitating diseases. As a fully-integrated, global biopharmaceutical company, Alkermes applies its scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

We are the pioneers of allergy solutions. Allergy is the most common chronic disease globally and it has profound impact on people’s lives. More than 500 million people worldwide live with respiratory allergies, more than 200 million people have some sort of food allergy, and more than 100 million children are living with allergic rhinitis. These numbers are only expected to increase, and as a result, the need for allergy solutions is ever-growing. For more than a 100 years, ALK has been at the forefront of long-term allergy treatment. Building on our strong heritage, we are now stepping into the next 100 years with a mission to help even more people, with more solutions, more efficiently. We call it Allergy+. ALK is a global company with production sites in Denmark, France, Spain and the United States. ALK was founded in Copenhagen in 1923 and today we employ around 2,900 people around the world. Our global headquarters is located in beautiful surroundings in Hørsholm, north of Copenhagen. Read more about ALK at www.alk.net

Alladapt was co-founded in 2018 in Palo Alto, California, by allergist and protein biochemist Kari Nadeau, MD, PhD, and biotechnology entrepreneur, Ashley Dombkowski, PhD. Academic clinical research conducted by Dr. Nadeau has demonstrated that a food allergic immune system in an individual person can be receptive to remodeling by gradually increasing exposure, under tightly controlled clinical supervision, to the proteins that activate the inappropriate cascade of reactions. This work, combined with research illuminating disease mechanisms and pathways, led the founders to envision a biopharmaceutical intervention capable of addressing food allergy provoked by a wide-ranging set of antigens.

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

Founded in 1984, All American Pharmaceutical is a leading manufacturer of dietary, food and nutritional supplements. We specialize in producing private label and custom formulations for almost anything from general health and sports nutrition to anti-aging products and food products. All American Pharmaceutical has the capability to produce liquids, capsules, powders and tablets products from concept all the way to finished packaging. We are also the exclusive manufacturer and patent holders of two branded ingredients: Kre-Alkalyn® and Kre-Celezine® Formulating and producing effective, high-quality products is not as simple as mixing a few ingredients together and then dumping them into a bottle. Most people who hire a contract manufacturer don't even realize there are major differences between companies, regardless of price. Before hiring any manufacturer, you need to know what their quality standards and current certifications are, how quickly they can turn your products around and if they even have the capability to pull off your job in the first place. After all, your brand's credibility, integrity and hard-earned image are on the line. All American Pharmaceutical has been developing quality products for the past three decades. Over the years, we've listened to your needs and have responded to offer a variety of production and packaging capabilities. And we do it all in our cGMP certified, state-of-the-art 150,000 square foot facility located in Billings, Montana.

Allander biotechnologies is a biotech company at the R&D stage focusing on drug development for unmet medical needs in tissue regeneration.

Built on 30+ years of foundational expertise, Allarta’s proprietary platform is designed to overcome immune rejection, prevent cell escape and safely deliver cell and stem cell therapies. Our lead product is a cell therapy focused on type 1 diabetes (T1D) as a first indication.

At Allay Health and Wellness, we offer a new approach to health and wellness by focusing on the individual as a whole. Picking a provider is a crucial step and Allay is approaching 3000 Infusions! Clinical Trials are showing great success in helping those with Alzheimer's, Parkinson's, addiction, and multiple ailments. We want to focus on the mind, body, and soul so that you can continue to have the best quality of life. We believe that by taking care of yourself, you will have the ability to make better decisions, process information better, and have the tools necessary to deal with physical and emotion pain. We believe that our low dose approach to ketamine infusion therapy, teamed with Cognitive Behavioral Therapy will help you to take care of yourself. Our team of licensed medical providers and mental health clinicians will work with you to develop a treatment plan that best suits your needs. We want to be the starting point of your recovery.

Allay Pharmaceuticals, LLC. has been helping pharmaceutical companies worldwide, bringing products to market - from concept to commercialization, assisting every step of the way.

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.

AllCells is a biotechnology company that specializes in high-quality human primary cells and hematologic tissue products. Founded in 1998, it has become a leader in blood donor cell collections and supports drug discovery, development, and manufacturing of cell therapies. In July 2022, AllCells was acquired by Discovery Life Sciences, which enhanced its capabilities through access to a larger biospecimen inventory and multi-omic biomarker services. The company offers a variety of services to support cell and gene therapy programs. These include donor management services to help clients find ideal research donors, as well as support for both prospective and retrospective clinical studies. AllCells also provides multi-omic analytical solutions for characterizing biospecimens and CGT products. Its product portfolio features blood and marrow-derived products, autoimmune diseased cells and tissue products, and hyper-annotated biospecimens, all essential for biomedical applications.

Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Lead product candidate, cefepime/enmetazobactam, has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled, double-blind, global Phase 3 trial, and the Company is preparing submissions for marketing approval in the U.S. and EU based on these results. The Company has significant patent protection covering proprietary enmetazobactam in major territories. Allecra’s investors are: Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMedPartners. Allecra’s wholly owned French subsidiary is a beneficiary of financial support from Bpifrance and the Région Alsace.

Allegheny Health Network is an integrated health care delivery system serving the greater Western Pennsylvania region. More than 2,600 physicians and 22,000 employees serve the system's 14 hospitals as well as its ambulatory medical and surgery centers, Health + Wellness Pavilions, and hundreds of physician practice locations. AHN is a proud part of Highmark Health.

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical researchers. The company was founded by scientists and other professionals with the goal of advancing discovery and innovation. Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge products at a reasonable cost, and providing excellent customer service in addition to the technical knowledge needed to facilitate their use. Our knowledgeable scientists and technicians are available to answer questions regarding any of our products. Over the past decade, Allele has become a reliable source for a wide variety of Molecular Biology reagents, superior fluorescent proteins, camelid derived nano antibodies (nAb), cellular reprogramming services and reagents, and immundiagnostic kits and various other products and custom services.

Allele Diagnostics, Inc., located in Spokane, WA, was established in 2014 to offer superior genetic testing services. We feel that high-quality testing, reporting, and services can be offered to you with quick results. We pride ourselves in being a laboratory that offers the genetic counseling services clinicians need in a genetic testing company. We combine this service with reliable, fast, accurate test results provided to you via user-friendly and conveniently accessible reports. At Allele Diagnostics, we are passionate about providing reliable answers as quickly and accurately as possible. We continuously strive to improve the efficiency of our workflow and improve the quality of our test results. We encourage feedback from our clients on how we can improve or assist in bringing your ideas into a clinical testing environment. Utilizing our extensive experience in genetic testing, we can work with you to develop solutions to the challenges you have previously experienced in receiving fast, accurate results. Additionally, we are always looking for new and better ways to provide answers to genetic questions and are continuously evaluating novel technologies to see how they can fit into our laboratory given the rapidly evolving clinical genetic testing space. Allele Diagnostics is a CLIA and CAP certified clinical laboratory committed to providing superior testing services for the best patient care possible. We are currently licensed in California, Florida, and Pennsylvania and are pursuing various other state specific licenses.

Allelica is a software and research company democratizing access to clinical-grade Polygenic Risk Score. Allelica is the first Company to have developed a Software as a Service and on-premise infrastructure to allow clinical genetics labs and biopharma companies to perform Polygenic Risk Score analysis in multiple ancestries. Our research work has been published in the American Heart Association Journal, Circulation and presented in the most prestigious conferences in genomics (ASHG) and cardiology (ESC). Our mission is to reduce human suffering making better medicine. We believe in a data-driven primary prevention, able to detect high risk individuals who benefit from personalised prevention and screening plans. www.allelica.com

The mission of the Allen Institute is to unlock the complexities of bioscience and advance our knowledge to improve human health. Using an open science, multi-scale, team approach, the Allen Institute focuses on accelerating foundational research, developing standards and models, and cultivating new ideas to make a broad, transformational impact on science. Founded by philanthropist and visionary Paul G. Allen, the Allen Institute is a recognized leader in large-scale, open science research. Its research institutes include the Allen Institute for Brain Science, Allen Institute for Cell Science, Allen Institute for Immunology and The Paul G. Allen Frontiers Group. The Allen Institute believes that team science significantly benefits from the participation of diverse voices, experiences and backgrounds. High-quality science can only be produced when it includes different perspectives. We are committed to increasing diversity across every team and encourage people from all backgrounds to apply for our open positions.

Allergy Therapeutics is a visionary immunology business with specialist experience in the research and development of allergy treatments. We have a well-established commercial presence in Europe and are focused on the US market. We specialise in the diagnosis and treatment of allergy. We mainly sell our products in European countries and our pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, as well as a peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside of allergy are also under evaluation.

Allevi Develops 3D printers fof bioinks. Bioinks are materials that mimic an extracellular matrix environment to support the adhesion, proliferation, and differentiation of living cells. From GelMA to Collagen and from Hyperelastic Bone to Graphene, Allevi offers the widest range of material capabilities.

Alleviant Medical is a medical device company developing next-generation therapies for heart failure.

Allgenesis is a privately-held, clinical stage ophthalmology company based in Taiwan. The company is focused on novel multi-specific fusion proteins for treating diabetic macular edema and wet-age-related macular degeneration; and small molecule eye drops for dry eye and pterygium diseases.

At Alliance Pharma plc (AIM: APH) we are a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world. We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. We have previously enhanced our organic growth through selective, complementary acquisitions. Headquartered in Chippenham, UK, we employ around 290 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. Over the last year, Alliance has sharpened its purpose, vision and strategy to align with the stated move towards a predominantly consumer healthcare company, to better position the company for the future, and in response to changing underlying market dynamics. In line with this new strategy, Alliance will focus on the global priority categories of helping damaged skin and supporting healthy aging. Our vision is to be a high performing consumer healthcare company, built on a portfolio of leading, trusted and proven brands. Consumer health products currently deliver 75% of our revenue sales and this continues to be an area of focus going forward. For more information, please visit our website: www.alliancepharmaceuticals.com Adverse Event Reporting Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Pharmacovigilance at Alliance Pharmaceuticals (tel: 01249 466966, email: pharmacovigilance@alliancepharma.co.uk)

Alli Connect is a mental health care service for first responders that proactively promotes wellness and positive change in public safety.

Allied Healthcare Products, Inc. is a leading manufacturer of medical gas construction equipment, respiratory therapy equipment, home healthcare products, and emergency medical supplies. Our products appear worldwide in a range of medical applications, including hospital care, sub-acute treatment, long-term care, home healthcare, and medical emergencies. Allied Healthcare Products, Inc. is a U.S. manufacturer of FDA approved respiratory medical devices and immobilization products with over 60 years of experience in the industry. Our products are produced in an ISO13485:2016 facility and we carry the capability to apply the CE mark to the products we produce. Allied manufactures transport ventilators, airway products, and immobilization devices under the Life Support Products (LSP) brand. For more information, please visit www.alliedhpi.com or www.ahp300.com.

Harvesting the power of Nature, Allied Microbiota develops advanced microbes to clean-up environmental contamination faster, more sustainably, and more cost-effectively than traditional remediation methods. Our products tackle the toughest contaminants like those from manufactured gas plants, chlorinated organics, and even emerging contaminants like per- and poly-fluoroalkyl substances (PFAS). We developed a heat-loving microbe called ThermO+ that breaks down contaminants at a fraction of the cost and significantly faster than traditional methods. Powered by heat and on oxygen, our microbes can clean difficult contaminants such as chlorinated compounds like polychlorinated biphenyls (PCBs), petroleum products, and dioxins from the soil, turning brownfields into greenfields. We don't bury the problem. We solve it. Site cleans ups can be expensive, but our technology makes this possible for companies, developers, and communities. We aim and strive to create cleaner, healthier, and productive areas around the world. Make Allied Microbiota your fast, affordable, and go-to solution for a cleaner tomorrow.

Allievex is committed to developing first- and best-in-class therapies to benefit children with rare and devastating neurological diseases. Using intracerebroventricular administration of enzyme replacement therapy, we safely deliver our therapies where they’re needed most—to the cells of the central nervous system. Data from ongoing clinical trials for our first drug, tralesinidase alfa, provide preliminary, promising results for Sanfilippo syndrome type B patients. These findings offer exponential hope: an effective treatment for one rare pediatric neurological disease can uncover the keys to countless more.

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator´s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more than 60 billion unique antibody fragments. FIND® (Fragment Induced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. Immunotherapy of cancer: The immune system protects the body from attacks by pathogenic microorganisms (e.g. viruses and bacteria) and by cancer cells. Cancer cells usually evade the immune system, for example by producing immunosuppressive substances. Thus, although tumors often contain a large number of immune cells that should be able to attack the cancer cells, they are unable to do so due to the immunosuppression caused by the tumor. With immunotherapy, the ability of the immune system to fight cancer cells is improved in an effective manner, and the defense mechanisms used by the tumor are blocked or weakened. In addition, immune cells capable of destroying the cancer cells will survive in the body and thus protect it from metastases that may arise after treatment has ended. This "vaccination effect" is unique for immunotherapy.

Allinaire is developing humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies, which are currently being progressed as a potential disease-modifying treatment for PAH. Allinaire was founded in 2016 by BioMotiv (www.biomotiv.com; now managed by Advent Life Sciences, www.adventls.com), with the licensed technology from Indiana University. EMAP II is a non-classical cytokine which impacts apoptosis, cell injury, endothelial cell function and inflammation. Based on the pioneering work by the scientific founders, Matthias Clauss, PhD and Irina Petrache, MD, and their colleagues at Indiana University and National Jewish Health, Allinaire Therapeutics and their network of preclinical and clinical scientists, have demonstrated a pivotal pathogenic role of EMAP II in cardiopulmonary diseases, including pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and viral-induced acute lung injury.

Founded in 2023 and based in Shanghai, China, Allink Biotherapeutics is a biotech company dedicated to expediting the development of a diverse pipeline of FIC/BIC therapeutic candidates for oncology and immune diseases. Our goal is to harness our proprietary bispecific antibody and ADC technology platforms, along with efficient execution and business collaboration , to address critical unmet clinical needs.

Health Products For You (healthproductsforyou.com) is a premium online health and wellness retailer. Celebrating our 20th year of delivering quality health care and healthy living products directly to your doorstep, we are committed to making a difference in the lives of our customers and the communities we are privileged to serve. Our 10+ health and wellness stores carry a wide array of products dedicated to women’s health and wellness, incontinence, ostomy, rehabilitation, mobility, respiratory, wound care, and more. Having developed relationships with the top 2000+ manufacturers over the past 20 years, we can provide our B2C and B2B customers with the ultimate streamlined purchasing experience, offering the best quality products at the lowest possible prices. Enter our #giveaway contest: https://www.healthproductsforyou.com/sweepstakes.html

Allodynic Therapeutics is a clinical-stage biopharma company engaged in developing naltrexone-acetaminophen (ALLOD-2) as an oral investigational product for the acute treatment of migraine. Both naltrexone and acetaminophen individually can simultaneously reduce physical and emotional pain, potentially enhancing treatment outcomes. Naltrexone-acetaminophen U.S. patents extend to 2037.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.

At Allogenica, we are transforming cell therapies for a healthier tomorrow. Our mission is to 𝗱𝗶𝘀𝗿𝘂𝗽𝘁 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗳𝗼𝗿 𝗰𝗮𝗻𝗰𝗲𝗿, 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀, 𝗮𝗻𝗱 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀. We're developing a breakthrough cell therapy platform with the potential to: • 𝗥𝗲𝗽𝗹𝗮𝗰𝗲 𝘁𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁𝘀: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options. • 𝗘𝘅𝗽𝗮𝗻𝗱 𝗮𝗰𝗰𝗲𝘀𝘀 𝗳𝗼𝗿 𝗮𝗹𝗹: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population. • 𝗗𝗿𝗮𝗺𝗮𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝗿𝗲𝗱𝘂𝗰𝗲 𝗰𝗼𝘀𝘁𝘀: By streamlining production, we aim to significantly lower the cost of cell therapies, making transformative treatments more accessible globally. 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 Founded in 2022, Allogenica has rapidly emerged as a pioneer in the field. Our innovative approach includes: • 𝗣𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗣𝗿𝗲-𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀: Enhancing compatibility with patients' immune systems, reducing the risk of rejection. • 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲, 𝗕𝗿𝗼𝗮𝗱 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Our platform has the potential to treat a diverse range of diseases, ensuring scalability and reaching more patients in need. • 𝗖𝗼𝘀𝘁-𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲, 𝗥𝗮𝗽𝗶𝗱 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: Delivering affordable and faster-to-market therapies, to change lives on a global scale, potentially impacting millions.

Alloplex Biotherapeutics is dedicated to exploring the higher order combinatorial space of immunomodulators to develop an effective anti-tumor vaccine. This approach is applicable to all tumor types and is particularly suited to combinations with checkpoint inhibitors. Alloplex is a private company and currently supported by angel investment

Founded in 1994, AlloSource is a nonprofit leader in providing allografts that maximize tissue donation to help surgeons heal their patients. The company has grown into one of the largest tissue networks in the country creating more than 200 types of precise bone, skin and soft-tissue allografts for use in an array of life-saving and life-enhancing medical procedures. As a leading manufacturer of cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource’s products bridge the proven science of allografts with the advanced technology of cells. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO.

Allotrope Medical is committed to helping surgeons safely and easily identify the ureter during pelvic operations. The Houston-based company's first product –StimSite™–is designed to assist surgeons in the critical step of ureter identification in millions of operations performed every year. It received funding from Y-Combinator the Mountain View, CA based group that also invested in Door Dash, Dropbox, and Airbnb, and has been voted Top Innovation by a panel of expert surgeons at SAGES (Society of American Gastrointestinal and Endoscopic Surgeons). It also was the past runner-up in the MedTech Innovator contest out of over 600 companies from around the world, and took home top prize at the 2020 Texas A&M New Ventures Competition. Our vision is to advance smooth muscle stimulation technology as the standard of care to help improve minimally invasive surgical outcomes and drive healthcare efficiency. We are building a dynamic team of high performing, accountable, attentive individuals looking to serve patients, partners and institutions in focused surgical specialty markets.

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From academics and biotechs of every size to large pharma, we democratize access to foundational, pre-competitive biologics discovery technologies and services to enable drug discovery across six biologic modalities. When you partner with Alloy, you can: • Access our ever-growing stable of services and cutting-edge technology platforms to help you discover the best therapeutic antibodies against your targets • Unlock the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCR Discovery service offering • Reach intracellular disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the drug-like properties of antisense • Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; San Francisco, CA; and Athens, GA. We reinvest 100% of our revenue into innovation and access to continuously develop new groundbreaking platforms and protocols to make our collaborators more successful.

Allozymes is a fast-growing biotechnology company that applies its proprietary ultra-high-throughput platform technology to rapidly develop novel enzymes and unlock the bioeconomy across sectors. Leveraging this ultra-high screening power, Allozymes aims to build the largest enzyme data library in the world to address the current and future needs of building robust biosolutions.

Allterum Therapeutics is a biopharmaceutical company developing an immunotherapy for pediatric acute lymphoblastic leukemia.

All Things Bugs manufactures and sells finely Milled Whole Cricket Powder for food production.

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna’s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.

Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. The company is purpose-built through the convergence of leading providers to address this unmet need. Today, Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics and clinical pharmacology across a variety of therapeutic areas. With more than 30 years of experience in over 60 countries, Allucent's individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients.

Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and over 1,000,000kg lost worldwide.

Allvivo Vascular is a medical device company that develops biomimetic coatings for devices, offering dual function coatings with nonthrombogenic and antibacterial properties.

Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical focused on rare diseases with high unmet needs. We are developing first-in-class therapeutic peptides with multiple biological actions, including anti-fibrotic, anti-inflammatory, cell regenerative, and beneficial metabolic effects that provides development opportunities across multiple diseases. Our lead drug, ALY688ER, an extended release formulation designed for extended delivery of ALY688 throughout the body, is a potent and specific activator of adiponectin signaling pathways. Adiponectin is a beneficial cytokine produced mainly by adipose cells and which protects against obesity-associated diseases. ALY688 is the first adiponectin receptor agonist to enter human testing. Our lead indication is Duchenne muscular dystrophy (DMD), a serious rare genetic disease of boys in which muscle tissue damage due to muscle cell injury, inflammation and replacement of muscle by fibrotic tissue results in progressive loss of skeletal muscle function. In relevant animal DMD models, ALY688 reduced muscle cell death, enhanced muscle regeneration, and reduced inflammation and fibrosis, resulting in preservation of muscle strength and endurance. In addition, ALY688 has shown similar benefits across a range of other inflammatory and fibrotic conditions potentially expanding its use in additional indications.

Allyx Therapeutics is a clinical stage biotechnology company aiming to develop disease modifying therapies for Alzheimer's and Parkinson's. They are developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease.

Alma Therapeutics is developing a novel drug delivery platform for the oral delivery of complex molecules and biologics such as: Peptides, Proteins and Antibodies

Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have three additional medicines on the market: GIVLAARI (givosiran), OXLUMO (lumasiran) and LEQVIO (inclisiran) in partnership with Novartis). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,700 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 3 years in a row ('19-'21), a Boston Globe Top Place to Work 7x in a row ('15-'21) and one of Fast Company's Best Workplaces for Innovators for 2021.

Aloe Therapeutics is a biotech start-up aimed at delivering cancer cures. We have designed a therapy, termed Allo-Immunotherapy (AIM), to trigger an influx of activated immune cells to traffic to the tumor microenvironment - turning "cold" tumors "hot" and "hot" tumors "hotter." INFLAME WITH AIM.

Alopexx Enterprises works with scientists and entrepreneurs to build successful new companies. We invest in novel health care technologies at all stages of development and can serve as a lead investor or collaborate with a group of investors to advance important science. We also have the capabilities to provide management and development expertise where needed. To date, our initial investments have ranged from $1-20M. The Alopexx team consists of experts who have deep industry knowledge and technical expertise in all areas of drug development including, pharmacology, CMC, toxicology, medical and clinical operations, quality and regulatory affairs. We form collaborations with academic institutions, biotech and pharmaceutical companies to advance our portfolio companies to deliver breakthrough therapies to patients in need. Our business model is to invest and develop to an important inflection point and then partner the asset for further development and/or commercialization. Portfolio companies include: -Alopexx Pharmaceuticals -Alopexx Oncology -Alopexx Vaccine -Valerion Therapeutics -Janus Biotherapeutics -Cognoptix

We are a leading global developer and provider of innovative molecular and immunodiagnostic products focused on Infectious and Gastroenterological Diseases. We are a trusted partner creating value for research and clinical laboratories with high-quality, user-friendly, reliable and accurate solutions. We achieve this through a culture of respect, dedication, empowerment and creativity.

Alpex Pharma is a pharmaceutical company active in Research & Development and Production of ODT (Orally Dispersible Tablet) called also “fast melt” and effervescent tablets. Alpex Pharma has developed a unique proprietary covering ODT technology. The high production capacity and advanced R&D technologies makes Alpex Pharma to be one of the most important company of the world in the field of fast melt and effervescent tablets. The company has a state-of-the-art manufacturing and R&D facilities of some 7000 square meters, with separate pharmaceutical and nutritional plant GMP compliant.

Alpha-1 Biologics is a biotherapeutics company developing innovative treatments for cancers and immune deficiencies. The company is dedicated to their mission to develop patented therapeutics related to the generation of immune cells from stem cells within the body to treat immunodeficiency with disease applications including immune cell replenishment in cancer therapy, HIV/AIDS, patients with inherited deficiency of α1PI, and in the most prevalent cause of immune deficiency, malnutrition. Alpha-1 Biologics is currently testing their orally-available, small molecules in studies to determine their ability to increase the number of tumor infiltrating CD4+ T cells and coordinate with immune checkpoint inhibitors to eliminate tumors. The discoveries at the core of Alpha-1 Biologics therapeutic approach resulted from basic research conducted by Dr. Bristow and supported for many years by the non-profit research organization, Institute for Human Genetics and Biochemistry (IHGB) funded by the Harry Winston Research Foundation.

Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.

Since 1987, Alpha Analytical, Inc. has provided full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is 6th largest environmental laboratory in the country, and is the largest environmental laboratory in the Northeast with services and support extending into New York,New Jersey, Ohio, Kentucky, and Michigan. Our core services include air, water and soil analysis, with particular expertise in the highly-specialized fields of emerging contaminants, sediment and tissue analysis and petroleum forensics. Please contact your Alpha technical sales representative to learn more about our capabilities, experience and certifications. Visit us on the web at www.alphalab.com.

AlphaBiolabs provides DNA testing to members of the public.

Alpha Biopharma – Specialized in drug innovation from clinical development to commercialization success. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha Biopharma establishes strategic partnership with leading international pharmaceutical company/R&D institute.

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with platform technologies in Immunotherapy and Immuno-Oncology. These platforms under development treat auto-immune disease indications and cancer. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP).

Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.

AlphaDERA Labs, LLC. is a full-service medical laboratory providing wellness testing, routine blood chemistry, prescription & illicit drug test including urinary tract testing, respiratory pathogen testing, and COV-19 antigen testing for healthcare facilities, clinics, and PCR Covid-19 testing for patients.

Alpha Fusion Inc. is a clinical-stage startup committed to transforming cancer treatment through the design and development of powerful and precise radiopharmaceuticals. Our radiopharmaceuticals utilize Astatine-211 (211At), alpha-emitting particles that are both effective against cancer and safe for patients. This innovation will significantly impact cancer patients who currently have limited treatment options.

Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing Antibody Drug Conjugates (ADCs) and natural killer (NK) cell therapies, supported by Companion Diagnostics. Our team are industry veterans with experience in both large pharma and biotechnology startups committed to transforming the lives of cancer patients.

Alphalyse has pioneered the use of mass spectrometry analysis since 2002. Our scientists have completed over 5,000 protein characterization analyses, including forced degradation studies and over 400 LC-MS-based residual/host cell protein projects. Currently, we are the only CRO in the World certified to offer LC-MS-based MRM analysis under GMP for release testing. As a specialist contract research organization (CRO), we offer protein analysis services to support biopharmaceutical companies in developing and manufacturing patient-safe products such as mAbs, vaccines, recombinant proteins, and cell & gene therapies. You can count on us to work closely with you on developing well-characterized biologics by challenging and improving analysis methods using top-of-the-line mass spectrometry technology (LC-MS). Our comprehensive reports will allow you to carry out data-driven process development and regulatory documentation under ICH Q6B guidelines. Our services include analytical characterization of biopharmaceuticals, mass spectrometric peptide mapping, host cell protein analysis, and quantifying specific proteins in complex samples.

AlphaMa is a pioneering drug R&D company based in Suzhou, China, established in 2018. With artificial intelligence (AI) as the driving technology, DNA-encoded library (DEL) technology is cross-applied to establish a cutting-edge Intelligent DEL (iDEL) platform(including the first-class technology of on-demand DEL synthesis, DEL screening, hit confirmation, macrocyclic peptide DELs, customized glue library, etc.). The iDEL platform at AlphaMa features first-class DNA-encoded library (DEL) technology specializing in small molecule, macrocyclic peptide and covalent hit discovery, etc. With its mature screening technology and high success rate, providing global partners with a cost-effective and efficient one-stop DEL screening service. Our flexible service model, diversified services and excellent service system cover all stages of early drug discovery. We provide flexible and cost-effective approaches to meet customers' diverse needs with professional technology and high-quality services. AlphaMa is your ideal partner for drug discovery, assisting you in accelerating the drug discovery process. Reach out to learn more: liuyulin@aiphama.cn

Alphamab Oncology (Stock code: 9966.HK) is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and we are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.

Alpha Medical Instruments,developer, manufacturer, Balloon flotation catheters, venous catherization, right heart, measurements, venous, pulmonary artery pressures, cardiac output

Licensed worldwide rights to develop and commercialize ALPHA-1062IN in TBI and related disorders from Alpha Cognition, Inc. ALPHA-1062IN: Potential first treatment for Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) - Plans to develop and commercialize ALPHA-1062IN in TBI and related disorders - US Cognitive Impairment in TBI market is estimated at $17B+ with no currently approved product - ALPHA-1062IN pre-clinical data has demonstrated positive cognitive effects and protects brain from damage - No toxicity observed in completed studies - Patents extending to 2042

ATEC is a medical device company dedicated to revolutionizing the approach to spine surgery through innovation. ATEC’s Organic Innovation Machine™ is the greatest concentration of spine knowhow in the industry and committed to the creation of clinical distinction. Leveraging 100% spine focus and expertise, we seek to improve spine surgery by rethinking, redesigning and seamlessly integrating the technologies required from the ground up. The innovation that results from that process is being rapidly adopted because, like us, spine surgeons covet informatic and procedural sophistication that enables more predictable, more reproducible care. Our flagship technology, the Prone TransPsoas (PTPTM) Procedure, leveraged decades of experience to advance first-generation lateral surgery with a more familiar patient position and elevated neuromonitoring.   EOS imaging, the backbone of ATEC’s informatic ecosystem, provides radiographic imaging, enabling standing, full-body, global alignment assessments. We are further developing EOS technology to elevate spine care with unprecedented capabilities. Our vision is to be the standard bearer in spine. Visit our website for more information: www.atecspine.com

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

Zen Cart! : - Products for Cell Biology Products for Molecular Biology ecommerce, open source, shop, online shopping, store

The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man. These immune responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell) immune responses, confirming the promising data we have obtained in over a decade of intensive pre-clinical work with this vector platform.

Alphazyme was founded in 2018 by Christopher Benoit, Stephana Petrino and Chad Decker. Our experienced team has a track record of success and a passion for supporting molecular biology innovators. Our mission is to be the world’s premier partner for custom, industrial-scale, molecular biology enzymes. We are enzyme development and production experts, and partner with the manufacturers of nucleic acid therapies and detection platforms to develop and produce affordable, reliable enzymes which meet the specifications of the rapidly expanding market for custom DNA and RNA molecules, genomic medicines and genetic tests. Consistent quality, scalable processes, and compatibility with regulatory requirements are the hallmarks of our business.

Alpheus Medical, Inc, is a privately held company based in Oakdale, Minnesota, developing a novel sonodynamic therapy platform targeting solid body cancers. The company's lead product utilizes a novel, non-invasive drug device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM). Alpheus Medical's work has been developed in conjunction with some of the most accomplished names worldwide in neuro-oncology, and with support from the American Cancer Society and National Brain Tumor Society.

Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. Its lead product candidate, AB-101a, is a topical treatment for atopic dermatitis (AD), the most common form of eczema, and has completed a Phase 2a clinical trial. AB-101a has demonstrated a strong safety profile and is in development to uniquely target AD's bacterial and immune system components, making it ideal for treating infected and non-infected AD. Alphyn's AB-101 platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics with potential safety, efficacy, and regulatory marketing authorization advantages. Alphyn is based in Annapolis, Maryland, and Cincinnati, Ohio, and has a wholly-owned subsidiary in Australia. We became operational in 2020 and have raised approximately $6.7 million.

Alpine Research is a Clinical Research Center that conducts clinical trials for major pharmaceutical companies.

Technology that leverages customer value. ALPINION's an innovative and recognized ultrasound brand ‘E-CUBE' principles (‘Extreme Clarity', ‘Efficient Workflow', ‘Ergonomic Design') reflect ALPINION's technological philosophy that provides customers with uniform image quality throughout the product lifetime. ALPINION has focused on acoustic engineering and front-end technology since we initiated our ultrasound business. There has traditionally been a strong focus on back-end processing in ultrasound; however, we shifted attention to the front-end with a focus on the signal quality sent to system processors. ALPINION focuses on continuous innovation in acoustic technology. ALPINION has developed a range of transducer array types and applied them to ALPINION's innovative E-CUBE series of ultrasound systems. Based upon proprietary superior acoustic technology, ALPINION continuously strives to expand the medical business from diagnostic ultrasound to therapeutic ultrasound.

ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with diabetes. ALRT has developed the FDA-cleared Health-e-Connect System which uploads the data from blood glucose meters onto a secure website where clinicians and Diabetes Care Facilitators can better monitor and coordinate the care of diabetes patients. ALRT's system goal is to assist patients to adhere to their care plan, improving the quality of diabetes care and making such care more cost effective to providers

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS).

ALSTEM is an early stage biotech company based in the San Francisco Bay Area specializing in Induced pluripotent stem cells and reprogramming technologies. Founded in early 2012 by a team of scientists with deep experience in both academic and industrial biotechnology, ALSTEM is advancing frontiers in genome editing, virus packaging, cell immortalization, and iPS cell technology.

Altamira Therapeutics (former Auris Medical) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: • the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), • nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2) • the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003, under the name Auris Medical, and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”

Outsourcing made easy with a one-stop solution to early phase drug development. We are an integrated drug development solution company, offering pharmaceutical and biotechnology companies a proven, flexible approach that removes the need for multiple service providers during the early stages of drug development. Whether for one study or an end-to-end program, we help you reach critical decision-making milestones sooner by improving speed and ease from lead candidate selection to clinical proof of concept, and beyond. When partnering with Altasciences, you can experience up to 40% in time savings thanks to our integrated, one-stop solution offering. We strive to create a true partnership with our clients, our partners, and our colleagues that enables a mutually supporting relationship built on a combination of excellent science and solid communication. Helping sponsors get better drugs to the people who need them, faster, for over 25 years. Our full-service offering is always tailored to your specific research needs: - Preclinical research - Clinical pharmacology - Drug formulation - Manufacturing and analytical services - Bioanalysis - Program management - Medical writing - Biostatics - Data management - And so much more!

AltaThera Pharmaceuticals is a specialty pharmaceutical company focused on identifying, acquiring, developing and commercializing therapies for the unmet medical needs of critical care patients and those with severe, often rare, disorders for which few effective treatments are available.

ALTEOGEN Inc., Daejeon(fifth-largest metropolis)-based in South Korea, is a leading biopharmaceutical company with a leading edge pipeline of novel biologics such as next generation biobetters including long-acting therapeutic proteins, Antibody-Drug Conjugate (ADC) therapeutic antibodies and monoclonal antibody biosimilars. The company was founded in 2008 and listed in KOSDAQ stock market (KRX:196170). Our innovative NexP™ fusion technology is applied to various proteins and peptides to allow longer activities in human beings. Long-acting human Growth Hormone, long-acting exenatide (for diabetes) and long-acting Factor VIIa (for hemophilia) are developed with the NexP™ fusion technology. Our proprietary ADC technology, NexMab™ ADC technology is well suited for the targeted therapy for the cancer drugs with lower side effect and better efficacy. With this NexMab™ ADC technology, we are developing ADC therapeutics for breast/gastric cancer and ovarian cancer. Alteogen's mostly distinguished Hybrozyme™ technology to a human hyaluronidase, which has been widely used to improve the absorption of drug biologics delivered via subcutaneous injection. The novel human hyaluronidase based on Hybrozyme™ technology showed improved enzymatic activity and thermal stability. Based on long and rich experiences, Alteogen has quickly developed its own cell lines with high expression, efficient process (upstream and downstream), and optimized analysis methods for monoclonal antibody biosimilars including Herceptin preparing for the phase 3 trials upon completion of global phase 2 testing, SC formulation of Herceptin biosimilar as well as working on Eylea biosimilar.

Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. We are a team with expertise in multiple areas of science and operations, dedicated to co-elevating toward our vision to bring life-changing and life-saving therapies to cancer patients. We believe in our journey, in each other, and in our ability to collaboratively develop therapies that will help end cancers. Thus, we seek the best people for our company and provide the resources they need to grow, develop, and accomplish our collective goals. We are moving forward with humility & empathy, fearlessness & resilience, with a sense of inclusion & belonging, open communication and a deep trust. And…we manage to have a lot of fun along the way!

Altesa is a clinical-stage pharmaceutical company dedicated to developing new treatments for age-old threats to human health: high-consequence viral infections. These infections are particularly severe in vulnerable people, including those with chronic health conditions, like lung diseases, as well as the elderly and many people in underserved communities. Altesa builds upon a proven, highly successful drug development platform that has already prevented countless deaths from the two most impactful pandemics of the past 100 years—HIV/AIDS and COVID-19. Our objective is to develop safe and effective antiviral medicines in simple oral dosage forms that, when prescribed for the right people at the right time, will halt the progression of infection before it becomes serious—or even prevent the infection altogether. This strategy extends the proven benefits of testing for viruses such as the flu or COVID-19, which have both caused suffering and death among vulnerable people but can be treated if properly diagnosed. Viral pathogens like these and others have plagued mankind for many thousands of years, but testing for and treating them is an effective strategy to blunt their impact and, ideally, to defeat them.

AltheaDx, Inc. is a commercial stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx). IDgenetix® is AltheaDx’s PGx product test for depression and anxiety and is supported by a published/peer-reviewed Randomized Controlled Trial that demonstrated clinical utility over standard of care when physicians used the test prior to prescribing a medication.

Altheia Science is a pioneering start-up founded by two world renowned Italian scientists, Prof. Alessandra Biffi, MD and Prof. Paolo Fiorina, MD, PhD, together with AurorA-TT. Altheia Science’s pipeline exploits pioneering therapeutic tools for autoimmune diseases and cancer. The modulation of PD-L1 expression at the molecular and protein level is key to devise advanced treatments. This can be achieved by first-in-class molecules controlling the PD-L1 pathway and/or by lentiviral vector-based engineering of patients’ hematopoietic stem cells. Altheia Science’s approach intends to drastically modify the natural history of diseases with high clinical impact in autoimmunity and cancer by modulating PD-L1 expression, achieving tangible and durable benefit for each patient.

Althera is focused on development and supply of innovative patient focused medicines. Althera’s medicines are approved and available to patients in more than 35 countries worldwide. ​Founded in 2010, we are leaders in development of innovative combination medicines in therapeutic areas of Cardiology and Diabetes, and work closely with our B2B partners in making these products available to patients in geographies across the world including all major markets in Europe and Emerging Markets including Asia, Latin America and Africa. ​Our strong R&D capabilities and network of manufacturing sites enable innovative and cost effective supply of medications to improve patient health.

AltiBio, Inc. is a San Francisco Bay Area biopharmaceutical company founded in early 2017 to bring relief to people living with rare and severe diseases. The management team has extensive experience developing and commercializing orphan therapeutics. The company currently has three projects in development, with two molecules. More news will soon be coming as the company nears its next big milestone...

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). P

Altitude Lab is a biotech and health care incubator offering lab and office space, funding, mentoring, and entrepreneurial education.